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Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder that results in 
progressive impairment of brain cognitive functions and memory. Amyloid beta (Aβ) 
peptides are protein fragments present as insoluble and misfolded polymeric depositions in 
the brain parenchyma and cerebral blood vessel walls of AD patients. Pathological 
accumulation of Aβ peptides within the cerebrovasculature, especially cerebral cortex and 
leptomeninges vessels, is referred to as cerebral amyloid angiopathy (CAA) and it can 
compromise the blood brain barrier (BBB) integrity. In addition, capillary dysfunction, 
such as pericyte degradation and pericapillary fibrosis, is also observed in AD. These 
conditions affect blood rheology and hemodynamics leading to impaired cerebral blood 
flow to tissues.  
Circulating blood platelets are responsible for haemostasis and thrombosis, and have also 
been shown to mediate immunity, tissue repair, and inflammation. Several studies have 
revealed that platelets in AD patients exhibited abnormalities, including an aberrant pre-
activation state. When combined together with compromised blood vessels integrity, a 
highly pro-thrombotic environment within the cerebrovascular system is established, 
which leaves AD patients extremely vulnerable to the formation of microthromboses and 
thromboembolic events. This further exacerbates brain tissue degeneration. The exact 
intracellular mechanisms underlying platelet activation triggered by Aβ peptides are not 
well established. Emerging evidence suggests a strong correlation between Aβ peptide 
effects on platelets and reactive oxygen species (ROS) generation, but a complete picture 
of the link between Aβ peptides and platelet redox homeostasis is still missing. Therefore, 
the present PhD project aimed to investigate the mechanisms underlying Aβ peptide-
dependent activation of platelets and the potential role of ROS in this pathophysiological 
event.  
In phase I, the effects of Aβ peptides on platelet functional responses were explored, such 
as adhesion, aggregation, and thrombus formation under static and physiological flow 
conditions. Phase II, explores different methodologies to assess oxidative changes in 
platelets upon treatment with Aβ peptides. Finally in Phase III, the redox- and NADPH 
oxidase-dependence of platelet functional alterations induced by Aβ peptides was 
investigated. Taken together, this work suggests that Aβ1-42 binds to platelets through 
collagen receptor GPVI, which induces intracellular redox stress and potentiates platelet 




induced significant platelet adhesion and thrombus formation in whole blood under venous 
flow condition, while other Aβ peptides did not. This suggests a role for this peptide in the 
cerebrovascular abnormalities associated with AD. Finally, we highlighted the importance 
of NOXs in the activation of platelets in response to Aβ1-42 peptides and have shown that 
both NOX1 and NOX2 are important for the induction of superoxide anion formation in 
platelets activated by Aβ1-42. This work sheds new light on the pro-thrombotic activity of 
amyloid peptides and provides new insights into the molecular mechanisms underlying 
cerebral microthrombosis and impaired blood flow in the cerebrovasculature associated 
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1.1. DEMENTIA AND ALZHEIMER’S DISEASE  
One of the hardest things to ever experience is to grieve the loss of a loved one who is still 
alive. Dementia is one the most common ageing-related pathologies and it is used as an 
umbrella term to define a state and a cluster of symptoms involving progressive impairment 
in brain cognitive functions and memory that can eventually lead to decreased quality of life, 
physical disability and institutionalization [1, 2]. It is estimated that there are approximately 
50 million dementia sufferers globally and the figures are expected to escalate to 152 million 
by the year 2050 if no cure is available causing concern for a future worldwide health crisis 
[3]. In the UK alone, dementia now is considered the leading cause of death and places an 
overwhelming economic burden on social and health care systems costing £26 billion 
annually [4]. There many types and causes of dementia but the most common ones are 
categorised into: Alzheimer’s dementia, vascular dementia, Lewy bodies dementia, and 
Frontotemporal dementia [5]. Table 1 below provides a summary of their clinical features. 
The most dominant causes that leads to dementia are Alzheimer’s disease (AD; 60-80% of 
dementia cases) and vascular dementia (VaD, approximately 20% of cases) [3, 5]. 
Table 1 | Summary of dementia types clinical manifestation [5]. 
Dementia Type Clinical Manifestation 
Alzheimer’s disease  Insidious onset and slow progressive decline 
 Short-term memory impairment in early stage; deficit on 3-word or 
5 word recall; executive function impairment in later stages 
 
Vascular dementia  
(multi-infarct dementia) 
 Sudden or gradual onset 
 Usually correlated with cerebrovascular disease (stroke, lacunar 
infarcts) and atherosclerotic comorbidities (diabetes, hypertension, 
coronary heart disease) 
 Mild memory impairment in early stage 
 Possible gait difficulties and falls (depending on the extent of the 
stroke) 
 
Lewy body dementia  Fluctuating cognition associated with parkinsonism 
 Poor executive function and visual hallucinations in early stage; 
deficits on tests designed to examine visual perception (pentagons, 
cube, trails, clock face) 
 
Frontotemporal dementia  More prominent personality changes (disinhibition) and behavioural 
disturbances (apathy, aggression, agitation with less memory 
impairment in early stage) 
 
Alzheimer’s disease (AD)  is a multifactorial severe and progressive neurodegenerative brain 
disorder that represents one of the most prominent causes of dementia with an increasing 
prevalence worldwide [3]. It was first described by the German psychiatrist Alois Alzheimer 




in 1906 as “a peculiar disease of the cerebral cortex” upon post-mortem histopathological 
examination of the brain of his patient, Auguste Deter, who had suffered the clinical 
symptomology of what was called pre-senile dementia [6]. Alzheimer discovered brain 
alterations and the presence of numerous forms of what he described as “plaques” and 
“tangles” in the cerebral cortex [7].This form of dementia later became referred to as 
“Alzheimer’s disease” since it was first presented and documented by Alzheimer. Re-
examination of Auguste Deter’s medical records and brain specimens in 1997 using modern 
scientific methods confirmed Alzheimer’s original observations [8].  
1.2. ETIOPATHOGENESIS AND ALZHEIMER’S DISEASE 
1.2.1. Neuropathology  
Since the initial observations by Alzheimer on brain alterations, significant advances have 
been made in understanding the neuropathological processes underlying this disease [9]. The 
prominent morphological hallmarks of the disease involve the presence of intraneuronal 
insoluble aggregates of the microtubule- associated protein, Tau, aberrantly found in a 
hyperphosphorylated state and forming neurofibrillary tangles (NFTs) [10, 11]. NFTs disrupt 
the communication and transportation system of neurons, and interfere with numerous 
intracellular functions, consequently leading to neuronecrosis [11-13]. 
The second prominent morphological hallmark is the presence of extraneuronal pathological 
accumulation of insoluble aggregates of misfolded polymeric protein fragments known as 
β-amyloid peptides (Aβ) in the form of oligomers, fibrils and plaques deposited in the brain 
parenchyma and mostly accompanied by inflammation due to neuronal and synaptic damage 
[14, 15]. There are two frequently observed forms of amyloid plaques and these are classified 
into diffused, and dense-core plaques [9]. Diffused plaques are composed of amorphous 
amyloid with irregular morphology and are commonly found in the normal ageing brain with 
no pathological association with cognitive impairment or synaptic loss [16]. Dense-core 
plaques however, are composed of dense fibrillar Aβ sheets at the core with random 
filaments projecting, and have a pathological association with neuronal degeneration and 
cognitive impairment [16, 17]. Soluble or monomeric form of Aβ peptides may also be present 
at elevated levels in the brain and cerebrospinal fluid [18]. In addition, accumulation of Aβ 
deposits have been observed within small to medium-sized cerebral blood vessel walls, 
especially areas of cortical and leptomeningeal arteries and capillaries [19, 20]. This contributes 
to cerebrovascular impairment and the development of cerebral amyloid angiopathy (CAA) 
[21]. These characteristic lesions are key diagnostic features and central to AD pathology [22] 




(summarised in Figure 1.1). They are usually accompanied by chronic inflammation and 
oxidative stress leading to blood hypoperfusion and cerebrovascular lesions that damage the 
integrity of the blood brain barrier (BBB) [23-25]. The manifestation of these pathological 
conditions eventually leads to neurovascular dysfunction, neuronecrosis, cognitive decline, 
and ultimately death [26]. 
 
 
Figure 1.1: Cross-sectional comparison between normal brain and atrophied brain in advanced AD.  
(Original figure but the images are modified [7, 27-29]). 
 
1.2.2. Amyloid Precursor Protein   
The misfolded proteins, Aβ peptides, that are present in AD are derived from the metabolism 
of a transmembrane protein called amyloid precursor protein (APP) [30]. APP is considered 
to be a molecule with diverse functionality, expressed ubiquitously in cells throughout the 
body with 3 main isoforms identified in humans, namely, APP695, APP751 and APP770, 
generated by alternative splicing of its mRNA transcript [30, 31]. APP isoform ratios differ 
depending on the tissue types [31]. For example, APP695, is mainly expressed by neuronal 
cells and lacks the Kunitz-type serine inhibitory domain (KPI), while, KPI is present in the 
extracellular domain of isoforms APP751 and APP770 that are mainly expressed by platelets 
and peripheral cells [32, 33]. Processing of APP follows two alternative pathways, non-
amyloidogenic and amyloidogenic.  
In the non-amyloidogenic pathway, the sequential cleavage of APP by membrane-bound 
proteases, namely α- and γ-secretases, generates a large soluble extracellular APPα fragment 
(sAPPα), via ectodomain shedding, and a membrane-tethered intracellular C-terminal 




fragment (C83) that is further cleaved by γ-secretase to generate P3 and APP intracellular 
domain (AICD) fragments [14, 34, 35] In the amyloidogenic pathway, β-, instead of α-secretase, 
together with γ-secretase, cleaves APP producing sAPPβ and C-terminal fragment (C99) that 
is also subjected to further γ-secretase proteolysis causing the liberation of Aβ peptides. Due 
to the fact that final γ-secretase proteolysis is not single-site specific, a variety of Aβ peptide 
species can be generated ranging from 37 up to 43 amino acids in length, with Aβ1-40 and 
Aβ1-42 being the most common species produced  [14, 34, 35].  
Under normal physiological conditions, the ratio of Aβ1-42 to Aβ1-40 in the brain is ~1:9, 
but in AD this ratio is altered and favours Aβ1-42 to Aβ1-40 [36].The hydrophobic and 
fibrillogenic nature of the longer Aβ peptides mean that they have a higher tendency to 
aggregate, especially Aβ1-42, which is the most commonly produced species in the brain [37, 
38]. This can result in the transformation and misfolding from soluble monomeric species to 
more toxic oligomeric, protofibrils and then fibrils, which constitutes the majority of 
amyloid senile plaques observed in AD brains [38, 39]. Figure 1.2 summarises APP metabolism 
and the physiological and pathological roles of its by-products.  






Figure 1.2: Summary of APP proteolytic processing in the amyloidogenic and non-amyloidogenic 
pathways, and putative physiological and pathological roles of APP and its generated fragments.  
(Created from [30, 34, 40-44])  
 
The aberrant build-up of aggregated Aβ fragments is a consequence of the imbalance 
between the rate of its production and clearance mechanisms [45]. 
 
1.2.3. Aβ peptide Production and Clearance  
Physiological metabolism and homeostatic balance between Aβ production and clearance 
are maintained via several pathways throughout the body. In the central nervous system 
(CNS), Aβ is produced (predominantly Aβ1-42) by various brain cells, such as, astrocytes, 
oligodendrocytes, microglia, and neurons [46, 47]. Aβ is also produced (predominantly Aβ1-




40) by peripheral cells, such as, endothelial cells, platelets, fibroblasts, skeletal myocytes 
and osteoblasts [47, 48]. 
In the brain, several mechanisms are utilized for Aβ clearance and they involve receptor-
mediated efflux (via lipoprotein receptor-related protein 1 or 2 (LRP1/2) and ATP dependent 
efflux transporter P-glycoprotein (P-gp)) of free Aβ and Aβ-bound to chaperone molecules 
(i.e. apolipoprotein E (ApoE) (APOE ε2 and ε3), ApoJ (Clusterin) and α-2-macroglobulin) 
into blood circulation across the blood brain barrier (BBB) [48, 49]. Aβ can also be cleared 
through transportation across the blood-cerebrospinal fluid barrier (BCSFB), by 
cerebrospinal fluid (CSF) absorption, and interstitial fluid (ISF) bulk flow drainage into the 
circulatory and lymphatic systems [50]. 
Extracellular soluble and oligomeric Aβ can be subject to degradation by proteolytic 
enzymes (e.g. neprilysin (a major amyloid-degrading enzyme that plays an important role 
neuropeptide signalling termination and brain function, but its activity decreases with age)[51-
53], insulin-degrading enzyme (IDE; degrades both insulin and Aβ peptides and its activity 
is also decreased with age) [53, 54], endothelin converting enzyme 1 and 2 (ECE-1 and ECE-
2; plays regulatory role of Aβ levels in the brain) [53, 55], angiotensin-converting enzyme 
(ACE; known to play a central role in renin-angiotensin system (RAS) for blood pressure, 
sodium, and body fluid maintenance) [56], plasmin, tissue plasminogen activator (tPA), and 
matrix metalloproteinases) [53, 57, 58]. Moreover, neuronal and glial cells can take up soluble 
Aβ via phagocytosis, endocytosis, and micropinocytosis and subject it to intracellular 
proteasomal and lysosomal degradation [59]. There are peripheral endogenous antibodies 
against Aβ and chaperone/bindable substances that are able to enter and exit the brain at low 
levels and have the ability to prevent Aβ aggregation and resolve Aβ fibrils [60]. 
Aβ present in the periphery is systemically cleared via peripheral cells, tissues or organs. 
This includes Aβ uptake and degradation via phagocytosis or endocytosis by immune cells 
(i.e. monocytes, macrophages, and neutrophils); Aβ clearance by blood-mediated proteins 
and cells (e.g. erythrocytes, albumin, and lipoproteins such as apolipoprotein E); or excretion 
from the body via the kidney or liver [48, 61-63]. A summary of Aβ production and clearance 
is presented in Figure 1.3. 






Figure 1.3: Normal physiological maintenance of the homeostatic balance between Aβ production and 
clearance in the brain and the periphery.  
Aβ is produced by a variety of neuronal and glial cells in the brain and also by peripheral cells throughout the 
body such as skeletal muscle cells (myocytes), platelets, osteoblasts (bone cells) and skin fibroblast. Aβ is 
mainly transported across the blood brain barrier (BBB) by receptor-mediated influx (RAGE- receptor for 
advanced glycation end products) and efflux by lipoprotein receptor-related proteins (LRP) and ATP dependant 
efflux transporter P- glycoprotein (P-GP) on endothelial cells. In the central nervous system (CNS), Aβ is 
subjected to various clearance mechanisms which include intracellular phagocytic degradation by 
neurovascular unit cells or extracellular proteolytic enzymatic degradation. Aβ is also released following 
interstitial fluid (ISF) bulk flow or cerebrospinal fluid (CSF) drainage pathways. Aβ clearance can also occur 
by preventing its aggregation and resolving fibrils through the entrance of peripheral anti-Aβ autoantibodies 
and chaperone/bindable substances into the brain at low levels. Anti-Aβ autoantibodies bound to Aβ that is 
present in the periphery can also act as a peripheral sink to promote the Aβ efflux from the brain. In the 
periphery, some Aβ can be phagocytosed by blood cells, degraded by proteolytic enzymes, and some may bind 
to carriers that are transported to peripheral cells or organs for degradation and excretion from the body. Created 
and modified from [48, 62]. RBCs: red blood cells; ApoE: apolipoprotein E.  
 




1.2.4. Amyloid and Vascular Hypotheses of AD Onset and Development 
There are many theories that describe AD pathogenesis that are evidenced or still postulated. 
Several preliminary genetic studies found a number of familial mutations associated with 
the gene (APP) and also in the genes encoding γ-secretase catalytic subunits presenilin-1 or 
2 (PSEN1/2). These mutations can lead to pathological overproduction of Aβ, which can 
ultimately result in its accumulation and oligomerisation and eventually lead to early onset 
of Alzheimer’s disease (EOAD, age<65 years) [64, 65]. The formation and presence of cerebral 
amyloid plaques has been considered the primary pathological hub that leads to AD 
development as a consequence of their neurotoxic effects [64]. Therefore, the notion of 
“amyloid cascade hypothesis” was put forward as the main cause of AD, where aberrant Aβ 
deposition serves as the initial trigger to subsequent formation of NFTs, neurodegeneration, 
and dementia [41, 64]. 
However, this hypothesis accounts as a main cause for only 5% of gene-mutations related to 
EOAD, but does not account for the rest 95% of sporadic or late onset AD (LOAD, age>65 
years) cases [66]. In the late onset form of AD, the underlying causality remains unknown due 
to its multifactorial nature. The increased risk of this form of AD has been associated with 
several genetic and non-genetic or environmental risk factors that most likely results in the 
failure of Aβ clearance mechanisms and not necessarily its overproduction [45, 67]. Genetic 
risk factors involved in LOAD include: certain TREM2 variants that expresses partial 
functional loss of TREM2 protein (a receptor aid in the uptake and clearance of Aβ by 
microglia cells) [68, 69]. In addition, individuals carrying ε4 allele of the apolipoprotein E gene 
(APOE) are at a greater risk of developing LOAD [70]. APOE gene exists as 3 polymorphic 
alleles (ε2. ε3, and ε4) and apolipoprotein E (ApoE) protein is a cholesterol transport protein 
that regulates lipid homeostasis by mediating its transport from one cell type to another [71]. 
ApoE is primarily synthesized by astrocytes and microglia in CNS, while in the peripheral 
tissues is mainly produced by the liver and macrophages [71, 72].  
Aside from lipid transport, ApoE protein shown to play an important role in Aβ metabolism, 
where it facilitates Aβ uptake through cell surface receptors, e.g. LRP1 and LDLR (low 
density lipoprotein receptor), in an isoform-dependent fashion (E2>E3>E4) and influences 
the transport of Aβ within the CNS and also the formation of parenchymal amyloid plaques, 
especially with carriers of ApoE4, as it shown to be less effective in promoting enzyme-
mediated degradation of Aβ and direct Aβ clearance due to its lower binding affinity 
compared to ApoE3 and ApoE2 [71, 73, 74]. In addition, ApoE-ε4 genotype expression is found 
to be much higher in AD patients than age-matched control and thus contributing towards 




increasing the risk of AD by initiating and accelerating Aβ accumulation, aggregation and 
deposition in the brain. Other risk factors that may contribute towards the development of 
LOAD includes, ageing, hypercholesterolemia, obesity, type 2 diabetes, hypertension, and 
traumatic brain injury [75-80]. 
Epidemiological studies and post-mortem pathological examination have highlighted the 
substantial overlap between vascular risk factors and cerebrovascular dysfunction and AD 
[65]. These studies revealed significant shared pathophysiological correlations of AD with 
vascular diseases such as, hypertension, atherosclerosis, CAA, atrial fibrillation, 
macro/micro-infarcts, and strokes (ischemic and haemorrhagic) [81-84]. Numerous 
morphological and functional cerebrovasculature abnormalities were observed showing 
compromised BBB including altered endothelium processes, basement membrane 
thickening, and disruption due to collagen IV, laminin, proteoglycan deposition, intimal 
atrophy and decreased cerebrovascular density [30, 85].  
Experimental and neuroimaging observational studies on humans and AD animal models 
have proposed that cerebrovascular dysfunction precedes the development of cognitive 
decline and AD pathology, [30, 86, 87] placing forward the idea of vascular dysfunction or 
“vascular hypothesis” as a potential cause of AD pathology [30, 88]. The vascular hypothesis 
proposes that advanced ageing, cardiovascular and cerebrovascular risk factors, such as 
arterial stiffness, atherosclerosis, hypertension, dyslipidaemia, diabetes type 2, smoking, 
obesity, and CAA, can lead to chronic cerebral hypoperfusion and diminished oxygen 
delivery and blood flow to the tissues and brain [30, 88]. This can result in the accumulation of 
Aβ and other blood-derived neurotoxic molecules, BBB breakdown, abnormal 
microvascular remodelling, and eventually the development of ischemic lesions and 
microhemorrhages causing neuronal injury, neurodegeneration, and cognitive deficits [30, 88, 
89].  
It has been reported that early vascular dysfunction of BBB affects neurovascular unit cells 
(i.e. endothelium, pericytes, vascular smooth muscle cells, neurons, and glial cells 
(astrocytes, microglia, and oligodendroglia) [90].  Pericytes regulate pivotal neurovascular 
functions necessary for neuronal homeostasis, such as, blood flow regulation in capillaries 
and toxic cellular by-products clearance, vascular stability and structure, and BBB formation 
and maintenance [91]. Recent studies highlighted the link between pericyte loss and/or 
malfunction (even in the absence of Aβ) and sufficient vascular-medicated and AD-like 
neurodegeneration [90-94]. Normally, pericytes facilitate Aβ clearance and degradation via 
their LRP-1 receptor. However, reduction of the number of pericytes and increased Aβ 




accumulation in the brain can lead to increased uptake and cellular saturation of Aβ resulting 
in its degradation, thus contributing to further loss of perivascular cells [85, 95]. Pericyte loss 
and/or degeneration were observed in both the hippocampus and the cortex in human AD 
subjects and that is associated with key attributes of AD vascular pathology [93, 96].  
Interestingly, many enzymatic proteins involved in Aβ-degradation and clearance also have 
vasomodulatory and cardiovascular roles that have been shown to be altered in AD subjects 
thus further compromising the vasculature. One of these proteins is neprilysin (NEP), 
cleaves numerous cardiovascular vasoactive peptides, and has vasodilatory or 
vasoconstrictive effects, but its expression found to be reduced in AD brains [55, 97-99]. ECE 
is also known to hydrolyse big endothelin (ET) molecules into smaller vasoactive molecules 
that act as potent vasoconstrictors, in addition to other biologically active peptides, such as 
bradykinin, which contributes significantly to the physiological maintenance of human 
vascular tone [100, 101].  The two ECE isoforms (ECE-1 and ECE-2) have similar biological 
activity but few studies have shown elevated expression of ECE-2 that was also influenced 
by Aβ [102], while no significant difference on ECE-1 expression was documented in AD 
subjects [103]. However, overexpression of ECE-1 was shown to have a protective effects 
against AD [104, 105]. Abnormalities in the expression of ECE and accumulation of Aβ can 
result in the reduction of blood flow in local microvasculature and the potential development 
of CAA, but how significant the contribution of ECE expression abnormalities towards AD 
progression, is yet to be clarified.  
Other important Aβ-degrading enzymes are angiotensin converting enzymes (ACEs) that 
also play a key regulatory role in the renin-angiotensin system (RAS), which is an important 
hormonal system that maintains fluid homeostasis, and blood pressure regulation [106]. Renin 
present in plasma cleaves inactive angiotensinogen released by the liver into angiotensin I 
(Ang-I) which is then converted into a potent vasoconstrictor, angiotensin II (Ang-II), via 
the activity of ACEs. Ang-II acts on its receptors AT1R and AT2R throughout the body, 
thus exerting its hypertensive effects [106-108]. Under pathological conditions, RAS plays a 
critical role in the pathogenesis of hypertension, and can contribute towards associated 
cardiovascular diseases (CVDs) at variable severity, atherosclerotic lesions that compromise 
blood vessel integrity, and eventually the development of late onset AD and CAA (the 
sequence of these events is also referred to as the angiotensin hypothesis for AD) [107, 109-112]. 
Several components of RAS have been found to be altered in AD subjects including an 
increased perivascular ACE-1 activity with direct correlation to parenchymal Aβ load [113], 
and decreased activity of its homologue ACE-2 (the counter-regulatory enzyme that 




degrades Ang-II to angiotensin and provides other additional vaso-protective effects) which 
is correlated inversely to ACE-1 activity and Aβ levels [114, 115].  Taking together the studies 
mentioned previously, a great number of pathogenic pathways relevant to cerebrovascular 
alteration and dysfunction are suggested as primary triggers and risk factors for neuronal 
dysfunction, which further supports and favours the vascular hypothesis as the initial trigger 
of late onset AD.  
 
1.3. CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER’S DISEASE 
The presence of cerebral amyloid angiopathy (CAA) and atherosclerosis are considered the 
most prominent vascular lesions found in AD, with 80-100% of cases exhibiting CAA [116, 
117]. Around 25% of AD patients have severe forms of CAA, while the majority have a 
moderate form, and it is also present in 30% of normal aging individuals >60 years of age 
[118]. In both sporadic and familial AD, the type of CAA associated with it occurs in sporadic 
form itself, while the hereditary form of CAA are generally rare and has an early onset with 
severe clinical manifestation [119]. The term CAA is given to describe the progressive 
deposition of Aβ peptides containing all Aβ forms but with higher ratio of Aβ1-40 to Aβ1-
42 compared to the ones in senile plaques. Aβ peptides deposition occurs within neocortical 
and leptomeningeal small to medium sized arteries, especially areas of the vessel 
surrounding smooth cells, adventitia and the luminal side of tunica media [120-122]. Based on 
the presence or absence of Aβ in the capillaries, CAA was classified into 2 types: CAA-type 
1 and CAA-type 2. In CAA-type 1, Aβ deposits in arteries and cortical capillaries and it is 
strongly associated with ApoE ε4 allele, but it is not associated with CAA-type 2 where Aβ 
deposits in bigger blood vessels and lacks the involvement of capillaries [123, 124].  
 
1.3.1. Clinical Manifestation of CAA 
Histological neurovascular alteration and deposition of amyloid peptides was initially 
described by Gustav Oppenheim in 1909 from autopsies of AD and demented brains [125]. 
Oppenheim found similarities between deposited substances found within degenerating 
blood vessel walls and substances found adjacent to necrotic brain parenchyma, and since 
his original finding, significant evidence has emerged to support his observations [125, 126]. 
There are 3 CAA severity levels that can be distinguished they include: mild CAA (Aβ 
mainly deposits in the outer basement membrane of the blood vessel wall), moderate CAA 




(Aβ deposits in the outer basement membrane and between smooth muscle cells (SMCs), 
and severe CAA (extensive Aβ infiltration and focal fragmentations of the vessel wall and 
replacement of the other surrounding layers of the blood vessel) [123, 127, 128]. In severe CAA, 
loss of SMCs is apparent in tunica media with detachment and delamination of its outer layer 
causing a “double barrel” appearance, intimal alteration, fibrinoid necrosis and micro-
aneurysm formation, perivascular leakage, microbleeds and inflammation (vasculitis) [128-
132] (see Figure 1.4 for illustration). Ultimately this leads to vascular cerebrovascular 
degeneration, impaired blood flow and hypoperfusion, which further exacerbate the damage 
and contributes to the progression of cognitive decline [129, 133]. Clinical manifestations of 
CAA are associated with ischemic and intracerebral haemorrhages, cerebral infarcts, 
transient ischemic attacks, dementia, subarachnoid haemorrhage, and seizures [134, 135]. 
 
Figure 1.4: Types and development of CAA [123].  
 
1.3.2. Sources and Mechanisms of Aβ Deposition in CAA  
The sources and underlying mechanisms of the Aβ vascular deposits that lead to CAA are 
not well understood. There are three key hypotheses proposed with regards to the origins of 
Aβ observed in CAA: the vascular, systemic, and drainage hypotheses [136].  




The vascular hypothesis suggests that Aβ found in CAA is derived from vascular wall 
constituents, i.e. endothelial cells, smooth muscle cells (SMCs), pericytes, adventitia, etc., 
as they have been shown to express APP and produce Aβ [137-139]. Several experimental 
studies have shown that overexpression of APP and overproduction of Aβ take place in 
cultured SMCs and human cerebral perivascular cells that were degenerating [120, 140, 141]. 
However, contrary observations on how larger arteries are less affected in severity to CAA 
than arterioles or capillaries despite the large number of vascular cells and layers, might 
indicate that Aβ produced by the vessel walls might not be the sole origin of Aβ in CAA 
[142].   
The systemic hypothesis puts forward the notion that Aβ in CAA is primarily of 
haematogenous origin and it originates in the circulation from various APP-expressing cells 
throughout the body and enters the cerebral vessel walls and brain via a receptor for 
advanced glycation end-products (RAGE) [119, 136, 143]. A counterargument to this proposed 
hypothesis was raised when studies on transgenic mice inducing constitutive overproduction 
of human APP C-terminal fragment (C99) in multiple tissues showed significantly elevated 
plasma Aβ levels (approximately 17 times higher when compared to human Aβ plasma 
levels) [144]. However, no Aβ deposits occurring in cerebrovasculature were found in these 
mice up to age 29 months with the exception of some transgenic mice of one founder line, 
where Aβ deposits in the intestine were observed [144].  
In the drainage hypothesis, it has been suggested that neuronal and glial cells are the source 
of vascular Aβ and this occurs due to failure of Aβ clearance from the brain along the 
perivascular lymphatic drainage pathway. Normally when Aβ is produced in the brain, it is 
cleared by its release from brain cells into the brain parenchyma extracellular space, and then 
into the capillary basement membrane from where it is drained and carried away by 
interstitial fluid (ISF) to arterial basement membranes. Aβ is then joined with other locally 
originated vascular wall Aβ and together they are carried away and out of the brain along 
the periarterial pathway via arterial pulsation [45, 142, 145, 146].  
Soluble Aβ movement and clearance is reduced along the vessel wall usually with aging and 
also under vascular damage or onset of arteriosclerosis, which affects vascular tonality 
causing rigidity and decrease in arterial pulsation amplitude [147]. Consequently, soluble Aβ 
precipitation and the formation of insoluble amyloid β-sheet aggregates occurs, which 
impedes further Aβ elimination resulting in CAA [148]. This Aβ blockage also affects the 
clearance of brain solutes, metabolites and fluids causing disruption to brain homeostasis [45, 
60, 149]. As a result, not only is Aβ metabolism affected in the brain, but it also invites a host 




of other complications along with it including chronic inflammation, oxidative stress, blood 
hypoperfusion and pathological thrombus formation [150]. This further contributes to 
cerebrovascular damage, aberrant Aβ accumulation in the brain and blood vessels, and 
ultimately impairment in neuronal function [150]. Platelet activation has a fundamental role 
in thrombus formation and increasing evidence suggests their potential role in mediating the 
onset and development of CAA [151-153], since they also contain APP and have been shown 
to contribute >90% of Aβ in circulation [154-157].  
 
1.4. PLATELETS AND ALZHEIMER’S DISEASE 
1.4.1. Platelet Overview 
Platelets are small enucleated discoid-shaped fragments released during megakaryocyte 
maturation processes and range in size from 2-4 µm in diameter [158, 159]. They are normally 
present at a physiological count of 2 to 3 x 108 / ml in human blood with a life span of about 
10 days, whereupon they are transported to the spleen and removed from the circulation by 
neutrophils and macrophages [159]. Platelets are well known for their regulatory role in blood 
haemostasis and thrombosis, and their primary physiological aim is to prevent blood loss 
when blood vessels are injured by forming a platelet plug or clot at the site to seal the wound 
[160]. Platelets show versatility in their function in both health and disease due to their 
substantial content of receptors and secretory molecules, and they have been shown to act as 
a central hub mediating immunity, tissue repair, inflammation, cancer metastasis, 
angiogenesis, and thrombosis [161-167].  
1.4.2. Platelet Morphology 
Structurally, platelets consist of a standard biological phospholipid bilayer plasma 
membrane embedding an asymmetrical distribution of a wide range of constituents which 
include: neural membrane phospholipids, e.g. phosphatidylcholine and sphingomyelin 
(SPH); polar phospholipids e.g. phosphatidylinositol (PI), phosphatidylethanolamine (PE), 
and phosphatidylserine (PS); esterified cholesterol; integral transmembrane proteins; and a 
carbohydrate-enriched surface membrane coating, called glycocalyx, consisting of 
glycoproteins, proteoglycans, glycolipids, glycosaminoglycans, and oligosaccharides [168]. 
Upon platelet activation, the platelet surface membrane provides a pro-coagulation platform 
by rearranging its membrane composition and exposing its negatively charged phospholipids 
[168, 169]. In AD, there is an increased internal membrane fluidity[170], an altered ratio of 
cholesterol to phospholipid [170], and altered APP fragments[171]. 




The platelet surface plasma membrane also possesses a unique membrane system where the 
membrane invaginate inwards forming a cavity or canal, referred to as surface-connected 
open canalicular system (OCS). This provides an additional membrane reservoir that can be 
utilized for platelet shape change and spreading post-activation, and also as a bidirectional 
exchange area of substances between the platelet and plasma [172]. A remnant of the 
megakaryocyte rough endoplasmic reticulum called the dense tubular system (DTS), 
presenting intracellularly and aligned closely to OCS, provides the main storage sites for 
free calcium ions (Ca2+), and enzymes involved in platelet activation, such as, phospholipase 
A2 (PLA2), thromboxane synthetase (TBXAS), and cyclooxygenase (COX) [168, 173].  
The convex morphology of platelets is maintained by the circumferential microtubule system 
and the micro- and intermediate filament (actin filaments) network. Actin is a highly 
conserved protein present in a dynamic equilibrium inside the cell between the globular (G-
actin) and polymeric filamentous form (F-actin), which can reversibly disassemble into G-
actin subunits. The dynamics of both forms of actin are regulated by actin-binding proteins 
[168, 174] .  
 
Figure 1.5: Summary of discoid platelet structural features seen from an equatorial plane view.  
(modified from [173]) 
 
Platelet cytoskeleton reorganisation occurs upon platelet activation, where an increase in 
intracellular calcium (Ca2+) induces the polymerisation of G-actin into F-actin in the 
intracellular submembrane area and the rapid formation of newly bundled actin filaments 
pushes the plasma membrane to form filopodia causing shape change [175]. Platelets contain 
different important cytosolic organelles aside from their cytoskeletal components, and they 
include specific secretory vesicles (α-granules, dense granules), lysosomes, peroxisomes, 




glycosomes, free cytoplasmic glycogen, and a few randomly dispersed mitochondria[174]. A 
summary of platelet structure is shown in Figure 1.4.  
Activated platelet secrete more than 300 active substances from their intracellular granules. 
Dense granules or dense bodies usually contain small pro-aggregation molecules, such as, 
Ca2+, ADP, serotonin and ATP. On the other hand, platelet α-granules carry a cargo of 
diverse soluble proteins and membrane receptors categorized into adhesive proteins (e.g. P-
selectin, fibrinogen, αIIbβ3, von Willebrand factor), mitogenic and angiogenic factors (e.g. 
platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
transforming growth factor β (TGFβ)), cytokine-like proteins (e.g. β-thromboglobulin, PF4), 
coagulation factors (e.g. plasminogen, factor V, factor XI), chemokines and immune 
mediators (e.g. RANTES, CXCL1, complement C4, IgG), as well as an interestingly high 
content of APP and Aβ peptides [161, 176].  
 
 
1.4.3. Platelet Role in Haemostasis  and Thrombosis 
Haemostasis is an intricate physiological process that occurs to prevent blood loss or 
haemorrhage from damaged blood vessels by sealing the injury with a localized clot while 
maintaining blood fluidity within the circulatory system [177]. This highly complex process 
provides a regulated interactive balance between blood vessels, platelets, plasma coagulation 
factors, and fibrinolytic proteins involved in blood clot formation or dissolution [177, 178] . 
Thrombosis on the other hand, is the pathological formation and development of blood clots 
within the blood vessels, both in arteries and veins, which can obstruct blood flow, impede 
blood vessel function, and lead to serious medical consequences [167, 177]. Under normal 
physiological conditions, the vascular system is under haemostatic balance, where 
procoagulant, anticoagulant, and fibrinolytic components are in equilibrium [179]. If the 
procoagulants are too active, this may lead to spontaneous thrombus generation causing, for 
example, deep vein thrombosis (DVT) and pulmonary emboli when present in veins, or 
myocardial infarction (heart attack) and strokes when present in the arteries [179, 180]. If the 
anti-coagulant or fibrinolytic proteins are too active, then bleeding problems will occur [177, 
180]. Response to vascular injury occurs in two main phases called, primary haemostasis and 
secondary haemostasis [178].  
 





Vasoconstriction is the earliest and most short-lived response to a vascular injury and can be 
initiated from various sources [181]. These include nerve endings around the injured site, 
where it is called neurogenic reflex vasoconstriction (NRF), myogenic constriction (MC) 
from injured smooth muscles [182], or endothelin release from injured endothelial cells that 
then acts on smooth muscles and contracts them [182, 183]. This event occurs instantaneously 
and is most relevant to minor injuries of small vessels to reduce blood loss and increase local 
shear forces [181]. Vascular injury also causes direct exposure of blood components to the 
sub-endothelial extracellular matrix (ECM) of blood vessels, which contains several 
adhesive proteins, such as collagen fibres, laminins, von Willebrand factor (VWF), 
fibronectin, and tissue factor (TF) [184]. These proteins serve as ligands that play a key role 
in the activation of specific platelet membrane receptors and their immediate adhesion to the 
injury site [185].  
Platelets and Blood Flow  
The localisation and adhesion of circulating platelets towards vascular injury sites is 
generally determined by local hemorheological and hemodynamic factors, such as blood 
density, velocity, shear rate, and vessel wall shear stress [186, 187]. Within the cardiovascular 
system, the normal fluidic motion of the blood in the vessels is in a laminar flow moving 
with a parabolic profile, where concentric layers of blood move in parallel along the length 
of the blood vessel with blood nearest the vessel wall having the lowest velocity (V=0), due 
to high blood-vessel wall friction [188, 189] .As the blood layers slide past one another moving 
forward and away from the vessel wall towards the centre of the lumen, they progressively 
increase in velocity to reach the highest value (Vmax) at the centreline 
[188]. Blood velocity 
can be described as the rate of linear displacement of the blood within the circulatory system 
and it is inversely proportional to the cross-sectional area of the vessel through which the 
blood is passing. The high velocity at the centre generates shear forces between adjacent 
blood layers that progressively becomes maximal towards the vessel walls [188, 189]. Shear 
rate is defined as the velocity nearest to the vascular wall divided by blood flow distance 
from the wall, while wall shear stress is the force exerted on the vessel wall by the near-wall 
fluid [187]. The shear stress is dependent on blood viscosity (blood density) and wall shear 
rate [187, 188].  
Constriction or obstruction of the blood vessel causes narrowing of the lumen, which can be 
imposed by stenotic, atherosclerotic, or thrombotic lesions. As the streamline blood flow 
passes, the layer of the blood is disturbed and the parabolic arrangement is disrupted 




resulting in turbulent blood flow, where blood is now moving radially and axially with 
different streams having different velocities. In these conditions, higher physiological shear 
rates and shear stresses occur, as the relationship is inversely proportional to the cross 




Figure 1.6: Summary of parabolic velocity profile and blood flow properties under physiological and 
pathological conditions.   
Blood flows through the blood vessel in a laminar fashion with a parabolic profile. This results in minimum 
shear rate and maximum velocity at the centre of blood streamline, progressively changing to maximum shear 
rate and minimum velocity when it reaches the vessel wall. Blood flow profile changes to become turbulent, 
generating radial and axial streams that have different velocities, when there is an obstruction within the vessel 
lumen, such as, stenotic or atherosclerotic lesions. (Original figure modified from [187-189]).  
 
In normal physiological blood flow conditions, vascular wall shear rates range from low 
values in venous systems, generally between 20-200 s-1 (per second), to higher wall values 
in arterial systems ranging between 300-1600 s-1. However, under pathological flow 
conditions, such as in case of stenotic or atherosclerotic arteries, vascular wall shear rate can 
reach up to 40,000 s-1 [187, 188, 190]. In AD, the cerebrovasculature is compromised and is 
shown to have diminished blood flow, resulting in brain hypoperfusion and contributing 
further to the progression and pathogenesis of AD [191, 192].  
Within the circulatory system, red blood cells (RBCs or erythrocytes) dominate the cellular 
constituents of the blood, comprising 40% of total cell mass. Due to their physical 
deformation and rotation within the blood stream, they create erratic motion and migrate 
laterally toward the central axis of the stream causing local stirring of the flow [187, 189, 193]. 
This mechanism expels and diffuses circulating platelets and white blood cells (leukocytes) 
away from the blood central streamline in the lumen towards the periphery allowing it to 
occupy regions near the vessel wall [187, 193]. Consequently, this arrangement allows platelets 




to be regulated in close vicinity by healthy endothelial cells and also allows them to perform 
their physiological role in case of endothelial damage [193].  
 
Mechanisms of Platelet Adhesion, Activation, and Signalling 
As the platelets travel throughout the body, they exist in an inactivated state. However, upon 
encountering exposed ECM, platelets can become activated by binding directly or indirectly 
to several ECM proteins, as they possess multiple cell-surface adhesion receptors or by 
exposure to agonists present in the vicinity of exposed ECM [184]. This process can occur at 
both low and high shear flow conditions, but the mechanism by which platelets adhere to 
receptor sites is distinct in the two cases [186, 194]. Under low shear rate conditions, such as in 
veins and large arteries, platelets are able to adhere directly to exposed collagen, fibronectin, 
and laminin, and become activated forming a monolayer of cells (thrombi) to cover the injury 
site which contains relatively more trapped RBCs and a fibrin network [195, 196]. On the other 
hand, under high shear rate conditions, such as in small arteries and stenotic vessels, platelets 
are unable to bind directly to the injury site, thus their adhesion is predominately facilitated 
by the interaction of the GPIB-V-IX receptor complex with VWF present in the exposed 
ECM [195, 197]. Since higher concentrations of platelets are marginalized towards the vessel 
wall under these conditions, thrombus growth increases rapidly resulting in platelet-rich 
thrombi “white thrombi” containing less fibrin and are deprived of trapped RBCs [195, 196]. 
Primary platelet adhesion occurs when circulating VWF binds to exposed collagen at the 
vascular injury site [195, 196].  
 
Collagen  
Collagen is a potent highly thrombogenic platelet activator and the most abundant protein 
found in the body (abound 30% of total protein mass) [198]. Collagen is considered a main 
component of ECM and is usually present in a fibrillar form. Collagen is a triple-stranded 
helical molecule consisting of 3 polypeptide chains twisted together into a helix [199]. The 
structural orientation is stabilized by electrostatic interactions and hydrogen bonds formed 
among its characteristic repeating three amino acid motif of proline, hydroxyproline, and 
glycine [199]. The triple helix strands can assemble into bigger molecular complexes like 
fibrils, but that depends upon the type of collagen present. Humans carry more than 25 forms 
of collagen with types I, II, III, IV, V, VI, VIII, XII, XIII and XIV found in the vascular wall 




[198, 200, 201]. The most abundant fibrillar collagen types found in the superficial luminal layer 
of the vascular wall (accounting for 80-90% of total collagen in blood vessels), are type I 
and type III, while in the deeper layer (subendothelial basement membrane) collagen type 
IV is found [199, 201, 202]. Platelets express three main receptors that facilitate the interaction 
with exposed collagen, either indirectly, via its GPIB-V-IX receptor complex that binds to 
VWF on collagen or directly via integrin α2β1 and immune receptor homologue 
glycoprotein VI (GPVI) receptors. VWF can adhere to collagen types I, II and VI firmly 
facilitating GPIB-V-IX interaction, while GPVI and α2β1 binding affinity varies depending 
on the different regions of exposed collagen fibrils [201, 203]. In general, collagen is a powerful 
inducer of platelet activation and supports their adhesion and aggregation.  
 
Von Willebrand Factor (VWF) and GPIB-V-IX 
VWF is a glycoprotein present in circulating blood that exists as a heterogeneous mixture of 
multimers varying in size and linked by disulphide bridges [204]. Smaller multimers are 
constitutively secreted into the plasma by endothelial cells and megakaryocytes, while larger 
multimers are stored within endothelial cells in organelles known as Weibel-Palade bodies, 
and in platelets in α-granules [204]. Larger VWF multimers have higher adhesive efficacy and 
activity than the smaller ones, and thrombogenic effects are maintained and regulated by a 
proteolytic enzyme called ADAMTS13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) [204]. This enzyme cleaves large VWF multimers 
into smaller sizes in the blood circulation hence maintaining normal haemostasis. Reduction 
in the activity of this enzyme can lead to a life-threatening condition called thrombotic 
thrombocytopenic purpura (TTP), where a patient develops microscopic blood clots 
throughout their body [205, 206].  
VWF amino acid sequence analysis shows distinct repetitive domains identified as Domains 
A, B, C, and D, which are arranged in the following sequence: D1-D2-D'-D3-A1-A2-A3-
D4-B1-B2-B3-C1-C2-CK, with several specific domains serving as binding sites [205]. 
Domain A1 is a binding site for glycoprotein Ibα (GPIbα or CD42), which is a component 
of platelet receptor complex GPIB-IX-V, while Domain D'-D3 binds heparin, coagulation 
factor VIII and possibly P-selectin. Domain A2 serves as a cleavage site for ADAMTS13, 
with Domain C1 providing a binding site for integrin αIIbβ3 via its peptide motif Arg-Gly-
Asp (RGD) sequence, and Domain A3 binding to fibrillar collagen type I and III [205].  




The vascular injury site creates local turbulence in the blood flow and brings inactivated 
platelets close enough to it so that the GPIB-V-IX platelet receptor complex binds to 
immobilized VWF on collagen [207]. This triggers platelet downstream intercellular 
stimulation of tyrosine kinases, such as focal adhesion kinase (FAK), and protein tyrosine 
kinase 2 (Pyk2), and spleen tyrosine kinase (Syk) activation, which is mediated through 
clustering and phosphorylation of GPIB-V-IX associated with the Fc receptor γ-chain (FcR 
γ-chain) and the low-affinity receptor for IgG [205, 208-210]. The activation of these tyrosine 
kinases among other intracellular proteins, such as 14-3-3 proteins (commonly isoform 14-
3-3 zeta (ζ)), results in the activation of phospholipase C γ2 (PLCγ2), cytosolic 
phospholipase A2 (cPLA2), and phosphoinositide 3-kinase (PI3K). Several intracellular 
messenger molecules are produced, e.g. diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3), eliciting multiple signal transduction pathways [205, 208-210].  
 
 
Figure 1.7: Simplified diagram for the process of platelet initial tethering, rolling and firm adhesion and 
to collagen through VWF and the three main adhesion receptors as shown. (Modified figure from [211]) 
 
Ultimately, these signalling pathways cause a transient increase in intracellular calcium ions 
(Ca2+), inside-out activation of integrin αIIbβ3 (which promotes platelets aggregation), and 
activation of cytoskeletal and actin-binding proteins, such as filamin, F-actin, talin, and α-
actinin [212]. This mediates the attachment of the GPIB-V-IX receptor complex to the 
cytoskeleton leading to cytoskeleton rearrangement and shape change that includes the 
extension of filopodia [212, 213]. The rapid initial interaction of VWF with GPIB-V-IX receptor 
complex is considered reversible [212, 213]. The hydrodynamic drag forces of blood flow 
causes captured platelets to tether, roll, and translocate along vascular injury site [214]. This 
process slows down the platelets and allows the engagement of two other main important 




adhesion receptors that bind directly to exposed collagen, namely integrin α2β1 (GPIa/IIa) 
and immune receptor homologue glycoprotein VI (GPVI). This results in irreversible firm 
cell adhesion [211-213], as shown in Figure 1.7 which simply demonstrates this process of 
platelet adhesion.  
 
Integrin α2β1 (GPIa/IIa) 
Integrin α2β1 is a class-I transmembrane glycoprotein that exists as non-covalently bound 
heterodimeric complexes of α and β-subunits. Both of these subunits consist of a large N-
terminal extracellular domain, a single hydrophobic membrane-spanning region, and a short 
C-terminal cytoplasmic tail [215]. The extracellular domain of the α2 subunit harbours a 
segment containing 191 amino acids called I (inserted)-domain, which serves as a ligand-
binding site with the aid of divalent metal ions (e.g. Mg2+ and Mn2+), and is considered 
essential for platelet-collagen binding [215]. The extracellular domain of the β1 subunit also 
contains the I-like domain and is thought to regulate α2 I-domain binding affinity. The β1 
subunit is one of three types of integrins present in platelets, and the others are β2 and β3. 
There are three members that belong to the β1 family, that are: α2β1 (binds to collagen), α6β1 
(binds to laminin), and α5β1 (binds to fibronectin) 
[216]. αLβ2 is the only known member of the 
β2 family, and is known as the intracellular adhesion molecule 2 (ICAM-2) that facilitates 
platelet-leukocyte interaction [217]. Platelets contain two important members of the β3 family, 
which are αVβ3 and αIIbβ3 
[216, 217]. The αVβ3 receptor mediates platelet adhesion by binding 
to vitronectin, fibrinogen, VWF, prothrombin and thrombospondin, while integrin αIIbβ3 
promotes platelet aggregation by binding to fibrinogen, VWF, fibrin, fibronectin, 
vitronectin, and thrombospondin [217].  
Integrin α2β1 adhesion to collagen has been shown to play a supportive role to strengthen 
firm adhesion rather than an essential one [218]. The GPVI receptor is considered central to 
mediating platelet adhesion and activation on collagen and it has been shown to upregulate 
integrin α2β1 activity via the inside-out activation, through the GPVI–FcRγ chain complex 
and activation of PLCγ2 [216, 219]. This causes a conformational change of the integrin from 
the closed bent state of α and β subunits to an open active form, where detachment of 
transmembrane and cytoplasmic domains of both subunits occur. Activated integrin α2β1 
allows FAK binding to its cytoplasmic domain resulting in its phosphorylation, which in 
turns activates PI3K converting phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3). This then phosphorylates and activates the 
downstream effector protein kinase B, ultimately resulting in platelet activation. Activated 




α2β1 can also activate PLCγ2 generating a second signalling pathway thus amplifying platelet 
activation [216] [211].  
 
Glycoprotein VI (GPVI) 
GPVI is a paired class-I transmembrane glycoprotein that belongs to the immunoglobulin 
superfamily. It contains two immunoglobulin-like domains and a mucin-like Ser/Thr-rich 
region which are extracellular, a transmembrane region (with a positively charged arginine 
residue), and a short intracellular cytoplasmic tail [215, 220]. GPVI is associated with one Fc 
receptor-γ (FcRγ) chain homodimer via forming a salt bridges between the arginine residue 
within the GPVI transmembrane region and an aspartic acid residue in the transmembrane 
region of the FcRγ-chain. The FcRγ-chain contains an immunoreceptor tyrosine-based 
activation motif (ITAM) that is important in relaying signal transduction [215, 221]. The 
GPVI/FcRγ-chain complex exhibits high affinity towards collagen and upon binding to it, 
crosslinking within the receptor complex occurs, inducing GPVI clustering and 
phosphorylation of ITAM tyrosine residues in the FcRγ cytoplasmic domain by Src-family 
kinases (SFKs), mainly Lyn and Fyn. Subsequently, this leads to engagement and activation 
of Syk, via its two Src-homology 2 domains (SH2), initiating a downstream phosphorylation 
cascade of several adaptor proteins including: transmembrane linker for activation of T cells 
(LAT), lymphocyte cytosolic protein 2 (SLP-76), Vav, Bruton's tyrosine kinase (Btk) and 
Tec kinases (Itk). This causes the activation of phosphoinositide 3-kinase (PI3K) and 
phospholipase C γ2 (PLCγ2) [215, 222].  
PLCγ2 cleaves phosphatidylinositol 4,5-bisphosphate in the plasma membrane to generate 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) causing Ca2+ mobilisation from 
intracellular stores and resulting in an increase in cytosolic Ca2+ levels and activation of 
protein kinase C (PKC) [222]. These molecules are key signalling elements that result in 
platelet response, leading to secretion of the content of granules, arachidonic acid 
mobilization and thromboxane A2 release (activating platelets in an autocrine and paracrine 
fashion by binding to its G protein coupled receptor GPCR), exposure of receptors on the 
platelet surface (e.g. αIIbβ3 expression), membrane phospholipid scrambling, cytoskeletal 
rearrangement, and coagulation initiation [215, 223]. Figure 1.7 illustrates the main platelet 
receptors and corresponding agonists involved in activation and downstream signalling. 






Figure 1.8: Main platelet receptors and their signalling mechanisms involved in initial adhesion and 
activation to collagen.  
(A) Main receptors: both integrins and G-coupled protein receptor (GPCR) with their ligands and the 
consequence of their activation. (B) Main adhesion receptors signalling involved in platelet adhesion to 
collagen and the subsequent activation of aggregation receptor αIIbβ3 (image in A is original, but B is from [224]) 
 
Cytoskeleton Rearrangement 
In this phase of platelet activation, rearrangement of the internal cytoskeleton occurs 
transforming platelets from a discoid shape to highly irregular morphologies with multiple 
filopodial extensions in different directions [175, 225]. This provides an increase in platelet 
surface area and gives them the ability to physically interlock with and adhere to 
neighbouring platelets. Resting platelets contain a pool of G-actin monomers that bind to 
A 
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profilin, forming a G-actin-profilin complex, and F-actin polymers that are capped by 
capping proteins, such as gelsolin [175, 225]. When platelets are activated, an increase in 
intracellular Ca2+ induces dissociation of actin-profilin complexes freeing actin monomers 
that then become available for F-actin growth. Ca2+ also activates free cytosolic gelsolin to 
sever longer F-actin filaments and cap them resulting in shorter F-actin chains [224-226].  
Signal-mediated PIP2 inactivates F-actin- bound gelsolin and F-actin becomes uncapped 
causing rapid filament growth. F-actin filaments are then bundled together with some 
phosphorylated myosin light chain (MLC) and crosslinked by actin bundling proteins, such 
as, α-actinin. Formation of filopodia, which are finger-like projections, occurs by rapid 
growth of actin filaments that push the membrane forward. Branching of growing actin 
filaments is induced by activated PKC that phosphorylates the WAS family of proteins, 
which in turns activates the ARP2/3 complex that acts as the nucleation and branching point 
from which new actin filaments can growth and push the plasma membrane forward to form 
filopodia [227, 228]. Lamellipodia, which are thin-sheet-like structures, are formed when the 
growing actin filaments start to fill the gaps between projecting filopodia, resulting in a 
complex network of actin filaments and the observed spreading morphology [224, 226, 227].    
Secretion of Granule Contents 
The secretion of the platelet granule contents provides concentrated and local delivery of 
key molecular substances at the injury site that amplify platelet activation, mediate adhesion, 
promote migration and activation of other cells, and initiate aggregation and thrombus 
formation [176]. Upon platelet activation, granule centralization occurs concurrently with 
cytoskeletal rearrangement, which appears to play a role in the movements of granules. The 
secretion of granule contents to the extracellular domain is mediated by intracellular vesicle 
fusion with the surface-connected open canalicular system (OCS) in the process of 
exocytosis. The membrane lipid bilayers of both platelets and granule vesicles contain two 
lipid components, PIP2 and phosphatidic acid (PA) that serve as protein attachment and 
signalling sites for membrane fusion [176, 229].  
Normally in the unstimulated state, the opposing lipid bilayer membrane can be in close 
vicinity to one another without fusing. This is due to repulsive electrostatic and hydration 
forces in between the two membranes that require a certain energy to overcome them. Fusion 
of opposing membranes can occur with the aid of a distinct family of proteins known as 
SNARE contained within the lipid bilayers. These membrane-associated proteins are 
orientated in such a way that most of them are cytosolic. The term SNARE, stands for SNAp 




REceptor, where SNAP referred to as Soluble NSF (N-ethylmaleimide-sensitive fusion 
protein) Attachment Protein [176, 228, 230].  
Platelets that contain SNARE proteins are termed vesicle-associated membrane proteins, 
VAMP 3 and 8, which are concentrated on the membranes of granules membrane, while 
SNAP-23, and syntaxin 2 (necessary for dense granule release) and syntaxin 4 (necessary 
for α-granule release) are located in the platelet membrane. Chaperone proteins, such as 
NFS, Sec1 protein (PSP), Rab proteins and their effectors, are able to bind to and direct the 
function of SNARE proteins. SNARE proteins present in the platelet membrane are referred 
to as target or t-SNAREs, and those on the vesicles as v-SNAREs. PSP is associated with 
regulating the docking of vesicles onto t-SNAREs by binding to syntaxin and blocking its 
binding to SNAP-23 in t-SNARE, which is itself important for interacting with v-SNAREs. 
Upon cellular activation, activated PKC can directly phosphorylate certain SNARE proteins 
and their chaperones, including PSP. Phosphorylation of PSP causes conformational changes 
and thus the release of Syntaxin [176, 228, 230].  
The chaperone molecule Rab may interact with PSP through its effector molecules and play 
a role in docking the opposing membranes, however, its precise role in exocytosis remains 
unclear. The N-terminal ends of both t-SNARE and v-SNAREs become closely associated 
with their respective coiled-coil domains and form a 4-helix bundle ternary complex termed 
the exocytotic core complex. This complex is capable of overcoming the energy barrier 
normally present between opposing membranes and results in membrane fusion and the 
release of granule contents. The process of exocytosis and storage granule release serves to 
amplify platelet activation at the injury site and recruitment of inactivated platelets in the 
circulation towards it [176, 228-230].  
The bioactive molecules released from alpha and dense granules act in an autocrine and 
paracrine fashion, thus initiating a positive feedback cascade and promoting rapid platelet 
aggregation and primary platelet plug formation.  Some of the most potent soluble platelet 
agonists released are adenosine diphosphate (ADP), platelet-derived thromboxane 
A2 (TxA2), and thrombin, which act synergistically to induce full platelet activation and 
more surface expression of membrane-bound and soluble proteins, e.g. integrin αIIbβ3, GPVI, 
platelet endothelial cell adhesion molecule (PECAM), and P-selectin, CD63, fibrinogen, 
more VWF. The release of adhesion proteins such as fibrinogen and VWF contributes to 
platelet-platelet adhesion mainly via integrin αIIbβ3 and contributes to thrombus growth 
[176, 
229]. Table 1.1 summarises the major constituents and bioactive molecules present in platelet 
granules.  








































GTP binding proteins  
     Ral1  
Glycoproteins   
     GPIb,  
     GPIIbIIIa  
Granulophysin  
      LIMP1/CD63 
LAMP2  
Src  
P-selectin (CD62)  
Adenine nucleotide  
     ATP  





Guanine nucleotides  















































GTP binding proteins   
     rab4,  
     GMP33,  
     Rap1 
Receptors & antigens  
     P-selectin (CD62) 
     GPIIbIIIa 
     GPIb-XI  
     GPIV (CD36) 
     p24 (CD9)  
     PECAM (CD31) 
     GLUT-3  

































     Platelet specific 
          βTG,  
          PF4. 
     βTG Ag molecules 
          PBP 
          CTAP-III 
          NAP-2 
Adhesive glycoproteins 
     Fibronectin 
     Vitronectin 
     VWF 
     Thrombospondin 
Haemostasis factors & cofactors  
     Fibrinogen,  
     Factors V, VIII, XI, XIII,  
     Kiningens 
     protein S 
     Plasminogen 
cellular mitogens  
     PDGF 
     TGFβ  
     ECGF  
     EGE  
     VEGF 
     IGF 
     Interleukin β 
Protease inhibitors  
     α2-macroglobulin 
     α2-antitrypsin 
     PDCI 
     α2-antiplasmin  
     PAI1  
     TFPI  
     PN-2/APP  
     C1 inhibitor 
Miscellaneous 
     Immunoglobulins 
          IgG 
          IgA 
          IgM,   
          Albumin,  

























     Cathepsins (D, E)  
     Carboxypeptidases (A,B) 
     prolinecarboxypeptidase 
     Collagenase 
     Acid phosphatase 
Glycohydrolases 
     Heparinase,  
     β-N-acetyl-glucosaminidase 
     α-D-glucosidase 
     α-D-fucosidase 




ADP and its Receptors  
Adenosine diphosphate (ADP) is an important physiological agonist released from dense 
platelet granules and damaged endothelial cells. ADP binds and activates three purinergic 
receptors, P2Y1, P2Y12 and P2X1. P2X1 is a ligand-gated ion channel that mediates early 
transmembrane calcium flux from the extracellular medium, thus causing a transient increase 
in intracellular calcium and causing platelets to change shape, however it does not lead to 
aggregation on its own. Both P2Y1 and P2Y12 are G-coupled protein receptors (GPCRs) 
and their co-activation is required for ADP-induced platelet aggregation [232].  
GPCRs are large tertiary structured membrane protein receptors possessing seven 
transmembrane helices with three intra- and extracellular loops (which can act as multiple 
interaction sites), an extracellular N-terminal tail (ligand binding domain), and an 
intracellular C-terminus (effector domain). The intracellular C-terminus domain is bound to 
a group of heterotrimeric peptides (α, β, and γ) subunits, called G-coupled proteins, coupled 
with the energy unit guanosine diphosphate (GDP) or guanosine triphosphate (GTP). The α-
subunit has three domains, where two domains are for β and γ subunits, while the third is for 
GDP or GTP. When G-coupled proteins are inactive, the α-subunit is at a low energy level 
(bound to GDP), but when activation occurs, the α-subunit loses its GDP and acquires GTP 
resulting in its detachment from the β and γ subunits (β/γ complex). The released β/γ 
complex also play a role and can activate downstream effectors [224, 232, 233].  
There are four main families of G-proteins that can elicit different signalling pathways 
termed as, Gi, Gq, Gs, and G12/13. The P2Y12 receptor is coupled with Gi while P2Y1 is 
coupled with Gq. Signalling through P2Y1/Gq mediates the activation of PLC, PIP2, IP3, 
DAG, calcium, and the PKC signalling pathway, resulting in platelet activation. ADP 
activation of P2Y12/Gi however, follows a different signalling pathway, and this involves 
the inhibition of the enzyme adenylyl cyclase (AC), cyclic adenosine monophosphate 
(cAMP), and cAMP-dependent protein kinase A (PKA), which is generally involved in the 
inhibition of platelet function [224, 232, 233]. P2Y12/Gi downstream signalling also involves 
activation of PI3K, Rap1, Akt, and potassium channels leading to platelet activation, 
aggregation and signal amplification for other agonists. ADP is secreted locally from 
activated dense platelet granules and acts in an autocrine and paracrine fashion, where it can 
bind to the same secretory platelets or activate inactivated platelets in its immediate vicinity 
[224]. 
 




Thromboxane A2 (TxA2) and its Receptor  
Thromboxane A2 (TXA2) is an unstable and short-lived molecule that is diffused from 
activated platelets, and acts as a potent vasoconstrictor and platelet activator working in an 
autocrine and paracrine fashion. TXA2 is an example of an eicosanoid, which are an 
important and diverse group of 20 carbon, polyunsaturated fatty acids that act as signalling 
molecules. Other examples include prostacyclin (PGI2, which inhibits platelet activation) 
and prostaglandins. TXA2 is synthesised from arachidonic acid (AA) released from 
membrane phospholipids by phospholipase A2 (PLA2) in a multistep process. The 
cyclooxygenase enzyme, COX1, is involved in converting AA to prostaglandin G2 (PGG2), 
then into prostaglandin H2 (PGH2), which is then finally converted into TXA2 by 
thromboxane synthase.  The TXA2 receptor (TP) belongs to the GPCR family, and is 
coupled with Gq which upon binding to TXA2  signals through PLC, PIP2, IP3, DAG, 
calcium, PKC, PLA2 (generating more TXA2), with inside-out integrin αIIbβ3 activation 
causing platelet activation and aggregation. The generation of more TXA2 creates an 
amplified platelet activation loop resulting in more platelet activation and aggregation 
present in its proximity. Activation of signalling by collagen-adhered platelets is powerfully 
enhanced by the combined effects of TXA2 and ADP [224, 234, 235].   
 
Integrin αIIbβ3 (GPIIb-IIIa) 
Integrin αIIbβ3 is the most abundantly expressed surface receptor in platelets and is critical in 
mediating platelet aggregation. This receptor plays an important role in mediating platelet 
activation and aggregation upon Aβ stimulation, which will be further elaborated on in 
Chapter 3 and 5, including how it might contribute towards the progression of AD. The 
structure of αIIbβ3 is similar to the previously described collagen adhesion receptor, α2β1. 
Integrin αIIbβ3 is also a class-I transmembrane glycoprotein that exists in non-covalently 
bound heterodimeric complexes of α and β subunits. Both of these subunits consist of a large 
glycosylated N-terminal extracellular domain, a single hydrophobic membrane- spanning 
region, and a short C-terminal cytoplasmic tail [216, 224, 236-239]. The αIIb subunit consists of 2 
chains, a so-called heavy and light chain. The heavy extracellular chain contains 7 
homologous repeating segments of around 50 amino acids and it folds into a β-propeller-like 
structure that offers four cation-binding sites.  This heavy extracellular unit that is part of 
αIIb chain is joined by disulphide bridges to a short light chain consisting of 21 amino acids 
that occupies the transmembrane region and the cytoplasmic tail, where the C-terminus 




contains high-affinity cation binding sites on it.  The extracellular domain of the β3 subunit 
features a long disulphide loop that folds at the mid-region into a I-domain-like structure 
with 5-6 α-helices and β-strands containing metal ion-binding motifs, and a middle section 
composed of cysteine-rich tandom repeats, while the cytoplasmic tail of the β3 subunit 
contains tyrosine and threonine phosphorylation sites. The heterodimer subunits are 
maintained together non-covalently and this is calcium ion dependent. Cations are required 
to facilitate the binding of ligands, mainly fibrinogen, to αIIbβ3 in the extracellular region 
[216, 
224, 236-239].  
Fibrinogen (Factor I) is a coagulation factor primarily secreted by the liver and is normally 
present within the blood circulation. Fibrinogen exists as a homodimer with each of the 
monomers composed of 3 polypeptide chains of Aα, Bβ, and γ that are linked parallel to 
each other by disulphide bridges [240]. Both monomers form a hexameric complex with the 
N-terminus of each monomer’s polypeptide chains arranged facing each other and forming 
a central E-domain that extends outwards in a coiled-coil arrangement prior to the C-
terminus forming two peripheral globular D-domains. At the D-domain, the end of the 3 
polypeptide chains are referred to as αC, βC, and γC. Both βC and γC form the globular 
region, while αC, being the longest, extends out of the globular region. At the D-domain, a 
stretch of amino acids are present in γC (KQAGDV) and in αC (RGD) that act as recognition 
and binding sites for the αIIbβ3 receptor 
[240, 241]. Figure 1.8 below further demonstrates the 
structure of fibrinogen.  
 
Figure 1.9: Fibrinogen molecular structure. [240] 
 




 The fibrinogen E-domain contains thrombin cleavage sites within it on the Aα and Bβ 
chains. Removal of the N-terminal regions of these chains via proteolytic cleavage by 
thrombin results in an active E-domain that then binds to the D-domains of other fibrinogen 
molecules, eventually forming the fibrin network that is required for clot stabilization. 
Fibrinogen can also be negatively regulated through the binding of plasmin, (a proteolytic 
enzyme produced from circulating plasminogen by the action of tissue plasminogen activator 
(tPA) present on ECs), to its specific plasmin cleavage site in the coiled-coil region between 
E and D-domains, thus limiting fibrin network formation [240, 241].  
Despite the presence of a high fibrinogen concentration in the blood, αIIbβ3 does not interact 
with it due to its tightly regulated affinity state. Integrin αIIbβ3 in circulating inactive platelets 
primarily exists at a low-affinity state preventing its binding to its ligands. Upon activation, 
αIIbβ3 transitions from a low- to high-affinity state causing a conformational change within 
the receptor that thereby allows it to become competent for its ligand binding [241-244]. The 
importance of integrin αIIbβ3 activation is due to its bidirectional signalling properties where 
its activation can occur in an “inside-out” and “outside-in” manner, causing significant 
platelet activation. The process by which ligands, such as fibrinogen, VWF, fibronectin, and 
vitronectin, bind to integrin αIIbβ3 and trigger its activation is termed as “outside-in” 
signalling, while activation of platelets by other external agonists, such as ADP, TXA2, 
collagen, and thrombin that results in the activation of αIIbβ3 via internal signalling pathways 
is referred to as “inside-out” signalling [241-244].  
Platelet activation by agonists, such as ADP, thrombin, TXA2 and collagen, elicits diverse 
signalling pathways that converge into a common pathway that promotes downstream 
signalling and a phosphorylation cascade involving PLC, PI3K, Akt, PKC, DAG, Ca2+, and 
the small GTPase Rap1. Activated Rap1 promotes the recruitment of the cytoplasmic 
proteins Talin-1 and Kindlin-3 to the β3 subunit cytoplasmic tail of integrin αIIbβ3 and 
triggers a conformational change from low to high affinity in an “inside-out” manner. This 
process now favours the binding of αIIbβ3 to its ligands and promotes platelet aggregation 
[243, 245].  
Following the inside-out signalling, binding of fibrinogen or VWF to activated αIIbβ3 triggers 
another activation signalling pathway (in an outside-in signalling manner) influencing actin 
dynamics, cytoskeletal reorganization, and initiating platelet morphological changes that 
support bridging and aggregation between two activated platelets [246]. In a high affinity 
configuration, the non-receptor tyrosine kinase c-Src becomes associated to an RGT motif 
of β3 cytoplasmic c-terminal tail via its Src homology 3 (SH3) domain. Outside-in signalling 




mediates surface integrin clustering into hetero-oligomers and brings activated c-Src 
proteins into close proximity, clustering them and thus allowing trans-autophosphorylation. 
Activated c-Src then supports Syk activation and recruitment to the β3 tail or to 
phosphorylated ITAM of the FcRγ-chain [239, 244-246]. Subsequently, this facilitates the 
assembly and activation of the SLP76/LAT/Btk/Vav complex and initiates a downstream 
activation signalling cascade involving PLCγ2/ PI3K/ Akt/ DAG/ Ca2+/ α-actinin, and 
ultimately cytoskeletal reorganisation, granule secretion, spreading, stable adhesion, and clot 
retraction. It is noteworthy that despite the extensive progress in the platelet field, the exact 
cellular mechanisms involved in integrin αIIbβ3 outside-in and inside-out signalling have not 
yet been fully identified [239, 244, 245].   
 
Thrombin and its Receptors 
Thrombin (activated factor II (IIa)) is a potent serine protease agonist for platelet activation 
and plays a central role in haemostasis and thrombosis. The coagulation cascade is a series 
of enzymatic conversions of proenzymes (also called zymogens) to activated enzymes 
(coagulation factors) that culminate in thrombin formation [247]. This results in amplification 
of platelet activation and ends with the formation of fibrin strands, by the action of thrombin 
on the newly formed platelet plug. Thrombin is involved in activating several coagulation 
factors, e.g. factor V, VIII, and XI, and also in stabilizing the new clot and cross linking the 
fibrin polymer via activating factor XIII. Thrombin possesses two positively charged binding 
sites, namely Exosite 1 for fibrinogen cleavage and Exosite 2 for heparin and platelet PAR 
receptors. It also has a catalytic site for coagulation factors [247, 248].  
Thrombin activates human platelets mainly through specific protease-activated receptors 
(PAR1 and PAR4), which are GPCRs (coupled to Gq) 
[249]. Thrombin binds the extracellular 
N-terminus of PAR1/4 and cleaves it, causing the newly exposed portion of the receptor to 
bind to itself and induce a conformational change and receptor activation. Downstream 
signalling through PAR1/4/Gq mediates the activation of PLC, PIP2, IP3, DAG, calcium, 
and PKC signalling pathways, resulting in shape change, release of active substances from 
granules, more thrombin, intra- and extracellularly, exposure of receptors on the surface, and 
membrane phospholipid scrambling and coagulation initiation [250]. The following Figure 9 
shows an overview of the different GPCR intracellular signalling processes upon stimulation 
with ADP, TXA2 and thrombin [248, 251, 252].  






Figure 1.10: Platelet signalling downstream for different GPCRs upon stimulation with its soluble 
agonists ADP, thrombin, and thromboxane A2. [224] 






Primary haemostasis entails multifaceted interactions between injured vascular endothelial 
cells, adhesive proteins, and platelets that ultimately result in platelet adhesion, activation, 
aggregation, and the formation of a primary platelet plug post-vascular injury [178].  
Secondary haemostasis involves a coagulation cascade and the formation of a fibrin mesh 
(clot) that entraps the loose primary platelet plug resulting in its stabilisation. This process 
can be initiated spontaneously along with primary haemostasis [178]. The liver produces most 
of the procoagulants and anticoagulants, with the exception of factor III, IV and VIII, and 
the former are present in the blood circulation in inactive forms [253]. The majority of 
coagulation proteins undergo post-translational modification on their glutamic acid residues 
with the aid of vitamin K to become functional [254], and a suffixing letter “a” is assigned to 
their Roman numeral depicting their activation. Vitamin K is considered an essential 
coenzyme in the post-translational modification of several coagulant and anticoagulant 
proteins including, factor VII, IX, X, II (prothrombin), protein C, and protein [253-255]. It aids 
in the carboxylation of glutamic acid residues to form γ-carboxyglutamyl residues on these 
proteins which allows them to become functional and biologically active [254-256].  
The γ-carboxyglutamyl residues provide a slight overall negative charge on these proteins 
and allows the attraction of coagulation factors to the phospholipid membrane surface of 
platelets [255, 256]. As these factors sit on the platelet membrane surface they may slightly 
repel each other when they come into contact due to their negative charge. Calcium released 
from the dense granules of activated platelets can bind to the negatively charged factors 
resulting in their fixation to each other and activation on the surface of the platelets [257]. The 
asymmetrically distributed platelet membrane contains phospholipid species that are 
negatively charged and are predominantly located in the inner membrane leaflet, such as 
phosphatidylserine (PS) [257, 258]. The increase in intracellular calcium upon platelet 
activation causes the activation of ATP-independent transmembrane transporter proteins 
called flippase or scramblase, leading to membrane scrambling and exposure of PS to the 
outer cell surface, which then acts as a platform for the assembly of coagulation protein 
complexes [257, 258].  
The coagulation cascade is a dynamic series of enzymatic processes that traditionally can be 
categorised into two distinct pathways known as, the extrinsic and intrinsic pathways, which 
ultimately converge into a common pathway [247]. This eventually ends with the formation 
of fibrin strands, termination of the cascade by antithrombotic mechanisms, and finally 
fibrinolysis to dissolve a clot post-wound healing. The extrinsic pathway is considered the 




initial phase, where vascular injury exposes a glycoprotein expressed in vascular adventitia 
known as tissue factor (TF) [259]. TF binds to circulating factor VII (FVII) and becomes 
activated (FVIIa) forming a (FVIIa/TF) complex that binds with factor X (FX) on the plasma 
membrane. This interaction forms a multicomponent complex referred to as extrinsic X-ase 
or tenase, which in turn activates its substrate, factor X (FXa). Activated factor X (FXa) then 
binds to activated factor V (FVa) in the presence of calcium and membrane phospholipids 
on the surface of platelets, forming a multicomponent complex called prothrombinase 
(FXa/FVa), which binds to and activates prothrombin (FII) to produce thrombin (FIIa). 
Factor X forms the common link between the extrinsic and intrinsic mechanisms in 
producing thrombin [247, 253, 259]. Figure 1.10 illustrates a summary of coagulation cascade 
pathways. 
 
Figure 1.11: Summary of coagulation cascade model (modified from [260]). 
 




Factor XII becomes activated (FXIIa) when it comes into contact with exposed collagen 
from endothelial damage or activated platelets, initiating the intrinsic pathway that runs in 
parallel with the extrinsic pathway. FXIIa or thrombin can then activate factor XI (FXIa) 
that binds and activates Factor IX (FIXa) [261]. TF can also activate factor IX. FIXa then 
binds to activated factor VIII (FVIIIa) in the presence of calcium and membrane 
phospholipids on the surface of platelets, forming a multicomponent complex (IXa/VIIIa) 
referred to as (intrinsic X-ase or tenase). This in turn activates its substrate, factor X (FXa), 
which again results eventually in the formation of thrombin. Thrombin converts fibrinogen 
that is circulating or that is released from activated platelets to fibrin. The soluble fibrin 
monomers spontaneously form relatively weak threads, and Factor XIII, which is activated 
by thrombin to FXIIIa then crosslinks and strengthens the overlapping fibrin strands [247, 253, 
262, 263]. 
The above phases of secondary haemostasis may not alone yield significant amounts of fibrin 
that then results in a blood clot. Therefore, amplification and propagation process occur, 
where in this phase the limited amount of thrombin already produced activates local inactive 
platelets to release the contents of their granules to produce more prothrombin and 
coagulation factors [264]. Thrombin also activates more coagulation factors present locally 
including FVa, FVIIIa and FXIa, while the FVIIa/TF complex and activated factor XIa is 
able to activate factor FIX [263]. Activated FIXa binds to VIIIa (IXa/VIIIa) thus activating X 
to Xa too. Each activated FXa converts more prothrombin to thrombin, which in turn further 
accelerates the process [247, 253, 264].  
VWF plays a key role in the amplification phase as it binds to circulating inactive FVIII and 
prolongs its half-life by preventing its premature degradation [265, 266]. The propagation 
process ensures continuous thrombin generation and the subsequent formation of the fibrin 
meshwork that is then crosslinked and stabilized by the action of FXIIIa (secondary 
haemostatic plug) [266]. The 3-dimentional meshwork of fibrin in which RBCs and platelets 
become trapped represents the final step in the conventional coagulation cascade [247, 253, 266]. 
Thrombin also activates activatable fibrinolysis inhibitor (TAFI) that protects the fibrin 
network by cleaving the C-terminal residues that are important for the action of plasmin, 
thus making fibrin relatively resistant to degradation (fibrinolysis) [267]. Table 3 provides an 
overview of the Roman numerical nomenclature for coagulation proteins, the coagulation 
pathways they are involved in, and their physiological functions [253]   
 




Table 3 | Coagulation proteins nomenclature, pathways involved, and function. [253] 
















Activation of I, V, VII, VIII, XI, XIII, protein C, 
and platelets. 















Co-factor of X-Prothrombinase complex. 
 
VI  Accelerin Both Same as activated factor V.  
VII 
 Stable factor proconvertin 
Extrinsic  
 
Activates factors IX and X. 
 
VIII Antihaemophilic factor A Intrinsic Co-factor of IX-tenase complex.  
IX 
 




Activates factor X: forms a tenase complex with 







Prothrombinase complex with factor V and 







Activates factor IX.  
 
XII Hageman factor Intrinsic Activates factor XI, VII and Prekallikerin.  
XIII Fibrin-stabilising factor Both Crosslinks fibrin and stabilizes fibrin clot. 
XV 
 












Co-factor in kallikrein and factor XII activation, 
necessary in factor XIIa activation of XI.  




  Inhibits activated factors II, II, and other proteases. 
XVIII Heparin cofactor II  Inhibits activated factor II.  
XIX Protein C  Inactivates activated factors V and VIII. 
XX Protein S  Co-factor for activated protein C. 
 
In order to prevent spontaneous thrombosis, clot overgrowth, or runaway activation of 
vascular coagulation proteins, the healthy endothelium expresses and produces a number of 
anticoagulant and antiplatelet factors that serve to localize procoagulant activity at the injury 
site, thus maintaining haemostatic balance. These factors include:  surface-expressed heparin 
sulphate, which binds to antithrombin III (a serine protease inhibitor) and inactivates 
thrombin FVIIa, FIXa, FXa, and FXIa; nitric oxide (NO release vasodilates vessels and 
inhibits platelet activation and aggregation); ADP dephosphatases (which break down ADP); 
and prostacyclin (released PGI2 - binds to platelet receptors and prevents their activation and 
aggregation) [178, 268, 269]. In addition, the endothelial surface expresses thrombomodulin, which 
binds to thrombin and induces conformational changes in the presence of a proenzyme called 
Protein C, thereby altering thrombin’s capacity to activate platelets or to convert fibrinogen 
into fibrin. Activated Protein C is associated with its cofactor Protein S, and inactivates FVa 
and FVIIIa, and also inhibits the function of prothrombinase and intrinsic tenase complexes.  




Tissue factor pathway inhibitor (TFPI) is another molecule with inhibitory effects that 
circulates in the blood, but is mostly found adhered to the endothelium, and which can 
reversibly bind and inhibit FVIIa/TF complex and FXa [270]. Fibrinogen in the circulation is 
also subjected to degradation by endothelial surface-expressed tissue plasminogen activator 
(tPA) that converts plasminogen to plasmin for fibrin degradation. Plasmin works on 
crosslinked fibrin essentially by severing the fibrin threads, and then cleaving fibrinogen and 
other clotting factors at multiple sites resulting in clot dissolution [269]. The processes of 
primary and secondary haemostasis are mechanistically intertwined and occur spontaneously 
along with the production of procoagulant physiological inhibitors, thus providing a 
synergistic action in response to vascular injury and preventing blood loss. Figure 1.11 
summarises the stages of haemostasis.   
 
Figure 1.12: Summary of the different stages for maintaining haemostasis, and mechanisms of 
anticoagulation system involving endothelial cells. 
Negative regulatory mechanisms from healthy endothelial cells prevent pathological accumulation of 
procoagulants within the blood stream thus maintaining blood fluidity and protecting the blood vessel. 
However, upon vascular injury to the endothelial lining, several repair mechanisms are activated and a 
coagulation process initiates until the injury is sealed as shown in this Figure. (Original image created from 
[178, 268, 269]) 
 
In a variety of disease states such as Alzheimer’s disease, the balance between anticoagulant 
and prothrombotic mechanisms is altered. Endothelial dysfunction, vascular abnormalities, 
and compromised blood flow, result which can lead to thrombotic or haemorrhagic 




complications [86, 271, 272]. A prothrombotic state and altered coagulation profile have been 
documented in AD thus predisposing patients to higher risks of cardiovascular disease, 
microinfarcts and strokes [271]. Several studies showed altered fibrin clots which are resistant 
to degradation in the presence of Aβ peptides (decreased fibrinolysis) [273]. Aβ peptides were 
also shown to activate coagulation factor FXII, promoting thrombus generation, and elevated 
plasma fibrinogen levels were documented resulting in an increase blood viscosity, RBCs 
aggregation, reduced blood flow, and increased platelet activation [273, 274] .  
 
1.4.4. Platelet Abnormalities in AD  
Platelets are considered key contributing players in cerebrovascular pathophysiology, such 
as, strokes, and cerebral amyloid angiopathy (CAA), associated with AD [275]. Numerous 
studies have been conducted by different groups to investigate their potential role in AD 
which have revealed a number of abnormalities present in platelets from AD patients and 
animal models compared to their age-matched controls [171, 276]. Initially, platelet membrane 
abnormalities were reported in the 1990s, from membrane fluidity fluorescence studies on 
platelets from AD patients, and these studies indicated that there is a biophysical alteration 
of the platelet membrane [277, 278]. Higher intracellular membrane fluidity was observed, 
which might result in dysregulation of membrane biosynthesis with these alterations being 
significantly correlated with the severity of the disease [279].  
The preliminary work done by Rosenberg’s group in 1997 highlighted possible platelet 
activation in AD patients due to altered processing of APP isoforms [280]. Important work 
following up on these observations came from Sevush’s group in 1998, where they examined 
unstimulated platelets from AD patients and their age-matched control and reported a 
significant increase in the percentage of circulating platelet aggregates (39.5%), platelet-
leukocyte complexes (53.3%), and an increase in surface expression of p-selectin by 59.3% 
(a marker of platelet activation and α-granule secretion) [151]. These results strongly indicated 
that there is an aberrant and chronic pre-activation state of platelets in AD [151]. Further 
studies by other groups also supported these observations and also showed the activation of 
integrins αIIbβ3 on unstimulated platelets from AD subjects 
[281-283].  
In the early stages of AD, a high level of activated platelets called “coated” platelets are 
present in the blood [284, 285]. This is a platelet subset that retains high concentrations of 
several procoagulant proteins on its membrane, and expresses high levels of full-length APP, 
upon dual activation with thrombin and collagen when compared to platelets stimulated with 




a single agonist [284].  Platelets from AD patients have shown abnormalities in a host of 
membrane and cellular proteins including decreased receptor affinity for the 
neurotransmitter serotonin and impaired serotonin uptake, cytoskeletal abnormalities, 
cytochrome c oxidase deficiency and increase in monoamine oxidase-B activity in platelet 
mitochondria, which thus increases oxidative stress, as well as decreased phospholipase C 
(PLC) activity, and increased cytosolic protein kinase C (PKC) levels [286-291]. 
 Kinetic studies on platelet membrane β-secretase have shown a significant elevation of β-
secretase activity (17%) in AD patients compared to age-matched controls, suggesting that 
elevated platelet β-secretase activity may precede the onset of symptoms [292]. An interesting 
study documented that, β-secretase activity is modulated by platelet membrane cholesterol 
content in a biphasic manner, thereby linking dietary effects with AD [293]. Elevation of β-
secretase activity in AD patients can result in increased production and release of Aβ 
peptides into the circulation and thus an increased local concentration [294]. In addition, 
platelets in transgenic mouse models of AD pathogenesis were also found to display 
accumulation and activation at vascular Aβ deposition sites in CAA lesion and vascular 
injury [86, 295].  This can result in the activation of more platelets within the vicinity and the 
release of more Aβ peptides into circulation, creating a vicious cycle of platelet activation 
and potential thrombus formation and vessel occlusion at these sites, thus exacerbating and 
contributing towards the cerebrovascular complications associated with AD [86].  
 
1.4.5. Amyloid β Peptides and Platelet Activation 
A number of studies have explored the use of Aβ peptides to understand the effects of their 
exposure upon platelet activation. Several authors have utilized soluble or fibrillar forms of 
Aβ1-42, and Aβ1-40, and synthetic Aβ25-35 that retains the biological and toxic properties 
of the full length Aβ1-42 and Aβ1-40 [295-301]. A preliminary study by Herczenik’s group 
tested the effects of proteins with amyloid properties on human platelet activation, and 
demonstrated that fibrillar Aβ1-40 does indeed induce platelet activation and aggregation 
through binding to the scavenger receptor CD36/p83(MAPK)/TXA2 and through GPIbα 
mediating platelet aggregation [302]. Another study using Aβ25-35, showed that collagen and 
ADP-induced platelet aggregation was potentiated at concentrations of 1–2 µM, while at 
higher concentrations (2–10 µM), Aβ25–35 could directly promote aggregation through 
pathways involving PLCγ2, intracellular calcium mobilisation, and PKC pathway. The 
PAR1 receptor was also activated initiating a signalling cascade via Ras/Raf, PI3K, Akt, P38 
MAPK, cPLA2 and TxA2 formation [296, 297].  




Canobbio’s group conducted several studies utilizing Aβ25–35 on platelets and revealed that 
the first event in Aβ-induced platelet activation is the increase of intracellular Ca2+ 
concentration, and also showed the essential role for Ca2+ and ADP in platelet activation and 
thrombus formation [303]. They proposed that an increase of intracellular Ca2+ concentration 
as a result of exposure to Aβ was dependent upon the presence of extracellular calcium, and 
this first cellular event occurs possibly through the ability of Aβ to form cation-permeable 
pores in the plasma membranes [303]. The capacity of Aβ molecules to form ion channels was 
originally proposed in 1993 by the Arispe’s group, and their idea was that the Aβ peptide 
was capable of forming an amphipathic beta-sheet due to presence of alternating polar and 
nonpolar residues, which could result in channel formation at the membrane. In addition, 
they showed that calcium-dependent release of ADP is responsible for the activation of the 
small GTPase Rap1b and inside-out activation of integrin αIIbβ3, leading to platelet 
aggregation and increased thrombus formation [304, 305].  
Canobbio’s group also demonstrated that immobilized Aβ25–35, Aβ1-40, and Aβ1-42 
peptides induced platelet adhesion and spreading [300]. They also found that Aβ25–35 
accelerated platelet spreading over collagen or fibrinogen and enhanced platelet adhesion to 
collagen under shear flow, indicating the thrombogenic potential of Aβ peptides at vascular 
lesions or in CAA [300]. In order to understand the underlying molecular mechanism of Aβ 
on platelets, Sonkar’s group carried out a series of experimental studies on platelets using 
Aβ25–35 and found that 10-20 µM of the peptide was enough to induce strong platelet 
aggregation independently, and to a similar extent to that induced by physiological agonists 
[306]. Furthermore, Aβ25–35 was shown to substantially augment platelet spreading on 
immobilised fibrinogen and also clot retraction, which is greatly dependent on the 
engagement of integrin αIIbβ3. It also enhanced and stabilized platelet adhesion on 
immobilised collagen under arterial shear flow [306].  
Our group’s earlier work also highlighted that Aβ25–35-stimulated platelets induce an 
increase in intracellular Ca2+ that mediated dense granule release and ADP secretion as the 
earliest event taking place [303]. ADP is thus considered a major player in the subsequent 
propagation and activation of small GTPase Rap1b and consequently integrin αIIbβ3 in 
platelets [303]. Moreover, ADP released by platelets stimulated with Aβ25–35, resulted in the 
phosphorylation and activation of key signalling molecules including, Syk, PKC, PI3K, and 
p38MAPK and ERK1/2 [303]. In addition, it was suggested that Aβ25–35 might be interacting 
with GPCR coupled with G13 or Gq subunits to initiate a signal, since there was an 
observation of increased levels of Rho-GTP, Rho-associated coiled-coil protein kinase 




(ROCK) and phosphorylation of myosin light chain (MLC) and MLC phosphatase, 
respectively, thus mediating cytoskeleton reorganisation and actomyosin contraction [303]. 
Sonkar’s group evaluated thrombus formation in vivo in the presence of Aβ25–35 using a 
pulmonary thromboembolism model of Swiss albino mice [306]. The mice exhibited a 
significant number of thrombi in their pulmonary vessels and shorter bleeding time when 
compared to the ones treated with collagen plus epinephrine alone [306].  
Interestingly, Donner’s group, have shown that Aβ1-40 can bind to integrin αIIbβ3 and 
trigger the release of ADP and clusterin (chaperone molecules), which promoted the 
formation of Aβ1-40 fibrils and reinforced platelet activation via ADP binding to its P2Y12 
receptor [307]. Aβ promotion of platelet activation at an injured carotid artery model in vivo 
was also confirmed by Gowert’s group [295]. This group also carried out cerebral vessel wall 
analysis of APP23 and APP Dutch mice that are known to develop CAA upon aging. These 
mice displayed platelet accumulation at vascular amyloid plaques over time, showing that 
sustained platelet recruitment may eventually lead to full vessel occlusion [295].  
Recently, it has been demonstrated that mitochondrial respiration is increased in Aβ-
stimulated platelets and that cytochrome c oxidase, an enzyme that belongs to the complex 
IV of the respiratory chain, was diminished in platelets and hippocampal mitochondria of 
AD patients [308, 309]. This points towards a state of redox stress in AD patients. Several 
publications have suggested the important role of reactive oxygen species (ROS) as second 
messengers and as critical signalling modulators in platelet activity, such as in the inhibition 
of phosphatases, increasing tyrosine phosphorylation, and increasing ADP release and 
bioavailability [310-312]. However, excess production of ROS, i.e. oxidative stress, can itself 
lead to oxidative damage and platelet apoptosis [313].  
There are many sources of ROS in platelets, such as mitochondrial respiration, NAD(P)H 
oxidase (NOX), uncoupled endothelial nitric oxide, xanthine oxidase, lipoxygenase, and 
arachidonic acid-dependent phospholipase [312, 314].  Different ROS species are generated, 
e.g. superoxide anion radical, hydroxyl radical, hydrogen peroxide, nitric oxide, and 
peroxynitrite anion. However, NADPH oxidases (NOXs) are considered to have a pivotal 
role in regulating and modulating platelet haemostasis in response to different stimuli [310, 
312, 314-317]. Information gathered from these previous studies suggests the possibility that the 
stimulatory effects of Aβ on platelet activation are induced by redox stress.  
The exact cellular mechanism by which Aβ peptides activate platelets and regulate 
haemostasis and thrombosis is not well defined. Because of the complexity of the chemistry 




of ROS and the great number of regulatory enzymatic sources that are potentially involved, 
the role of ROS in platelet activation upon Aβ peptide stimulation and a complete picture of 
the link between Aβ peptides and platelet redox homeostasis is still missing. In particular, 
the types of ROS generated, their specific significance with respect to platelet activity, and 
the signalling mechanisms involved have not been determined clearly. Therefore, the present 
PhD project aimed to investigate the mechanisms underlying Aβ peptide-dependent 






















1.5. RESEARCH HYPOTHESIS 
Amyloidogenic Aβ peptides within the bloodstream cause cerebrovascular complications 
associated with Alzheimer’s disease via redox-dependent activation of platelets. 
 
1.6. AIMS OF THE STUDY 
The overall aim of the presented work is to investigate the mechanisms underlining β-
amyloid peptide-dependent regulation of platelets and the potential role of ROS in this 
pathophysiological event. This can provide new insights in understanding cerebral 
microthrombosis and impaired blood flow associated with Alzheimer’s disease progression.  
















PHASE I  
Investigate the effects of Aβ peptides on platelet functional responses, i.e. adhesion, 
aggregation, and thrombus formation under physiological blood flow conditions 
 
 
 PHASE II 
Explore different methodologies to assess oxidative changes in platelets upon 




Investigate redox- and NADPH oxidase-dependence of platelet functional alterations 





































2. MATERIALS & METHODS 
2.1. EXPERIMENTAL SECTION A:  PEPTIDE SYNTHESIS  
2.1.1. Aβ25-35 Solid Phase Peptide Synthesis (SPPS) 
The SPPS technique involves successive assembly of orthogonally protected amino acids 
from the C to N terminus to form any desired sequence in a step-wise manner. The basic 
process of SPPS is initiated by covalently attaching the activated carboxyl function of the 
first N-α-Fmoc protected amino acid to a polystyrene-based insoluble solid support. The 
temporary Fmoc amino protecting group is then removed (deprotection) under mild basic 
conditions and a second activated Fmoc protected amino acid added with the aid of a 
coupling agent to expand the peptide chain. The procedure of deprotection and 
addition/coupling of an amino acid is known as a cycle and SPPS consists of a series of 
repetitive cycles with washes in between allowing the removal of excess reagents, amino 
acids, and soluble by-products via simple filtration. Once the synthesis is complete, the new 
peptide is cleaved from the resin into solution under strongly acidic conditions that also 
remove side chain groups. The nascent peptide is then purified and characterized using high 
performance liquid chromatography (HPLC) and mass spectroscopy (MS) [318, 319]. Figure 
3.1 illustrates the basic steps of SPPS. 
 
Figure 2.1: Illustration of the basic principles in SPPS.  
The first step involves resin swelling and anchoring the C-terminus of the first amino acid to the resin, typically 
after its activation. Deprotection of the amino acid N-terminus takes place followed by coupling of the second 
amino acid by its C-terminus to the first one. The cycle is repeated until the desired peptide is completed and 
finally all protecting groups are removed and the peptide is detached from the resin. (Original figure created 
from [319, 320]) 






Materials & Instruments:  
Materials and chemical reagents were purchased from Sigma-Aldrich®, Fluka®, Acros 
Organics®, VWRTM Merck and Novabiochem®. All solvents were reagent grade or HPLC 
grade (Fisher Scientific®). Anhydrous (dry) dichloromethane (DCM) was obtained via 
distillation over calcium hydride (CaH2). Conventional 9-fluorenylmethoxycarbonyl (Fmoc) 
chemistry protocols were followed using an Activo-P11 automated peptide synthesizer. For 
the synthesis of Aβ25-35, the following list of Fmoc-protected amino acids from 
Novabiochem® were utilized as shown in Table 3: 














Analytical Reverse Phase High Performance Liquid Chromatography (RP-HPLC) was 
performed at 35 ± 0.1 °C on a Dionex UltiMate 3000 HPLC system (Dionex, UK) equipped 
with a Phenomenex Gemini 5μm C-18 (150 x 4.6 mm) column with a flow rate of 1 mL min-
1. Preparative RP-HPLC was performed on a Dionex HPLC system using a Phenomenex 
Gemini 5µm C-18 (250 x 30 mm) column and a flow rate of 2.5 mL min-1. Mobile phase A 
was 0.1% TFA in water and mobile phase B was 0.1% TFA in MeCN for both devices.  
Analytical HPLC gradient was T= 0.0-10.0 min, B = 5-95%; T= 10.0-15.0 min, B= 95%; 
T= 15.0–15.1 min, B= 95-5%; T= 15.1–18.0 min, B= 5%. 
Preparative HPLC gradient was T= 0.0-6.0 min, B = 5%; T= 6.0-26.0 min, B= 5-95%; T= 
26.0–36.0 min, B= 95%.  
Mass spectrometry (Bruker Daltonics; Bremen, Germany) was performed using a microTOF 
instrument in positive-ion mode.  
 
 






Coupling of 1st Amino Acid 
250 mg of 2-chlorotrityl CTC resin (Bachem, 200-400 mesh, loading 1.4 mmol/g) was 
weighed into a 10 mL SPPS reaction vessel with bottom filtration. The resin was pre-swollen 
using 3 mL of dry DCM (~1 mL/100 mg resin) for 15 min twice. The first amino acid was 
preloaded by dissolving Fmoc-Met-OH (1.2 eq. relative to the resin) and DIEA (4eq. relative 
to the carboxylic acid) in dry DCM (3 mL). The mixture was then added to the reaction 
vessel containing the resin and was left on a rotator for 1 hr. The solvent was drained off and 
the resin was washed 3x3 min in DCM/MeOH/DIEA (17:2:1), 3x3min DCM, 2x3 min DMF, 
2x3 min DCM and then left to dry in vacuo overnight.  
Determination of Resin Loading  
A small amount of dried Fmoc amino acid-resin was accurately weighed (24 mg, 
approximately 5 µmole with respect to Fmoc) into a 10 mL graduated flask. 2% DBU in 
DMF (2 mL) was added to the resin and left to agitate gently for 30 min. The solution was 
then diluted to 10 ml with acetonitrile (MeCN) and mixed. 800 µl of resin solution was 
transferred carefully to another graduated flask and was further diluted up to 10ml with 
MeCN. A reference solution was also prepared using the method mentioned previously but 
without the addition of the resin. The optical density of the resin and reference solutions was 
measured at 304 nm using a spectrophotometer (Helios Gamma Unicam, 190-1100 n 
Wavelength). The actual Fmoc loading (0.34 mmol/g) and estimated first residue attachment 
were obtained by using the following equation: Fmoc loading mmol/g = (Abs sample – Abs 
reference) X16.4/mg of resin. The actual Fmoc loading obtained was used to adjust the   
required amount of amino acids and chemical reagents (i.e. required weight = resin loading 
x resin/g x eq. x MW of AA) required in subsequent cycles.  
Fmoc Cleavage (Deprotection) 
Dried Fmoc amino acid-resin was first washed with DMF (2x 2 min). 20% piperidine in 
DMF (3 ml) was added to the resin and was placed on the rotator for precisely 2 min. The 
solution was then drained under reduced pressure and this step was repeated again, but for 
15 min. The resin was washed thoroughly with DMF (5x 2 min) and then with DCM (2x 2 
min). A Kaiser test [321] was performed to confirm successful deprotection.  For the expected 





positive result, the resin beads show a colour change to deep blue/purple. Negative results 
display no colour change.            
Automated Peptide Synthesis 
The total resin was transferred to the peptide synthesizer reactor vessel which was fitted with 
a reactor heating jacket. All the remaining amino acids where loaded and coupled using the 
following Fmoc-based SPPS protocol: 3 eq. of each amino acid; 3 eq. of coupling agent, 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 0.15 M in 
DMF); 6 eq. of the base N,N-diisopropylethylamine (DIEA, 0.48 M in DMF); 25% v/v 
piperidine in N,N-dimethyl formamide (DMF). The reactor vessel temperature was 
maintained at 70oC for both coupling and deprotection steps. 
Final Peptide Cleavage  
After completing the peptide synthesis, the resin was washed with DCM (2x2 min). The 
resin was then cleaved using a cleavage solution mixture of trifluoroacetic acid (TFA), 
Triisopropylsilane (TIS), deionised water, and 1,2-ethanedithiol (EDT) (TFA/TIS/H2O/EDT 
(94:2.5:2.5:1 v/v/v/v)) for 3 h. The resin solution was then added to diethyl ether (Et2O) to 
produce a white precipitate that was collected by centrifugation, and the Et2O was discarded. 
The crude peptide was then re-dissolved in MeCN. The solution was filtered using a 0.2 µ 
PTFE membrane filter. Analytical and preparative HPLC were performed for peptide 
analysis and purification, while mass spectrometry was used for peptide identification and 
characterization. 
 
Confirmation of Commercially Synthesized Aβ Peptides (LifeTein) by Liquid 
chromatography and Mass Spectrometry   
Materials & Instruments:  
Several Aβ peptides were purchased from LifeTein® (New Jersey, USA) and their details 









Table 5  | Sequences and molecular formulae of Life Tein Aβ peptides  
















Aβ25-35 GSNKGAIIGLM C45H81N13SO14 1060.28 
 
 
Samples of these peptides were submitted to the Materials and Chemical Characterisation 
Facility at the University of Bath for analysis by liquid chromatography (Dionex Acclaim 
RSLC Polar Advantage II (PA2), 2.2 µm, 120 Å, 2.1 x 50 mm and mass spectrometry using 
a MaXis HD quadrupole electrospray time-of-flight (ESI-QTOF) instrument (Bruker 
Daltonik GmbH, Bremen, Germany), operating in ESI positive-ion mode and coupled to a 
Ultimate 3000 UHPLC (Thermo Fisher Scientific, California, USA). Data were analysed 
using Analysis software version 4.3 (Bruker Daltonik GmbH, Bremen, Germany). 
 
Method: 
Analysis of LifeTein peptides was conducted using a Quadrupole electrospray time-of-flight 
mass spectrometer (QTOF) coupled with an Ultimate 3000 UHPLC (QTOF-UHPLC) as 
detailed above. The capillary voltage was set to 4500 V, with the nebulizing gas at 3 bar, 
and drying gas at 10 L/min at a drying temperature of 210°C. The time-of-flight (TOF) scan 
range was from 150 – 2200 mass-to-charge ratio (m/z). Liquid chromatography was 
performed with a flow rate of 0.4 ml/min at 40°C, and an injection volume of 10 µl. Mobile 
phases A and B consisted of 0.1% v/v formic acid in water, and 0.1% v/v formic acid in 
MeCN, respectively. Gradient elution was carried out with T= 0.0-10.0 min, B = 5-95%; T= 
10.0-15.0 min, B= 95%; T= 15.0–15.1 min, B= 95-5%; T= 15.1–18.0 min, B= 5%. The mass 
spectrometer was calibrated using a range of sodium formate clusters introduced by 10 µl 
loop-injection prior to the chromatographic run. The mass calibrant solution consisted of 3 
parts of 1 M NaOH to 97 parts of 50:50 water to isopropanol with 0.2% formic acid. The 
observed mass and isotope pattern perfectly matched the corresponding theoretical values as 
calculated from the expected elemental formula using analysis software.   





2.2.  EXPERIMENTAL SECTION B:  PLATELET STUDIES 
2.2.1. MATERIALS  
Most commercially available materials and chemical reagents were purchased from Sigma-
Aldrich® and the following are the materials used specifically for the platelet studies.  
Table 6  | Platelet Stimuli 







Collagen Related Peptides  (CRP) Collagen Toolkits, University of 
Cambridge 
-  
Native Collagen Fibrils (Type I) Chrono-Log Corporation, USA #P/N 385 
Thrombin from human plasma (Lyophilized 
powder) 
Sigma-Aldrich, USA #T6884 
Low Density Lipoprotein (Oxidized, oxLDL) Kind gift from Dr. Katie Wraith and 
Dr. Khalid Naseem, University of 
York, Hull-York Medical School, 
UK 
-  
Low Density Lipoprotein (Normal, nLDL) Kind gift from Dr. Katie Wraith and 
Dr. Khalid Naseem, University of 
York, Hull-York Medical School, 
UK 
-  
Hydrogen peroxide solution (contains 
inhibitor 30 wt. % in H2O, ACS reagent 
Sigma-Aldrich, Germany #216763-M 
Fibrinogen from human plasma 50-70% 
(≥80% of protein clottable) 
Sigma-Aldrich, USA #F3879 
 
Table 7  | Platelet Inhibitors 




Sigma Aldrich,  USA 
 
#175226 
GP91 ds-tat Anspec Inc, CA #AS-63818 
GP91 ds-tat scrambled Anspec Inc, CA #AS-63821 
Indomethacin (≥99% (TLC) Sigma-Aldrich, USA #I7378 
Losartan Potassium Tocris Bioscience, UK #3798 
ML161 ≥98% (HPLC) Tocris Bioscience, UK #4570/10 
NOXA1ds  scrambled Kind gift from Professor Patrick 
Pagano, University of Pittsburgh 
-  
NOXA1ds   Kind gift from Professor Patrick 
Pagano, University of Pittsburgh 
-  
N-Acetyl-L-Cysteine (NAC) Sigma-Aldrich, China #A9165 
Prostaglandin E1 (PGE1; ≥98% (HPLC) 
synthetic 
Sigma-Aldrich, USA #P5515 
Sulfosuccinimidyl Oleate sodium salt (SSO) Cayman Chemical Company, USA #11211 
VAS2870 Sigma-Aldrich, USA # SML0273 
Citrate Concentrated Solution (4% (w/v) Sigma-Aldrich, USA # S5770  





Table 8  | Amyloid Peptides β 







Aβ1-40 LifeTein, USA #LT1148-3 
Aβ1-42 LifeTein, USA #LT1148-2 
Aβ1-42 Scrambled LifeTein, USA #LT1148-5 
Aβ1-42 fibrils Kind gift from Dr. Janet Kumita and 
Prof. Christopher Dobson, University 
of Cambridge, UK 
-  
 
Table 9  | Antibodies, Molecular & Fluorescent Probes 
Reagent Source Catalogue 
 





Anti-p-selectin (PE-Cy™5 mouse anti-
human CD62P) 
BD Biosciences USA #551142 
PAC1 (FITC Mouse Anti-Human PAC-1) BD Bioscience, USA #340507 
Phalloidin-Tetramethylrhodamine B 
isothiocyanate (TRITC conjugated) 
Sigma-Aldrich, USA #P1951 
Carboxy-H2DCFDA (6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate) 
Life Technologies, USA #C400 
Dihydroethidium (DHE) Life Technologies, USA #D11347 
CMH spin probe (1-hydroxy-3-
methoxycarbonyl-2,2,5,5-
tetramethylpyrrolidine) 
Noxygen GmbH, Germany # NOX-2.1 
DiOC6 (3, 3′-Dihexyloxacarbocyanine iodide) Sigma-Aldrich, USA # 318426 
 
Table 10 | Other Reagents 
Reagent Source Catalogue 
 
Bovine Serum Albumin (BSA; Heat shock 





Bidistilled water (ESR grade water) Noxygen GmbH, Germany #NOX-9.1-1L 
Deferoxamine methanesulfonate salt (DF) Noxygen GmbH, Germany # NOX-9.1 
D-(+)-Glucose monohydrate Sigma-Aldrich, France #49158 
Dimethyl Sulfoxide (DMSO, sterile-filtered, 
≥99.7%) 
Sigma-Aldrich, USA #D2650 
HEPES (4-(2-Hydroxyethyl) piperazine-1-
ethanesulfonic acid) 
Sigma-Aldrich, USA #H4034 
Kreb HEPE Buffer (ESR) Noxygen GmbH, Germany #NOX-7.6.1-
1L 
Paraformaldehyde 4 % w/v in PBS Sigma-Aldrich, USA #P6148 
Thioflavin T Sigma-Aldrich, India #T3516 
Triton-x100 SigmaUltra Sigma-Aldrich, Germany # T9284 
VECTASHIELD Mounting medium for 
Fluorescence 










Table 11 | Instruments & Software  
Instruments  
490D Aggregometer (Chrono-Log Corporation, Havertown, PA) 
Centrifuge (Thermo Scientific Heraeus™ Megafuge™) 
Ibidi Vena8 Fluoro+ microchips (Ibidi GmbH, Martinsried, Germany) 
Electron Paramagnetic Resonance (EPR) MS200spectrometer (Magnettech, Berlin, Germany) 
Exigo pump (Cellix Microfluidics Solutions, Dublin, Ireland). 
EVOS Fl microscope (Thermo Fisher Scientifics, Waltham, MA US) 
Flow Cytometry (BD FACSAria™ III, Becton Dickinson, Wokingham, UK) 
Leica Microsystems DM4000 B LED Fluorescence Microscope 
Microplate reader (FLUOstar Omega BMG Labtech) 
Platelet counter  (Z1 Series Beckman Coulter Particle Counter)   
Software 
AGGRO/LINK software 
BD FACSDiva software 
GraphPad Prism 5 for Windows Version 5.04 
Image J ( Version 1.47  and 1.52e, Wayne Rasband, NIH) 



















2.2.2.1. Platelet Isolation 
Human blood was drawn from healthy volunteers (both genders) by median cubital vein 
venepuncture under local ethics committee approval, either following University of Bath or 
Royal Devon and Exeter NHS Foundation Trust Code of Ethics and Research Conduct. 
Warm sodium citrate solution (4% w/v) was used as anti-coagulant at a ratio of 1:7 to blood 
(approximately 0.6% w/v). Platelet rich plasma (PRP) was then isolated from whole blood 
by first centrifugation at 200 xg for 20 min. PRP was then subjected to a second 
centrifugation at 500 xg for 10 min in the presence of indomethacin (10 μM) and PGE1 (40 
ng/ml) to isolate platelets. Once platelets were isolated, they were resuspended in warm 
Tyrode buffer (37 °C) at a density of 2 x 108 platelets/ml ready for further experiments. In 
most of the following experiments this was the standard platelet isolation protocol.  
 
2.2.2.2. Adhesion Assay 
Coating preparations: Round coverslips (22 mm) were placed in a clear bottom flat 6-well 
plate and then coated overnight at 4 °C with 10 μM Aβ1-42, Aβ1-40, Aβ25-35, scrambled 
Aβ1-42, or 5 mg/ml BSA, all diluted in PBS.  
Platelets adhesion assay: The platelet isolation method was followed, and after the first 
centrifugation, PRP was subjected to a second centrifugation at 200 xg for 20 min to remove 
any remaining erythrocytes before the final centrifugation at 500 xg for 10 min. PPP was 
discarded and the platelet pellet was re-suspended carefully in warm (37 °C) modified 
Tyrode’s HEPES buffer (145 mM NaCl, 2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, pH 
7.3; 5 mM D-glucose was added before use) at a density of 2 x 107 platelets/ml. Platelets 
were then left to rest for 30 min in a 37°C warm water bath. Excess solutions from coverslips 
were then gently removed and the coverslips were blocked with 5 mg/ml BSA in PBS for 1 
h at room temperature. The coated dishes were then washed gently and carefully with PBS, 
and platelets were added (0.5ml) and incubated for 30 min at 37°C. In case where inhibitors 
were used, after platelets were rested, they were incubated with different inhibitors for 10 
min prior to adding onto coated slides. Non-adherent platelets were discarded and the 
adherent ones were gently washed with PBS and then fixed with 4% paraformaldehyde for 
10 min at RT. The coated coverslips were then washed carefully with 3 x PBS, then 50 mM 
ammonium chloride/PBS was added for 10 min. 0.1% Triton-x100/PBS was added to 





permeabilized platelets after 3 x gentle washing with PBS. After 5 min, 0.1% Triton-
x100/PBS was removed and the coated coverslips were washed gently 3 x with PBS and 
then blocked with 5 mg/ml BSA in PBS for 30 min. The fixed platelets were then stained 
with TRITC-conjugated phalloidin for 1 hour at RT and then washed with 3 x PBS, and each 
coverslip was mounted onto a microscope slide using Vectashield. Evaluation of platelet 
adhesion and spreading was performed using a Leica LED Fluorescence Microscope, and 
digital images were acquired at 10 x and 100 x magnification. 
 
2.2.2.3. Platelet Aggregation Assay by Suspension Turbidimetry 
Human platelets were isolated and suspended in modified HEPES Tyrode with glucose at 
physiological density (2 x 108/ml) and rested in a water bath (37°C) for 30 min. Aggregation 
experiments were performed by either by adding agonists directly to platelets or pre-
incubating with ROS inhibitors/scavengers prior to adding agonists with continuous stirring 
at 800 RPM over 10 min measured by turbidimetry at 37°C using a 490D aggregometer. 
These agonists included thrombin (0.1, 0.05 and 0.03 units/ml), collagen (3 and10 μg/ml), 
Aβ peptides (20 μM, with scrambled Aβ1–42 as a control), CRP (3 μg/ml), or arachidonic 
Acid (AA, 30 μM). The ROS scavenger used was NAC (3 mM), and inhibitors were 
VAS2870 (10 μM), indomethacin (10 μM), NOXA1ds (10 μM), with scrambled NOXA1ds 
as control), or NOX2ds-TAT (10 μM, with scrambled NOX2ds-TAT as control). 
 
2.2.2.4. Thrombus Formation Assay under Physiological Flow  
Human platelets were isolated and fluorescently labelled by incubation with 1 μM DiOC6 
(green fluorescent dye in DMSO) for 10 min. Ibidi Vena8 Fluoro+ microchips were coated 
with 10 μM Aβ peptides or 0.1 mg/ml fibrillary collagen for 2 hours. Non-specific binding 
sites were saturated with 0.1% w/v BSA. Physiological flow conditions (200-1000 s-1) were 
applied using an Exigo pump and images of the thrombi after 10 min of flow were obtained 
with an EVOS Fl microscope. Platelet coverage was then measured using Image J (Version 
1.52e). 
 





2.2.2.5. Platelet α-Degranulation and αIIbβ3 Activation by Flow cytometry 
Human platelets were isolated and suspended in modified HEPES Tyrode with glucose at 
physiological density (2 x 108/ml) as described previously. Platelets were stimulated in 
suspension with Aβ1-42, Aβ1-40, Aβ25-35, scrambled Aβ1-42 (5-10 µM) or thrombin (0.5 
unit/ml) for 10 min at 37 °C. Platelets were then incubated for a further 10 min with PAC1 
and anti-P-selectin antibodies (1 in 1000) conjugated to FITC and PE-Cy5. After 1 in 10 
dilution with Tyrode’s buffer, surface fluorescence was assessed using a flow cytometer. A 
minimum of 3 experiments were performed with 3 repeats per condition and an average of 
50,000 events/sample were recorded. Data were obtained by BD FACSDiva software. Gate 
selection was performed using logarithmic side and forward scattering (SSC & FSC).  
 
2.2.2.6. Detection of Platelet binding to FITC-labelled Aβ Peptides  
FITC-Labelling of β-amyloid peptides was carried out by Dr. Abhishek Upadhyay and Dr. 
Mareike Posner in the Department of Biology and Biochemistry at the University of Bath. 
The following method was used.  
Preparation of FITC-labelled Amyloid peptides β: Stock solutions of FITC and β-amyloid 
peptides β (scAβ1-42 and Aβ1-42) were separately prepared in anhydrous DMSO at 1 
mg/ml. For each 1 ml of peptide solution, 50 µl of FITC solution was added very slowly in 
5 µl aliquots while gently and continuously stirring the peptide solution. After the required 
amount of FITC had been added, the reaction was incubated in the dark for 8 hours at room 
temperature (20 °C). Ammonium chloride was added to a final concentration of 50 mM and 
the reaction mixture was further incubated for 2 hours at 20 °C. Excess or unreacted FITC 
was removed by dialysis against DMSO using a ready dialysis kit (Pur-A-Lyzer™ Mega 
Dialysis Kit). Briefly, the sample was loading into the Pur-A-Lyzer tube and sealed using a 
cap provided in the kit. The Pur-A-Lyzer tube was then placed in the supplied floating rack 
and left in a measuring cylinder containing a 25-fold excess of DMSO. The dialysis buffer 
was changed 4 times. The samples were then pipetted out carefully from the Pur-A-Lyzer 
tube to a clean tube and frozen in aliquots and stored at -20°C until further use. 
Binding of FITC-labelled Amyloid peptides to platelets by flow cytometry: Isolated human 
platelets in suspension (at a density of 2 x 108 platelets/ml) were rested in a water bath (37°C) 
for 30 min before being incubated with FITC-Aβ peptides (10 µM) or FITC-Aβ peptides 





with thrombin at (0.03 and 0.1 units/ml) for 30 min. Samples were diluted (1:10) with room 
temperature modified HEPES Tyrode and analysed immediately by flow cytometry. 
 
2.2.2.7. Detection of ROS by Microplate Reader 
Platelet rich plasma (PRP) was isolated from whole blood following the method above, and 
afterthe first centrifugation at 200 xg for 20 min. PRP was carefully collected in a single tube 
and placed in a 37°C water bath. The molecular probe carboxy-H2DCFDA (10 μM) was 
added to PRP and incubated for 45 min in a water bath (working in the dark from this point 
forward). Carboxy-H2DCFDA (pre-incubated with PRP) was then centrifuged at 500 xg for 
10 min in the presence of PGE1 (0.1 μg/mL) and indomethacin (10 μmol/L) to obtain an 
isolated platelet pellet. Platelet-poor plasma (PPP) was discarded and the platelet pellet was 
resuspended in half PRP volume of modified Tyrode’s-HEPES buffer (145 mM NaCl, 
2.9 mM KCl, 10 mM HEPES, 1 mM MgCl2, pH 7.3; 5 mM D-glucose was added before 
use). Platelets were then rested for 15 min in a 37°C water bath. The platelet suspension was 
divided into sections to provide positive and negative controls. For negative controls, 
platelets were incubated with 1 and 30 mM ROS scavenger N-acetyl-L-cysteine (NAC) for 
10 min.  Different stimuli (H2O2, Aβ25-35, Aβ1-40, and Aβ1-42; 20 μM) were then added 
and incubated for another 10 min, then 200 µl of each condition were transferred to a 96-
well plate and samples were analysed for dichlorofluorescein (DCF)  using a microplate 
reader at excitation/emission wavelengths 485/530 nm.   
 
2.2.2.8. Detection of Intracellular ROS in Platelets by Flow Cytometry 
Following the platelet isolation method above, after the second centrifugation, the platelet 
pellet was resuspended in modified Tyrode’s-HEPES buffer with glucose at a density of 2 
x108 cells/ml and rested for 30 min in a 37°C water bath. Working in the dark, carboxy-
H2DCFDA (10 μM) was added to the platelet suspension which was incubated for a further 
30 min in the water bath. Where the ROS scavenger, NAC, was used, platelets were 
incubated with NAC prior to adding any stimulus. The effects of different concentrations of 
different stimuli on ROS generation in platelets were tested for 30 min. The samples were 
then further diluted with 1 ml cold Tyrode (4°C), placed on ice, and analysed by flow 
cytometry immediately. A minimum of 3 experiments were performed with 3 repeats per 





condition, and an average of 10,000 events/sample were recorded. Data were obtained by 
BD FACSDiva software. Gate selection was performed using logarithmic side and forward 
scattering (SSC & FSC) with the gain set at 40 and 220 mV, respectively. Fluorescence 
excitation was at 485 nm, and emission was detected at 535 nm. The baseline for 
unstimulated samples was set at 100 relative fluorescence units. Statistical analysis of the 
data was performed using GraphPad Prism.  
 
2.2.2.9. Detection of Superoxide Anion in Platelets by Flow Cytometry 
Following the platelet isolation method above, after the second centrifugation, the platelet 
pellet was resuspended in modified Tyrode’s-HEPES buffer with glucose at a density of 2 
x108 cells/ml and rested for 30 min in a 37°C water bath. Working in the dark, DHE (5 μM) 
was added to the platelet suspension which was incubated for a further 15 min in the water 
bath. Platelets were then stimulated for 15 min with different physiological stimuli. Where 
ROS scavenger or NOX inhibitor was used, they were added to the platelets for 10 min prior 
to stimulation of the platelets with agonists. At the end of the incubation time, platelet 
suspensions were diluted 1:10 in cold modified Tyrode’s-HEPES buffer and samples were 
then analysed immediately by flow cytometry using a 85 μ nozzle at low flow rate 3 
(corresponds to approximately 10–80 µL/min). A minimum of 3 experiments were 
performed with 3 repeats per condition and an average of 10,000 events/sample were 
recorded. Data were obtained by BD FACSDiva software. Gate selection was performed 
using logarithmic side and forward scattering (SSC & FSC) with the gain set at 40 and 220 
mV, respectively. Fluorescence excitation was with a violet laser at 405 nm and emission 
was collected at 580 nm with a LP600 filter. The baseline for unstimulated samples was set 
at 200 relative fluorescence units. 
 
2.2.2.10. Detection of Superoxide Anion by Electron Paramagnetic Resonance (EPR) 
Blood collection and  platelet isolation, for these studies was carried out with the assistance 
of Dr. Dina Vara, Department of Pharmacy & Pharmacology, University of Bath. Detection 
of of superoxide anion using EPR was carried out by Dr. Dina Vara.  
Preparation of EPR materials:  Stock solutions of CMH spin probe (10 mM) for detection of 
superoxide anion were freshly prepared for each set of experiments in Tyrode-HEPES buffer 





prepared with EPR grade water, containing 25 μM DF salt and 5 μM DETC. The solution 
was kept under argon on ice to keep an oxygen-free atmosphere.  
Detection assay: Following the platelet isolation method described previously, platelet 
suspensions were prepared at physiological density of 2 x 108 platelets/ml then they were 
stimulated in the presence of 200 μM CMH with Aβ peptides (20 μM) with or without the 
NOX inhibitors (10 μM VAS2870, 0.5 μM 2-APT, scrambled NOXA1ds and NOXA1ds (10 
μM), and scrambled NOX2ds-TAT and NOX2ds-TAT (10 μM). Inhibitors were pre-
incubated for 10 min prior to stimulation using an aggregometer for platelet activation. After 
10 min of stimulation, platelets were removed by a quick spin on a table top centrifuge and 
exactly 50 μl of supernatant was immediately transferred into the Hirschmann precision 
micropipettes and read using the e-scan. EPR spectra were recorded using the following EPR 
settings: field sweep, 80 G; microwave frequency, 9.39 GHz; microwave power, 2 mW; 
modulation amplitude, 5 G; conversion time, 327.68 ms; time constant, 5242.88 ms; 512 
points resolution and receiver gain, 1 × 104. Samples for calibration curves were obtained 
from a 10 mM stock solution of a standard CM* solved in Tyrode-HEPES, and diluted to 
concentrations of typically 5, 10, 25, 50, 100 and 500 μM. The EPR signal from samples 
was expressed in CMH oxidation rate (femtomoles per platelet per minute) from the platelet 
density.  
 
2.2.2.11. Amyloid Peptide β Fibrillation in Real Time Using Thioflavin T Assay 
Based on the BMG LABTECH protocol, aggregation buffer was prepared (50 mM 
phosphate and 150 mM NaCl) and warmed in a water bath at 37 °C. 20 µM Thioflavin T 
was then added to the buffer and 200 µl of the Thioflavin T solution was transferred to a 96-
well plate to make 3 replicates per condition. All β-amyloid peptides were then added at 100 
µM and the well-plate was sealed and then immediately placed in the microplate reader for 
measurements. The fluorescence increase was measured continuously every 30 min from the 
bottom of the well with prior plate shaking (double-orbit mode) for 30 s at 500 rpm. The 
instrument settings were as follows: detection mode (fluorescence intensity, plate mode 
kinetics), optic (bottom optic), orbital averaging (activated, 4 mm diameter), filters 
(excitation: 440-10 and emission: 480-10), number of cycles (90), cycle time (1800 sec), 
number of flashes (10), instrument temperature (37 °C). Raw data was obtained and analysed 


































Vascular pathologies and AD are age-related diseases that share significant overlaps in their 
pathophysiological mechanisms, including vascular dysfunction, atherothrombosis and 
blood hypoperfusion [81]. Hypoperfusion is particularly important in dementia (including 
AD), as it affects numerous cellular functions, such as glucose uptake, oxygen delivery, and 
regulation of cellular waste metabolites and toxins, which leads to chronic localised 
inflammation and oxidative stress [49, 322-326]. Hypoperfusion also interferes with Aβ 
elimination from the brain parenchyma resulting in its pathological accumulation in the brain 
and within the cerebrovasculature [327]. 
Platelets are considered major players in vascular diseases and a number of studies have 
revealed considerable abnormalities in platelets of AD patients or animal models of this 
disease. These include altered APP processing and APP isoform ratios that correlated with 
cognitive decline [280, 292, 328], aberrant pre-activation state [151], altered membrane fluidity [171, 
279], cytochrome c oxidase deficiency [309], increased platelet mitochondrial respiration, and 
oxidative stress [289, 309, 329-331], enhanced platelet adhesion, and accumulation of vascular Aβ 
deposition [295]. The observation of platelet adhesion to vascular Aβ deposition sites raised 
the question of how Aβ may modify haemostasis and thrombosis. An increasing number of 
studies have consequently investigated the relationship between Aβ and platelet activation 
and their contribution to cerebrovascular complications associated with AD and CAA 
progression [153, 275, 295, 298, 306, 307, 332-334]. 
Platelets are considered to be a major contributor of Aβ in the blood as they express large 
amounts of APP with all the enzymatic and machineries for its metabolism [154, 155]. Upon 
platelet activation, they release stored Aβ peptides from their α-granules [335] along with other 
potent platelet agonists into the blood to activate other platelets within its vicinity. Since 
vascular Aβ deposits have been shown to recruit platelets to the site of cerebrovascular injury 
and lead to their activation, the accumulation of Aβ may represent a positive feedback 
mechanism inducing platelet activation on one hand, and stimulating further Aβ deposition 
on the other [295, 298].   
In AD, platelets are in an aberrant pre-activated state [151],which creates a highly 
prothrombotic environment within the cerebrovascular system, but the mechanism by which 
Aβ triggers platelet activation is not well understood. In one study it was shown that the 
fibrillar form of Aβ1-40 induced platelet aggregation in a concentration-dependent manner, 




and when antibodies were used against integrin αIIbβ3, it blocked platelet adhesion to fibrillar 
Aβ1-40 but no direct peptide interaction with purified integrin αIIbβ3 was detected 
[336]. These 
observations suggested that the interaction of fibrillar Aβ1-40 with platelets is mediated by 
integrins with the indirect involvement of GPIIb/IIIa (i.e. integrin αIIbβ3), possibly through 
fibrinogen [336].  
A more recent study demonstrated that fibrillar Aβ1-40 does indeed induce platelet 
activation and aggregation through two pathways. One of these is a GPIbα-dependent 
pathway, where GPIbα is a VWF receptor and a component of platelet receptor complex 
GPIB-IX-V [302]. GPIB-IX-V activation triggers a downstream intercellular stimulation of 
tyrosine kinases, such as FAK and Pyk2 that mediates clustering and phosphorylation of 
ITAM tyrosine residues in the FcRγ cytoplasmic domain by Src-family kinases (SFKs) [337]. 
Subsequently, this leads to the engagement and activation of Syk, and downstream signalling 
activation of PI3K/PLCγ2/DAG/IP3/Ca2+/PKC causing platelet granule secretion, inside-out 
activation of integrin αIIbβ3, arachidonic acid mobilization and TXA2 release, thus mediating 
platelet aggregation [302, 338, 339]. The second is where fibrillar Aβ1-40 was shown to induce 
platelet aggregation through a second pathway where it binds to a scavenger receptor CD36-
dependent cascade following p38MAPK/COX1 activation pathway and results in TXA2 
release [302]. 
A number of studies have explored the use of the synthetic Aβ25-35 peptide, which retains 
the biological and toxic properties of the full length Aβ1-42 and Aβ1-40, in order to 
understand the effects of the endogenous peptides on platelets [296, 297, 300, 301, 303, 306, 340]. 
Aβ25-35 induced abnormal changes in intracellular calcium in normal human platelets [301]. 
In two studies, the authors mentioned that they carried out pilot work that was not published, 
where they compared the effects of Aβ25-35 and Aβ1-40 in inducing platelet activation. 
They stated that their initial experimental work showed that these two peptides had equal 
potencies in exerting their effects on platelets, hence they chose to use Aβ25-35 for their 
subsequent experiments in their publications [296, 297].  
The authors demonstrated that Aβ25-35 induces platelet activation through thrombin 
receptor PAR1 and activates platelets through Ras-PI3K-Akt-p38 MAPK-cPLA2 signalling 
pathway resulting in TXA2 release. Aβ25-35 also affected platelets in a dose-dependent 
manner, where at lower concentrations (0.5–2 μM), it potentiated agonist-induced platelet 
aggregation (collagen and ADP), while at higher concentrations (2–10 μM), it directly 
activated the aggregatory responses without the presence of co-agonists. Immunoblotting 
analysis revealed that Aβ25-35 at 2–10 μM produced marked phosphorylation of PLCγ2 and 




platelet activation, suggesting that Aβ stimulation of platelet aggregation is, at least partly, 
mediated by the PLCγ2-PKC signalling pathway [296, 297].  
A previous study done in our laboratory tested the effects of Aβ25-35 on platelet activation 
and signal transduction and showed that Aβ25-35 promotes an increase in intracellular Ca2+, 
dense granule mobilization, and ADP release that can act in an autocrine/paracrine fashion 
to activate platelets [303]. Aβ25-35 induced platelet aggregation was shown to be dependent 
on endogenous ADP release and immunoblotting analysis revealed time-dependent 
phosphorylation of several key signalling molecules involving Syk-PI3K/Akt-
MAPkinases/PKC substrate pleckstrin [303]. Another group, showed that Aβ25-35 increased 
platelet adhesion to collagen under flow conditions, and at 10 – 20 μM, it elicited similar 
effects to physiological agonists and induced strong platelet aggregation and integrin 
activation. Furthermore, at 20 μM, Aβ25-35 modulated cytoskeletal reorganization through 
RhoA/ROCK/MLC and its phosphatase (MYPT1); RhoA/Rap1b activation and inside-out 
integrin αIIbβ3 expression 
[306]. 
In the same year, a different group explored the effects and cellular mechanisms triggered 
by Aβ1-40 on platelets and highlighted additional important aspects of platelet signalling in 
response to these peptides [295]. The authors showed that exposure to Aβ1-40 induces ROS 
generation, membrane scrambling and phosphatidylserine exposure, mitochondrial 
depolarization, and activation of caspase-3. In addition, platelets were shown to mediate the 
organisation of soluble Aβ1-40 into a fibrillar form in a time and concentration-dependent 
manner [295]. A recent supporting study showed that soluble Aβ1-40 was able to bind to 
integrin αIIbβ3 via its RHDS amino acid motif and this stimulated the secretion of ADP and 
the chaperone protein clusterin [307].  
Clusterin promoted the formation of fibrillar Aβ1-40 aggregates, while ADP acted through 
its receptors P2Y1 and P2Y12 on platelets and enhanced the outside-in activation of integrin 
αIIbβ3, reinforcing the secretion of more clusterin and Aβ1-40 binding to platelets 
[307]. 
However, a follow up study showed that the RHDS amino acid motif of Aβ is important for 
integrin binding but not sufficient for binding Aβ to it and it requires other recognition or 
binding motifs for platelet-mediated fibril formation [341]. Another study showed that Aβ1-
40 enhanced platelet adhesion under static and dynamic flow conditions, and showed platelet 
localization at Aβ vascular deposit sites of the cerebral vessel wall in APP Dutch and APP23 
transgenic mice [295].  




These previously mentioned studies highlight the potential role of Aβ peptides in platelet 
dysfunction associated with CAA and AD. However, several aspects of the effects of Aβ 
peptides on platelets remain unclear. There is no previous study that has compared the effects 
of the different peptides side-by-side in a systematic manner, and the majority of these 
studies utilized Aβ25-35 as a representative peptide. Even though Aβ25-35 is known to 
represent the biologically active region that mediates full length Aβ toxicity, its effects do 
not entirely represent the effects of the full length Aβ1-40 and Aβ1-42. Therefore, the present 
study aimed at investigating the effects of such Aβ peptides (i.e. Aβ1-40, Aβ1-42, Aβ25-35, 
and scrambled Aβ1-42 as control) on platelets in order to understand the potential 
mechanisms involved in platelet recruitment to the vascular Aβ deposit sites in AD. 
Understanding the molecular mechanisms underlying the ability of Aβ peptides to modulate 
haemostasis and thrombosis may represent an additional therapeutic avenue in the treatment 

















3.2. AIMS & OBJECTIVES 
 Determine the effects of Aβ peptides i.e. Aβ25-35, Aβ1-40, Aβ1-42, and scrambled 
Aβ1-42 as control, on platelet adhesion, activation, and spreading using adhesion assay 
under static conditions.  
 Determine the effects of Aβ peptides as agonists or co-agonists on platelet aggregation 
using turbidimetric aggregometry.   
 Determine the effects of Aβ peptides on platelet adhesion under physiological shear 
stress using microfluidic pump. 
 Determine Aβ peptide-induced platelet activation by measuring P-selectin expression 



















3.3.1. Aβ25-35 solid phase peptide synthesis (SPPS) 
The initial aim was to synthesize a range of different Aβ peptides i.e. Aβ25-35, Aβ1-40, 
Aβ1-42, and scrambled Aβ1-42 as control. Full-length Aβ peptides have been typically 
regarded as ‘difficult sequences’ to synthesize by SPPS, like many peptides of > 30-50 amino 
acids. The quality and yield of such peptides may often be dramatically decreased due to 
incomplete coupling and deprotection reactions as a result of the formation of secondary 
structures and aggregation during the synthesis. 
Recent advances in SPPS methods, particularly the application of microwave activation, 
have allowed these problems to be overcome allowing the successful production of longer 
Aβ peptides [342]. By comparison, Aβ25-35 is a short peptide, which should not pose 
significant problems, and it was successfully and easily synthesised and characterised by 
mass spectrometry and HPLC as shown in Figure 3.1. Due to time constraints and the 
inherent synthetic challenges for the longer peptides, these peptides were obtained from 
commercial sources as they were required only as tools and their synthesis was not one of 
the main aims of this project.   
  
               
Figure 3.1: Aβ25-35 peptide synthesis.  
(A) MS analysis of synthesized Aβ25-35; Expected formula = C45H81N13O14S, Theoretical m/z = 1059.5746; 
found ESI = 1060.5870 [M+H]+. (B) RP-HPLC analysis between in-house synthesized Aβ25-35 and 
commercially available Aβ25-35 (Sigma), with tR = 5.917 min and tR = 5.908 min respectively.  
A 
B 




3.3.2. Aβ peptides support platelet adhesion under static conditions 
In order to determine the effects of Aβ peptides on platelet adhesion and morphological 
changes, collagen type I and fibrinogen, which are potent thrombogenic proteins that 
promotes platelets activation and aggregation, were used as positive controls in the present 
study. This allows the evaluation of platelet adhesion and spreading when compared to the 
effects of Aβ peptides on platelets. Platelet adhesion to collagen or fibrinogen was assessed 
under static conditions using an adhesion assay mentioned previously in Chapter 2.  
Briefly, isolated human platelets in suspension (2 x 107 platelets/ml) were allowed to adhere 
over collagen type I (25 µg/ml), fibrinogen (100 µg/ml), or BSA (5 mg/ml)-coated surfaces 
under static conditions for 30 min. Non-adhering platelets were washed off, then platelets 
were fixed with 4% paraformaldehyde (PFA), permeabilized with 0.1% Triton-x100/PBS, 
and stained with TRITC-conjugated phalloidin, then mounted on to a microscope slide using 
Vectashield. Digital images were taken of platelet adhesion and spreading area and analysed 
at 10x and 100x magnification. Representative images of platelet adhesion and spreading 
area for each of the conditions are shown in Figure 3.2 (A and B).  
Quantification and analysis of the average number of adhered platelets and spreading area 
are shown in Figure 3.2 (C and D). Both collagen and fibrinogen significantly induced 
platelet adhesion and spreading compared to BSA (P-value<0.05 and P-value<0.01 
respectively) in our experimental conditions. Morphological changes associated with platelet 
activation displayed in images (A and B), show different stages of platelet shape change. 
Some of the adhered platelets display round shapes morphology as shown with BSA, while 

























Figure 3.2: Platelet adhesion and spreading area over collagen or fibrinogen-coated surfaces under 
static conditions.  
(A-B) Representative images of platelets that were allowed to adhere onto glass coverslips coated with BSA 
(5 mg/ml), collagen type I (25 µg/ml), or fibrinogen (100 µg/ml). Platelets were then fixed, stained, then 
visualized under the fluorescence microscope and images were taken at 10x and 100x magnification. (C-D)  
Quantification and evaluation of the mean number of adhered platelets and mean spreading area per optical 
field from at least 4 independent experiments. Both collagen and fibrinogen show significant increase in the 
mean number of adhered platelets and spreading area when compared to BSA. Statistical significance was 
assessed using one-way ANOVA with Bonferroni post-test; P-value < 0.05 (*), and P-value <0.01 (**). Error 







































































































Normally, circulating plasma Aβ peptides are present at concentrations of around 
(mean±SD: 84.7±19.6 pg/ml for Aβ1-40, and 14.2±4.5 pg/ml for Aβ1-42) [343]. However, in 
order to carry out experiments in vitro, much higher concentrations were utilized in previous 
studies to measure an effect on platelets, as mentioned previously. With regards to 
physiological relevance, the effects of using higher Aβ concentrations may reflect and 
correlate to the levels of vascular Aβ deposits that have been shown to accumulate in 
atherosclerotic lesions and AD cerebrovasculature, and their ability to recruit platelets to the 
site of cerebrovascular injury and lead to their activation, enhancing thrombus formation at 
the site, which may eventually lead to full vessel occlusion [295].  
In order to assess the effects of Aβ peptides on platelet adhesion and morphological changes, 
adhesion assays were carried out as described in Chapter 2 (Methodology). Representative 
images for platelet adhesion and spreading area are shown in Figure 3.3 (A and B). The 
average numbers of adhered platelets and mean spreading area were quantified and 























Figure 3.3: Aβ peptides support platelet adhesion under static conditions.  
(A-B) Representative images of platelets that were allowed to adhere onto glass coverslips coated with 10 µM 
Aβ peptides (scrambled Aβ1-42 as control, Aβ1-42, Aβ1-40 and Aβ25-35). Platelets were then fixed, stained, 
then visualized under the fluorescence microscope and images were taken at 10x and 100x magnification. (C-
D) Quantification and evaluation of the mean number of adhered platelets and mean spreading area per optical 
field from at least 4 independent experiments. Only Aβ1-42 show significant increase in the mean number of 
adhered platelets and spreading area when compared to scrambled control. Statistical significance was assessed 

























































































Interestingly, only Aβ1-42 shows a significantly higher number of adhered platelets and 
increased spreading area (P-value <0.05) compared to the scrambled Aβ1-42 control and the 
other two peptides. With that being said, this study also shows moderate adhesion of platelets 
to Aβ1-40 and Aβ25-35 compared to scrambled control. To understand the thrombogenic 
potential of Aβ peptides and determine their ability to exacerbate vascular dysfunction 
within neurovascular lesions associated with CAA, this study also examined the concomitant 
presence of Aβ peptides with collagen or fibrinogen under static conditions following the 
adhesion assay mentioned previously.  
Representative images of platelet adhesion and spreading area are shown in Figure 3.4 (A 
and B) for collagen and Figure 3.5 (A and B) for fibrinogen. The average number of adhered 
platelets and mean spreading area were quantified and represented in Figure 3.4 (C and D) 
for collagen and Figure 3.5 (C and D) for fibrinogen. Aβ1-42 with collagen appears to induce 
similar effects on platelet adhesion compared to Aβ1-42 without collagen, as do the other 
peptides under our experimental conditions. However, while it is evident that the effects of 
Aβ peptides moderately enhanced platelets spreading, no statistical significance was 
obtained when compared to scrambled control.  
Previous studies have reported that platelets have shown strong integrin activation, 
degranulation, and spreading kinetics over fibrinogen in AD transgenic mice (APP23) [298]. 
Therefore, the effects of Aβ peptides with fibrinogen on platelets were also examined. The 
results show enhanced platelet adhesion to all the peptides, especially Aβ1-42, but not much 
change in terms of spreading area. The results in this study are in agreement with previous 
studies and show enhanced platelet adhesion. However, the results are not statistically 
significant and further experiments are required to obtain it. 
 














Figure 3.4: Platelet adhesion and spreading onto dual coated surfaces with collagen and Aβ peptides 
under static conditions. 
 (A-B) Representative images of platelets that were allowed to adhere onto glass coverslips coated with 25 
µg/ml collagen type I and 10 µM Aβ peptides (scrambles Aβ1-42 as control, Aβ1-42, Aβ1-40 or Aβ25-35). 
Platelets were then fixed, stained, then visualized under fluorescence microscope and images were taken at 10x 
and 100x magnification. (C-D) Quantification and evaluation of the mean number of adhered platelets per 
optical field from at least 4 independent experiments. No statistical significance was shown compared to 
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Figure 3.5: Aβ peptides potentially enhance platelet adhesion in the presence of fibrinogen.  
(A-B) Representative images of platelets that were allowed to adhere onto glass coverslips coated with 100 
µg/ml fibrinogen and 10 µM Aβ peptides (scrambles Aβ1-42 as control, Aβ1-42, Aβ1-40, or Aβ25-35). 
Platelets were then fixed, stained, then visualized under fluorescence microscope and images were taken at 10x 
and 100x magnification. (C-D)  Quantification and evaluation of the mean number of adhered platelets and 
mean spreading are per optical field from at least 4 independent experiments. No statistical significance was 
shown compared to scrambled control using one-way ANOVA with Bonferroni post-test. Error bars represent 
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3.3.3. Effects of Aβ peptides as agonists or co-agonists on platelet aggregation  
Since Aβ peptides had been shown to affect platelet adhesion and activation under static 
conditions, a series of experiments were carried out to examine the level of platelet 
aggregation in response Aβ peptides as agonists or co-agonists with two potent 
physiological platelet stimuli, thrombin or collagen. Initially, experiments were 
conducted to examine the level of platelet aggregation in response to thrombin at 
concentrations of 0.05 and 0.1 unit/ml, and collagen at concentrations of 3 and 10 µg/ml, 
measured by turbidimetric aggregometer (see Chapter 2 for methodology). This allowed 
the confirmation of the agonists’ ability to stimulate platelets under the chosen 
experimental conditions. Both thrombin and collagen were found to induce significant 
platelet aggregation to varying degrees at different concentrations as shown in Figure 3.6.  



























































































































Figure 3.6: Platelet aggregation in response to thrombin or collagen.  
Platelet aggregation experiments were performed using a 490D aggregometer. (A) Representative aggregation 
curves induced by two collagen concentrations (3 and 10 µg/ml). (B) Representative aggregation curves 
induced by two thrombin concentrations (0.05 and 0.1 units/ml). (C) Average percentage aggregation 
quantified from 4 independent experiments. Error bars represent mean + SEM.  
 
With regards to the physiological relevance of thrombin in blood, no diagnostic assay is 
currently available that enables the direct measurement of thrombin concentrations, and its 
presence in healthy individuals can trigger clot formation in circulating blood, However,  
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prothrombin (thrombin precursor) was reported to circulate at around 1.4 µM [344]. 
Representative aggregation curves are shown in Figure 3.6 (A and B), while the average 
percentage aggregation that was quantified from 4 independent experiments is shown in 
Figure 3.6 (C).The effects of Aβ peptides as agonists on platelet aggregation were assessed 
next following the previously indicated aggregation methodology and the results are shown 
in Figure 3.7. Representative aggregation curves are shown in Figure 3.7 (A-C), while the 
average percentage aggregation is shown in Figure 3.7 (D). Only Aβ1-42 showed statistical 
significance (P-value < 0.05) at a concentration of 20 µM (the most common in vitro 
concentration used in previous studies) and moderate platelet aggregation compared to 
scrambled peptide control while the other peptides did not.  
 


























































































































Figure 3.7: Examining platelet aggregation in response to amyloid peptides as agonists.  
Platelet aggregation experiments were performed using a 490D aggregometer. (A-C) Representative 
aggregation curves induced by 20 µM of scrambled Aβ1-42 as control and, Aβ1-42 (A), Aβ25-35 (B), or Aβ1-
40 (C). (D) Average percentage aggregation quantified from 4 independent experiments. Only Aβ1-42 show 
significant increase in percentage aggregation compared to scrambled control. Statistical significance was 
analysed using one-way ANOVA with Bonferroni post-test; P-value < 0.05 (*). Error bars represent mean + 
SEM.  
 
Further experiments were conducted to determine the effects of Aβ peptides on platelet 
aggregation upon co-stimulation with a submaximal concentration (assessed previously 
from Figure 3.6) of 3 µg/ml collagen type I and 0.05 units/ml thrombin. Representative 
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aggregation curves are shown in Figure 3.8 (A-C) for co-stimulation with collagen and 
Figure 3.9 (A-C) for co-stimulation with thrombin. Average percentage aggregation is 
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Figure 3.8: Potentiation of platelet aggregation in response to amyloid peptides with collagen.  
Platelet aggregation experiments were performed using a 490D aggregometer. (A-C) Representative 
aggregation curves induced by collagen 3 µg/ml and 20 µM of scrambled Aβ1-42 as control and, Aβ1-42 (A), 
Aβ25-35 (B), or Aβ1-40 (C). (D) Average percentage aggregation quantified from 4 independent experiments. 
Only Aβ1-42 potentiated significant increase in in average percentage aggregation compared to scrambled 
control in the presence of collagen. Statistical significance was analysed using one-way ANOVA with 
Bonferroni post-test; P-value < 0.05 (*). Error bars represent mean + SEM. 
 
Looking at the results in Figure 3.8, only Aβ1-42 in the presence of collagen potentiated a 
significant aggregation response compared to scrambled control. Other peptides did not 
induce significant aggregation response when compare scrambled control. Similarly, only 
Aβ1-42 in the presence of thrombin potentiated a strong and significant aggregation response 
compared to scrambled control as shown in Figure 3.9. In addition, Figure 3.9 (A) shows a 
secondary potentiation phase, which could indicate the release of secondary agonists, e.g. 
ADP, as mentioned in a previous study conducted in our laboratory [303]. 
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Figure 3.9: Potentiation of platelet aggregation in response to amyloid peptides with thrombin.  
Platelet aggregation experiments were performed using a 490D aggregometer. (A-C) Representative 
aggregation curves induced by thrombin 0.05 u/ml and 20 µM of scrambled Aβ1-42 as control and, Aβ1-42 
(A), Aβ25-35 (B), or Aβ1-40 (C). (D) Average percentage aggregation quantified from 4 independent 
experiments. Only Aβ1-42 potentiated significant increase in in average percentage aggregation compared to 
scrambled control in the presence of thrombin. Statistical significance was analysed using one-way ANOVA 
with Bonferroni post-test; P-value < 0.05 (*). Error bars represent mean + SEM. 
 
3.3.4. Aβ1-42 increases thrombus formation in whole blood under physiological 
venous flow conditions 
The previous adhesion assays showed that Aβ peptides, especially Aβ1-42, support platelet 
adhesion under static conditions, induce moderate platelet aggregation as agonists, and 
potentiate platelet aggregation in the presence of other physiological agonists (i.e. collagen 
or thrombin). Therefore, platelet adhesion and thrombus formation under physiological shear 
stress in vitro was next examined for Aβ1-42 using a microfluidic pump, as this resembles 
normal human physiological blood flow conditions within the systemic circulation. Platelet 
adhesion was tested using human whole blood at an arterial shear rate of 1,000 sec-1 and a 
venous shear rate of 200 sec-1. In the present study, Aβ1-42 peptide was also found to be 
sufficient by itself to induce thrombus formation under venous flow compared to scrambled 
Aβ1-42, Aβ1-40, and Aβ25-35 as shown in Figure 3.10. Representative images of platelet 
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adhesion under flow are shown in Figure 3.10 (A-F). The surface area coverage was 
quantified and analysed and the results are shown in Figure 3.10 (G). Aβ1-42 peptide had a 
remarkable and significant (P-value <0.0001 (****)) ability to induce platelet adhesion 






















Figure 3.10: Platelet adhesion to amyloid peptides under physiological shear stress.  
Vena 8 Fluoro microchips were coated with 10 μM Aβ peptides or 0.1 mg/ml fibrillary collagen. Platelet 
adhesion was tested in human whole blood at shear rates 1,000 sec-1 and 200 sec-1 using an ExiGo pump and 
images were obtained and shown in (A-E). (F) Surface area coverage was quantified from 3 independent 
experiments using Image J. Only Aβ1-42 induced significant increase in the percentage of surface area 
coverage with platelets compared to scrambled control. Statistical significance was analysed using one-way 

























































3.3.5. Aβ1-42 induces platelet activation and expression of integrin αIIbβ3   
 
Aβ peptide-induced platelet activation was next assessed by measuring P-selectin surface 
expression and integrin αIIbβ3 activation using flow cytometry and the results are presented 
in Figure 3.11. Integrin αIIbβ3 was significantly activated by Aβ1-42 (but not by Aβ1-40, 
Aβ25-35 or scrambled Aβ1-42 - see Figure 3.11 (F)). This reflects the profound ability of 
20 µM Aβ1-42 to induce signalling and activation in platelets under our experimental 
conditions. However, despite the ability of Aβ1-42 to induce integrin αIIbβ3 activation, 
platelet degranulation and P-selectin expression was not detected (see Figure 3.11 (G)). This 
indicates that Aβ1-42 has a partial role in stimulating platelets without inducing full 






















































































      
Figure 3.11: Activation of integrin αIIbβ3 by Aβ1-42.  
Isolated human platelets in suspension were stimulated with Aβ1-42, Aβ1-40, Aβ25-35, scrambled Aβ1-42 or 
0.5 unit/ml thrombin for 10 min and then labelled with FITC-PAC1 or PE-Cy5-P-selectin for further 10 
minutes. (A) Side scattering (SSC) / forward scattering (FSC) dot plot suggests high purity of the platelet 
preparation. (B-E) Representative histograms for the intensity of PAC1 staining in the different conditions. (F 
and G) evaluation of fluorescence detected for P-selectin expression or integrin αIIbβ3 activation from 3 
independent experiments. Significant fluorescence was detected with PAC1 staining for Aβ1-42 compared to 
scrambled control and the other peptides as shown in (F). However, no P-selectin surfaced expression was 
detected on platelets when stimulated with any of the Aβ peptides. Statistical significance was analysed using 


























































































Since Aβ1-42 was shown to be the most active peptide in our experimental conditions, as it 
activated platelet adhesion receptors and promoted moderate platelet aggregation, a further 
confirmatory study was carried out using only FITC-labelled Aβ1-42 and scrambled Aβ1-
42 (provided by Dr. Upadhyay and Dr. Posner, University of Bath) to visualise its ability to 
bind to platelets as an agonist or in the presence of another physiological agonist thrombin 
at two different concentrations (0.03 and 0.1 unit/ml). The results in Figure 3.12, show 
enhanced binding of Aβ1-42 to platelets in the presence of the secondary physiological 
agonist in a concentration dependent manner. Therefore, these results could possibly shed 
light on the ability of Aβ at vascular lesions or in CAA to support thrombus formation at an 






      
   
 
Figure 3.12: Binding of FITC-labelled Amyloid peptides to platelets.  
(A) Shows significant level of FITC-labelled Aβ1-42 binding to platelets alone or in the presence or 
physiological stimuli thrombin at two different concentrations. Isolated human platelets in suspension (at a 
density of 2 x 108 platelets/ml) were resting in water bath (37°C) for 20 min before incubated with FITC-Aβ 
peptides (10µM) or FITC-Aβ peptides with thrombin at (0.03 and 0.1 units/ml) for 30 min. Samples were 
diluted (1:10) with room temperature modified HEPES Tyrode and read immediately with flow cytometry. (B) 
Representative histograms of mean fluorescence intensity. (C) Representative dot plot figures of flow 
cytometry gating of detected platelets population (P1) shown in a forward (FSC) vs side scattering (SSC) plot. 
Y-axis is a logarithmic scale. FITC-labelled Aβ1-42 show significant binding ability to platelets when 
compared to scrambled control and this binding was enhanced in the presence of thrombin in a concentration 
dependent manner. Statistical significance was analysed using one-way ANOVA with Bonferroni post-test; P-












































3.4. SUMMARY OF RESULTS 
 Aβ peptides support platelet adhesion. 
 Aβ1-42 induced significant platelet adhesion and spreading under static conditions 
compared to the other peptides.  
 Aβ1-42 enhances platelet adhesion in the presence of fibrinogen but not collagen.  
 Aβ1-42 can directly bind to platelets in suspension and the bind is enhanced in the 
presence of secondary platelet agonist. 
 Aβ1-42 moderately induces platelet aggregation and potentiates aggregation in the 
presence of submaximal concentrations of collagen or thrombin.  
 Aβ1-42 increases thrombus formation in whole blood under physiological venous flow 
conditions.  



















The thrombogenic potential of Aβ peptides has been reported to exacerbate vascular 
dysfunction and neurovascular lesions associated with CAA and AD and has been shown to 
enhance thrombus formation at these sites [295, 306]. Several studies highlighted the important 
role of Aβ peptides in mediating platelet adhesion and spreading [295, 300, 306, 307, 336]. However, 
these studies lacked consistency in their methodology and the forms of peptides used, which 
made their precise effects on platelets unclear. Therefore, the effects of different Aβ peptides 
on platelets were examined side-by-side in a systematic manner. The present study of the 
effects of Aβ peptides on platelet adhesion, activation, and spreading under static conditions 
were initially investigated, as they can provide an insight into how these peptides affect 
platelet adhesion and recruitment to vascular Aβ deposit sites.  
The results demonstrated that platelets preferentially adhered to Aβ1-42 compared to other 
Aβ peptides, and noticeable platelet spreading was also observed over Aβ1-42. This 
suggested that only Aβ1-42 activates platelet signalling under our experimental conditions. 
However, closer investigation of the static adhesion results for the Aβ1-40 and Aβ25-35-
coated surfaces compared to the scrambled Aβ1-42 showed noticeable increases in platelet 
adhesion from 200 to 500 platelets/optical field, while Aβ1-42 reached over 900 adhered 
platelets/optical field. Evaluation of adhered platelet spreading at higher magnification 
revealed that Aβ1-40 and Aβ25-35 did not induce extensive platelet spreading and most 
adhered platelets displayed spherical morphology and modest filopodia formation, which are 
indicative of partial activation.  
These data therefore suggest that Aβ25-35 and Aβ1-40 possess some ability to induce 
platelet adhesion but are not able to induce full activation. On the other hand, platelet 
adhesion and spreading with extensive lamellipodia formation was very noticeable over 
Aβ1-42 indicating that this peptide induces platelet intracellular signalling. These results on 
Aβ peptides did not show the expected level of adhesion and spreading as observed in 
Canobbio’s study [300], when their methodology was followed. The slight modifications 
carried out in our study with their protocol, is most likely the cause behind the differences 
in the results obtained in this study.  
These modifications involved the preparation of platelet suspensions, where platelets were 
not washed with PIPES buffer before resuspension in HEPES Tyrode, which also lacked 1 
mM CaCl2. In addition, the coating of glass coverslips with two co-stimuli (i.e. Aβ peptides 
+ collagen or fibrinogen) was not done separately (i.e. coating and incubating with collagen 




or fibrinogen first, removing excess solution then coating with Aβ), but rather Aβ + stimuli 
were resuspended together and the coverslips were coated directly. The incubation time of 
platelets for the different conditions was also shorter (30 min instead of 60 min).  
The dual surface coating experiments with Aβ peptides and collagen or fibrinogen were 
carried out to investigate for different Aβ peptides the potential augmentation of platelet 
recruitment, activation and thrombus formation at the site of CAA. Aβ1-42 with collagen 
appears to cause platelet adhesion with a similar potency to Aβ1-42 alone without collagen, 
as do the other peptides. These results suggest that Aβ1-42 may induce platelet adhesion via 
an independent mechanism to collagen that is potentially mediated through a different 
receptor.  
However, a recent study in 2018 demonstrated the ability of Aβ1-42 to act as a ligand for 
GPVI, which is one of the main adhesion receptors for collagen [345]. Therefore, it is tempting 
to suggest that Aβ1-42 might possibly be competing with collagen for the same receptor. 
Further experiments testing inhibition of different receptors that are potentially involved in 
the presence of Aβ1-42 might be useful to gain more insight and additional experiments are 
required to detect potential phosphorylation of key signalling proteins, e.g. PKC or PI3K, 
with phosphoimmunoblotting to validate the effects of these peptides on platelets. 
The thrombogenic potential of Aβ peptides was also examined in the presence of fibrinogen, 
and the results showed enhanced levels of adhesion when compared to fibrinogen alone. 
These results are in agreement with those of other authors [273, 306]. These authors also showed 
that co-localisation of Aβ and fibrinogen results in fibrinogen binding to Aβ in vitro 
enhancing fibrinogen aggregation and Aβ fibrillization, which also confirmed earlier in vitro 
studies [346]. These studies could explain the enhanced adhesion levels of platelets to Aβ1-42 
and fibrinogen demonstrated in this study.  
Integrin αIIbβ3 is a known main receptor for fibrinogen but recent studies showed that 
immobilized fibrinogen does not only act through integrin αIIbβ3 but also through GPVI-
dimer D-domains and thus promoting platelet adhesion, activation and thrombus formation 
[347, 348]. Since co-localisation with fibrinogen shown to enhance Aβ fibrillization [346], Aβ1-
42 may act in a similar manner to fibrillar collagen and activate GPVI and other adjacent 
GPVI receptors and cause receptor dimerization [349, 350], that initiates and induces effective 
intracellular signalling in platelets leading to “inside-out” activation of integrin αIIbβ3. This 
can then lead to fibrinogen also binding to αIIbβ3 and causing “outside-in” activation and 




enhancing cellular signalling, and eventually causing full platelet activation, adhesion and 
spreading [351]. 
Interestingly, Aβ1-40 did not potentiate platelet adhesion in the presence of fibrinogen in 
our experimental conditions. Since fibrinogen promotes platelet aggregation and activation 
mainly through integrin αIIbβ3, it is tempting to suggest that Aβ1-40 and fibrinogen might 
also be competing for the same receptor as soluble Aβ1-40 has previously been shown to 
bind to integrin αIIbβ3 
[307]. In order to fully understand the binding regulation of Aβ peptides 
to platelets and the discrepancies found between this study and previous studies, further 
experiments are required, such as, protein-receptor co-immunoprecipitation or radioligand 
binding studies in order to provide a better explanation. The results of the present study 
reveals more information on the potential role of Aβ1-42 that accumulates in the perivascular 
space and vessel wall, or migrates into the bloodstream, on platelet activation. Aβ1-42 was 
shown to activate platelets, enhance their adhesion, and potentiate thrombus formation, 
which can create a vicious cycle of platelet hyperactivity within the bloodstream, and 
possibly contributing to the microthrombosis observed in AD neurovasculature.  
The second aim of this study was to investigate the effects of Aβ peptides as agonists or co-
agonists on platelet aggregation using turbidimetry. Only Aβ1-42 at 20 µM shown to induce 
significant moderate aggregation of around 10% compared to the other peptides and in the 
presence of another physiological agonist, i.e. collagen or thrombin, it potentiated platelet 
aggregation to around 70%. This highlights the potent role of Aβ1-42 in promoting platelet 
aggregation. A secondary potentiation phase was also observed when Aβ1-42 co-stimulated 
platelet with thrombin. This can be an indicator of platelet degranulation, and the release of 
secondary agonists, e.g. ADP, as noted in a previous study conducted in our laboratory [303]. 
However, the aggregation results with Aβ25-35 do not support our laboratory’s previously 
published work [303] that highlighted the important role of Ca2+ and ADP in platelet 
aggregation upon activation with Aβ25-35 that mediated integrin activation and endogenous 
ADP release in the presence of extracellular calcium. The lack of platelet responses observed 
with Aβ peptides might be due to the different buffer used during the aggregation assays, as 
our buffer did not contain Ca2+, and also 1mM extracellular Ca2+ was not added prior to 
aggregation unlike the previous work [303]. These differences points towards the potential 
important role of extracellular calcium in inducing platelet aggregation. Therefore additional 
future experiments are required to study the effects of extracellular calcium on Aβ peptide-
induced platelet activation and aggregation with our peptides.  




Upon examination of the effects of Aβ peptides on platelet adhesion and thrombus formation 
under physiological shear stress, Aβ1-42 demonstrated evident platelet adhesion and 
thrombus formation under venous blood flow condition, while the other peptides did not. 
This study therefore, presents the first evidence that Aβ1-42 alone is sufficient to induce 
thrombus formation under physiological flow. Our previous study [303] showed that Aβ25-35 
alone was unable to induce thrombus formation under flow conditions, and the present 
results are also support of these observations. Aβ1-42 was shown to have a negligible effect 
on platelets under high shear stress or arterial blood flow, while it appears to potentially have 
a greater influence upon inducing thrombus formation under venous flow. The present data 
are supportive of previously published observations with CAA on how larger arteries are 
less affected in severity to CAA than arterioles or capillaries [142].  Therefore, Aβ1-42 that 
accumulates within the microvasculature is most likely to contribute towards the 
thromboembolic complications observed in AD.  
The present study also revealed that Aβ1-42, but not Aβ1-40, Aβ25-35, or scrambled Aβ1-
42, induced integrin αIIbβ3 activation, which is a marker of platelet activation, but did not 
caused α-degranulation associated with full platelet activation. This highlights the profound 
biological effects of Aβ1-42 on platelets. It also suggests that Aβ1-42 induces partial platelet 
activation that involves platelet adhesion, but not degranulation and content release. The lack 
of Aβ1-40 and Aβ25-35 peptides efficiency in activating of integrin αIIbβ3 in this study, is 
partially in contrast with other previously published work, which showed the ability of these 
peptides to induce platelet activation, enhanced intracellular signalling, and phosphorylation 
of key signalling proteins [303, 307, 341].  
Some limitations should be acknowledged in the work presented, which also suggest areas 
for future additional investigations. For example, the monomeric form of Aβ peptides 
received from manufacturers was not verified using TEM microscopy, although a second in-
house analysis was conducted on Aβ peptides using HPLC and MS to verify the composition 
of the compounds received. Also, despite the extra precautions taken during the preparation 
of Aβ stock solutions in DMSO, potential formation of Aβ dimers or oligomers theoretically 
can occur. DMSO is a commonly used solvent that prevents β-sheet formation and maintains 
the monomeric form of Aβ in stock solutions. However, if there are existing pre-formed 
dimers, tetramers, or oligomers, then DMSO cannot reverse them back to their monomeric 
forms. The FITC-labelled Aβ peptides in this study were used only to visualize the ability 
of Aβ peptide to bind to platelets using flow cytometry, however, this fluorescence labelling 
technique does not reveal which part of the peptide sequence binds to platelets. Identifying 




the Aβ binding sequence or the portion of the peptide that binds to platelets would therefore 
be important in future studies. Finally, platelets in blood circulation have a different age, 
maturation state, size, and density, and they vary greatly within an individual, where some 
platelets have a more procoagulant and reactive capability compared to others [352]. These 
different features of platelets creates what is referred to as, platelet subpopulations, that carry 
out different biological functions [352]. In this research project however, platelet 
subpopulations were not investigated and how relevant the effects of Aβ on these 
subpopulations and their level of adhesion is not clear, but can potentially be investigated in 
a future research project.  
Overall, the present study highlights the profound biological activity of Aβ1-42 on platelet 
adhesion, activation, and aggregation. However, the receptor responsible for the initial 
engagement of Aβ1-42 to platelets still remains unclear. The engagement of many receptors 
has been now demonstrated with Aβ1-40 and Aβ25-35 in previous studies, including PAR1, 
CD36, GPIbα, integrin αIIbβ3, and partially APP 
[296, 302, 307, 341, 353, 354]. The most recent study 
last year by Elaskalani’s group [345], also demonstrated the ability of Aβ1-42 to act as a ligand 
for GPVI. This could explain the observations obtained from the experiment with thrombus 
formation under venous flow. The present study does not solve the question of which 
receptor may be involves in the interactions with Aβ1-42 and further studies are required. 
However, this study sheds a new light on the abilities of Aβ1-42 to support thrombus 
formation at vascular lesions or CAA at an accelerated rate, and further supports previous 














































Platelets are critical for the regulation of haemostasis and play a key role in cardiovascular 
pathologies. Understanding their intracellular physiological regulation is thus of great 
importance. Activation of platelets elicits an intricate physiological response leading to its 
adhesion, activation, aggregation, and secretion of a large range of biologically active 
substances that profoundly affect different cells and molecules within its vicinity. An 
important aspect of this response is, the ability of platelets to generate endogenous reactive 
oxygen species (ROS). Several studies have now shown that ROS are critically involved in 
platelet intracellular signal transduction pathways and subsequent amplification of platelet 
responses and agonist release [355-359]. 
ROS are considered secondary cellular signalling molecules that modulate the activity of a 
number of protein kinases as well as protein phosphatases [360, 361]. Ligand-induced activation 
and ROS generation can result in protein tyrosine phosphorylation, and also catalytic 
inactivation of PTP enzymes by oxidation. Decrease of intracellular ROS concentrations 
allows the recovery of PTP enzymatic activity, thus resulting in dephosphorylation of 
phosphorylated protein and signal termination. Therefore, ROS are considered critical 
regulators of platelet activation and thrombosis [361-363].   
ROS are short-lived diffusible molecules, typically possess one or more unpaired electrons 
that are generated by oxygen reduction or from oxygen-derived free radicals [316]. There are 
several sources of ROS identified in platelets including, mitochondrial respiration, NADPH 
oxidase, xanthine oxidase, lipoxygenases, cyclooxygenase, arachidonic acid-dependent 
phospholipase, and uncoupled endothelial nitric oxide synthase [317]. Several species of 
reactive oxygen are produced and they include superoxide anion (O2
-•), hydroxyl radical 
(OH•), Hydrogen peroxide (H2O2), and peroxynitrite (ONOO
-•) [312]. Platelets also contain 
an endogenous antioxidant system or are affected by exogenous antioxidants that counteract 
the damaging effects of these radical species to maintain redox homeostasis, such as 
glutathione reductase and peroxidase, superoxide dismutase (SOD), catalase, α-lipoic acid, 
vitamin E and C, and minerals, such as, Zn, Mn, Cu, Se…etc [364-366].  
Superoxide anion (O2
-•) is considered central to ROS chemistry and can act as a precursor 
for many other ROS species, due to its highly reactive nature [314]. Superoxide anion 
generated by xanthine oxidase, NADPH oxidase, or mitochondrial activities, can rapidly 




interact with nitric oxide (NO) and produce highly reactive nitrogen species, such as 
peroxynitrite (ONOO-•), which in turn gives rise to hydroxyl radical and nitrogen dioxide 
(NO2) that damages cells when protonated [87, 367-369]. Alternatively, O2
-• can be converted 
to hydrogen peroxide (H2O2) by the enzymatic action of superoxide dismutase (SOD), and 
it is more stable and membrane-permeable than superoxide anion [315]. H2O2 is most 
efficiently scavenged by the enzymatic action of glutathione peroxidase, which utilizes 
glutathione (GSH active and reduced form) to produce water and glutathione disulfide 
(GSSG, inactive and oxidised form). The oxidised GSSG is then reduced back to GSH by 
the enzyme glutathione reductase, which utilizes NADPH as an electron donor. H2O2 can 
also be degraded by the enzymatic action of catalase into water and oxygen. Some transition 
metals such as Fe2+ or Cu+, are able to breakdown H2O2 into the reactive hydroxyl radical 
that is extremely damaging to the cell in a reaction known as Fenton reaction [366].  
Normally, the intracellular redox environment of platelets is balanced and maintained at an 
equilibrium between the presence of oxidant agents (e.g. reactive oxygen species (ROS) and 
reactive nitrogen species (RNS)) and anti-oxidant systems e.g. glutathione and vitamins, that 
is crucial for the cell physiological functions [370]. However, if ROS generation is not counter-
balanced by the antioxidant system of the cell, oxidative stress is induced that modifies cell 
physiology and potentially damages proteins, cell membrane lipids, and nucleic acids. 
Oxidative stress can be caused by environmental agents, such as, pollution or radiation, and 
it also accompanies many pathological conditions, such as cancer, cardiovascular and 
neurodegenerative diseases, diabetes, and also ageing [370-378]. A summary of the sources of 
platelet ROS, free radicals, and antioxidants are represented in Figure 4.1.  
 
 
Figure 4.1: Summary of platelet sources of ROS, free radical formation, and antioxidant enzymes. 
(Original figure created from [312, 317, 366]).    




Superoxide anion is considered an important source of oxidative stress since it is central to 
ROS chemistry. One of the main sources of superoxide anion generation in platelets, are 
NADPH oxidases (NOXs), with their sole function is superoxide generation [367]. NADPH 
oxidases (NOXs) are complex multiunit enzymatic systems that are able to transfer an 
electron to oxygen resulting in superoxide anion formation [379, 380]. The constituents of this 
multi-protein complexes are comprised of a catalytic subunit, which contains a conserved 
six transmembrane-spanning regions of α-helices with cytosolic N- and C-termini, and 
several regulatory subunits that are localized in both the cytoplasm and cell membrane [381].   
Seven NOX family members have been reported, i.e. NOX1, NOX2, NOX3, NOX4, NOX5, 
Dual oxidase 1 (Duox1), and Dual oxidase 2 (Duox2), with NOX1 and NOX2 isoforms 
being shown to be expressed in mouse and human platelets [357, 382, 383]. NOX1 activation 
occurs when NOX1 binds to associated membrane protein P22phox with their cytosolic 
subunits NOX organizer 1 (NOXO1; analogue to p47phox), NOX activator 1 (NOXA1; 
analogue to p67phox), and small GTPase Rac, forming multicomponent protein complex [384]. 
NOX1 has also been shown to be able to utilize p47phox and p67phox subunits [385]. Similarly, 
NOX2 (gp91phox) binds to associated membrane protein P22phox with their cytosolic subunits 
p47phox, p67phox, and p40phox, and small GTPase Rac1/2 [384]. A representative diagram of 
NOX1 and NOX2 structures is shown below in Figure 4.2.   
 
Figure 4.2: Schematic representation of structure of NADPH oxidase enzymes (1 and 2) and assembly 
of subunits. (Modified from [386]) 
 
Several studies have demonstrated the critical role of ROS in regulating platelet activity. 
This includes the ability of O2
-• to increase ADP release and bioavailability, which leads to 




increased recruitment and activation of additional platelets [314]. Platelet stimulation with 
thrombin, collagen, or thromboxane has been shown to activate NOXs resulting in the 
generation of ROS, which modulated the activation of integrin αIIbβ3 that is independent of 
the NO/cGMP signalling pathway [387, 388]. Human and mouse platelets have also been shown 
to express both NOX1 and NOX2, and NOX1 inhibition using the NOX1-selective inhibitor 
2-acetylphenothiazine (2-APT), was found to significantly attenuate superoxide anion 
formation but not overall ROS generation when simulated with collagen [383]. NOX1 but not 
NOX2 was also shown to be involved in GPVI-induced ROS generation that was required 
for p38 MAPK signalling activation and subsequent release of TXA2 in platelets [389], while 
thrombin-induced ROS generation via GPIbα and PAR4 (but not PAR1) receptors was 
shown to be mediated via NOX1 and FAK proteins [357]. Finally, platelet activation and 
signalling through the scavenger receptor CD36 by oxidised low density lipoprotein 
(oxLDL) has been shown to involve NOX2-derived ROS generation and a PKC dependent 
pathway [390], while NOX1 and NOX2 knockout mice revealed a differential role for these 
NOXs in different platelet activation pathways and thrombus formation with their ROS 
involving Syk/PLCγ2/calcium signalling to promote platelet activation [391]. 
In previous studies, the inhibition of platelets and anti-thrombotic effects of antioxidants 
have demonstrated the dependency of platelet activation on ROS generation [392, 393]. 
However, few studies have reported the formation of ROS upon Aβ peptides stimulation of 
platelets. Aβ1-40 has been shown to induce ROS generation, mitochondrial depolarization, 
and increased cytosolic calcium in platelets [295], while another study used the ROS detection 
method known as electron spin resonance (ESR), to show that 2-10 µM of Aβ25-35 triggers 
hydroxyl radical formation [297]. An additional study showed that Aβ25-35 increased 
cytosolic calcium and ROS generation in platelets [340]. Information gathered from these 
studies suggests the possibility of Aβ peptide involvement in activating platelets via 
induction of redox stress. However, the exact cellular mechanism by which Aβ peptides 
activate platelets and regulate haemostasis and thrombosis remains to be defined.  
Redox-dependent regulation of platelets remains challenging due to the complexity of ROS 
biochemistry and the lack of a reliable and easily accessible ROS detection methodology in 
the platelets field [394, 395]. Understanding oxidants regulation in platelets relevant to Aβ 
peptides effects, can provide important insights into the mechanisms relating to its roles in 
haemostasis and thrombosis, both in health and disease. This information can be utilized for 
future development of pharmacological and antithrombotic treatments based on regulating 
ROS generation and platelet activation. The present study aimed to investigate the 




mechanisms underlying Aβ peptide-dependent activation of platelets and the potential role 
of ROS in this pathophysiological event. The challenging aspect of ROS detection 
methodology in the platelets field, prompted the exploration and utilization of different ROS 
detection techniques. The study in this chapter aimed to explore and assess oxidative changes 
in platelets upon stimulation with Aβ peptides (Aβ25-35, Aβ1-40, Aβ1-42, and scrambled 
























4.2. AIMS & OBJECTIVES 
 Determine whether the molecular probe DCFDA (6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate) allows the reliable detection of intracellular 
ROS in platelets using both physiological agonists and amyloid peptides as stimuli. 
 Determine whether the molecular probe DHE (Dihydroethidium) allows the reliable 
detection of intracellular superoxide anion in platelets using both physiological 
agonists and amyloid peptides as stimuli. 
 Determine the source of ROS produced upon Aβ peptide-induced platelet activation 
using ROS and NOX inhibitors.  
 Quantitative confirmation of Aβ peptide-induced platelet ROS using electron 



















4.3.1. ROS detection in platelet using DCFDA  
Subcellular detection and localization of ROS is crucial in understanding cellular redox 
status, therefore, the use of reliable ROS detection methods is important. The initial approach 
in this study was to utilize the wildly reported fluorescent molecular probe carboxy-
H2DCFDA (6-carboxy-2',7'-dichlorodihydrofluorescein diacetate; Life Technologies) to 
measure oxidative stress in platelets [357, 383, 387-390]. H2DCFDA has the ability to permeate 
the cell membrane into the cytosol as a non-fluorescent molecule, where it is then becomes 
subject to hydrolysis by cellular esterases into H2DCF carboxylate anion (non-fluorescent). 
H2DCF can be oxidised by hydroxyl radical, carbonate radical, and nitrogen dioxide, as well 
as by thiyl radicals resulting from thiol oxidation.  This results in H2DCF forming a DCF 
radical that is then further oxidised into fluorescent DCF [395-397]. Figure 4.3 (A) briefly 
demonstrates the conversion of H2DCFDA to fluorescent DCF. There are certain limitations 
associated with any ROS detection assay, therefore caution should always be taken, as 
artefacts can be generated in in vitro conditions that are not usually encountered in vivo.  
A pilot study was conducted where platelet rich plasma (PRP) was incubated with 10 μM 
carboxy-H2DCFDA for 45 min then centrifuged to isolate platelets in the presence of 
indomethacin and PGE1 to avoid mechanical stress-induced platelet activation. Platelets 
were then resuspended in modified Tyrode’s-HEPES buffer and tested in 96-well 
microplates using a fluorescence microplate reader at excitation/emission wavelengths 
485/530 nm. The results are shown in Figure 4.3 (B). H2O2 (20 μM) was used as a platelet 
stimulus and positive control when testing the effects of monomeric Aβ25-35, Aβ1-40, and 
Aβ1-42 (20 μM). ROS scavenger N-acetyl-L-cysteine (NAC) at 1 and 30 mM was used as 
a negative control. N-acetyl-L-cysteine (NAC) is an aminothiol that functions as a precursor 
for the intracellular antioxidants glutathione (GSH) and cysteine, which in turn act as 
substrates for ROS scavenging enzymes and play a pivotal role in apoptosis regulation [398, 
399]. Neither oxidative stress induced by H2O2 nor the antioxidant activity of NAC could be 
detected with this method, as shown by the lack of statistical significance of the data shown 


























































   
Figure 4.3: Preliminary study on ROS generation in live platelet suspension using microplate reader.  
(A) Summary of the formation of fluorescent compound DCF by ROS (Image was obtained from bio-
protocol.org). (B) DCF fluorescence levels detected in platelets that are tested with different stimuli (H2O2, 
Aβ25-35, Aβ1-40, and Aβ1-42; 20 μM). The effects of the ROS scavenger, N-acetyl-L-cysteine (NAC) at 2 
different concentrations (1 and 30 mM) on stimulated platelets are also shown. Statistical significance was 
analysed from 3 independent experiments using one-way ANOVA with Bonferroni post-test. Error bars 
represent mean + SEM. 
 
The results displayed high basal saturation levels causing inaccurate ROS readings. Several 
follow up experimental attempts (data not shown) exploring different concentration and 
incubation times were also a failure and generated varied and inconsistent results. Therefore, 
the idea of using the microplate reader was discarded and detection using flow cytometry 
was the next step followed to investigate ROS generation in live platelets. Adopting a 
previously published DCFDA protocol [387], several platelet agonists were investigated to 
assess the validity of this ROS detection method, including thrombin, collagen, collagen 
related peptides (CRP), arachidonic acid (AA), oxidised low density lipoprotein (oxLDL), 
or adenosine diphosphate (ADP). DCF fluorescence was detected by flow cytometry and the 
results obtained appeared to be more promising as shown in Figure 4.4. The results from the 
present study show significant ROS generation upon stimulation with collagen, thrombin, 
and CRP compared to resting platelets, but AA, ADP, and oxLDL did not induce ROS at the 





















































































































































































































































































Figure 4.4: Determination of optimum concentrations for 6 different stimuli to detect ROS generation 
in live platelet suspensions by flow cytometry.  
Platelets were stimulated with different agonists for 30 min. (A) Different concentrations of thrombin (1 and 
0.3 unit/ml) showing statistical significance compared to resting. (B) Different concentrations of collagen with 
only 30 µg/ml showing statistical significance compared to resting. (C) Different concentrations of collagen-
related peptide (CRP) with (3 and 10 µg/ml) showing statistical significance compared to resting. (D-F) 
Different concentrations of arachidonic acid, of oxidised low-density lipoprotein (oxLDL), and adenosine 
diphosphate (ADP) show no statistical significance ROS generation compared to their controls (i.e. ethanol, 
ctrl nLDL, or resting platelets respectively).  Statistical significance was analysed using one-way ANOVA with 
Bonferroni post-test; P-value < 0.0001 (****), P-value <0.01 (**), and P-value <0.05 (*). Error bars represent 
mean + SEM. 
 
In order to validate ROS detection in this assay, the effects of the ROS scavenger NAC at 
different concentrations (3 and 30 mM) and different pre-incubation times (3 and 30 min) 
were assessed before adding collagen (30 µg/ml) as a platelet agonist and the results are 
shown in Figure 4.5. Both collagen and thrombin were shown to have significant effects on 
platelet ROS generation, however, since thrombin had greater variability in results with 
DCFDA (error bars) compared to collagen, collagen was used in this experiment as positive 
control, and to also test the effect of NAC in scavenging collagen-stimulated ROS generation 
in platelets. Pre-incubation with 3 mM NAC showed a slight decrease in ROS, while 30 mM 
NAC at 3 and 30 min both show a marked decrease in DCF fluorescence. 
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Figure 4.5: Optimum time and concentration for use of NAC as ROS scavenger on stimulated platelet 
suspensions.  
Different NAC concentrations were tested with pre-incubation periods of 3 and 30 min before adding collagen 
to stimulate ROS generation. 30 mM NAC shows decreased DCF fluorescence to almost control level (resting) 
but not 3 mM NAC. Statistical significance was analysed using one-way ANOVA with Bonferroni post-test. 
Error bars represent mean + SEM. 
 
The effects of Aβ peptides on platelet ROS generation were assessed next and the results are 
shown in Figure 4.6. Aβ25-35 shows significant levels of DCF fluorescence when compared 
to resting platelets, but these are not significant when compared to scrambled Aβ1-42. Aβ1-








































Figure 4.6: Effects of different Aβ peptides on ROS generation in live platelet suspensions detected by 
flow cytometry.  
Aβ25-35 shows significant levels of DCF fluorescence when compared to resting platelets, but was not 
significant when compared to scrambled Aβ1-42. Aβ1-40 and Aβ1-42 did not show significant DCF 
fluorescence compared to resting or scrambled Aβ1-42. Aβ peptides were dissolved in DMSO 0.4%, so DMSO 
alone was also tested to check that it did not have any effects on platelets at that dose. Statistical significance 
was analysed using one-way ANOVA with Bonferroni post-test; P-value <0.05 (*). Error bars represent mean 
+ SEM. 





Looking at the overall results with DCFDA, DCF fluorescence values seem insufficient or 
diminished for the different physiological agonist used, as the concentrations to obtain a 
detectable response are too high compared to normal concentrations used in vitro. Therefore 
a second molecular probe for the detection of ROS, in particular superoxide anion, was 
investigated next.   
 
4.3.2. Superoxide detection in platelets using Dihydroethidium  
 
Dihydroethidium (DHE; Life Technologies) has been suggested as an accurate and non-
problematic molecular probe for intracellular superoxide anion detection [400]. When DHE 
enters the cell and interacts with ROS, it forms one of two detectable molecules that are 
retained within the cells known as, 2-hydroxy-ethidium (2OH-Et+), which is formed when 
DHE interacts with superoxide anion, or ethidium, which is when DHE interacts with other 
oxidants [395]. 2OH-Et+ absorbs light at 405nm and 480nm with emission at 580nm, while 
ethidium absorbs light only at 480nm with emission at 580nm. Therefore, fluorescence 
measurements at 405/580 ex/em enables the assessment of 2OH-Et+ generation, which is 
directly proportional to the amount of superoxide anion interacting with DHE. This dye can 
therefore be used to reliably determine the level of intracellular superoxide anion by flow 
cytometry. Figure 4.7 (A) shows the structural and spectral properties of DHE and its two 
oxidation products ethidium and 2-hydroxy-ethidium (2OH-Et+).  
A study was initially carried out to determine the optimum incubation time with DHE in our 
experimental conditions using the potent platelet agonist, thrombin, and the results are 
shown in Figure 4.7 (D). Since thrombin has previously been shown to have the greatest 
impact in generating ROS in platelets and because a new intracellular molecular probe 
(DHE) was being used to detect superoxide anion generation, thrombin was chosen as a 
positive control to test. In addition, not many studies on platelets have used DHE, and 
therefore, it was necessary to determine the ideal incubation time with DHE for the detection 
of superoxide anion under our experimental conditions. According to the results in Figure 
4.7 (D), 15 min incubation with DHE yielded the highest detectable fluorescence when 
platelets were stimulated with thrombin, and thus, all subsequent experiments were carried 









                



















































Figure 4.7: Use of DHE to detect superoxide anion formation in platelets.  
(A) Structural and spectral properties of DHE and its two oxidation products, ethidium and 2-hydroxy-ethidium 
(2OH-Et+). The excitation peak at 405 nm specific for 2OH-Et+ is highlighted with a blue rectangle [401]. (B) 
Flow cytometry gating shown in a forward (FSC) vs side scattering (SSC) plot. (C) Representative example of 
the fluorescence shift by thrombin-dependent stimulation of platelets in the 2OH-Et+ fluorescence (405/580 
nm ex/em). (D) Platelet suspensions were rested for 30 min at 37°C before incubation with 5 μM DHE for 15 
min. Platelets were then stimulated with physiological stimulus thrombin (0.5 unit/ml) at different time points 
to determine optimal stimulation time. The optimal stimulation time of platelet using DHE shown to be at 15 
min. Statistical significance was analysed from 4 independent experiments using one-way ANOVA with 
Bonferroni post-test; P-value < 0.0001 (****). Error bars represent mean + SEM. 
 
 
In order to examine the new optimised methodology with DHE, further tests on superoxide 
generation in platelets were carried out using varying concentrations of different 
physiological stimuli, i.e. thrombin, collagen, CRP, AA, oxLDL, and ADP. The results in 
Figure 4.8 (A-E) show statistically significant superoxide anion generation with thrombin 










oxidised LDL (30, 100, and 300 µg/ml), but not ADP compared to resting platelets (Figure 
4.8 (F)).  
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Figure 4.8: Determination of the concentration dependence of superoxide anion generation for 6 
different stimuli.  
Platelets were stimulated with different agonists for 15 min. (A) Different concentrations of thrombin 0.1, 0.3, 
and 1 unit/ml showing statistical significance compared to resting platelets. (B) Different concentrations of 
collagen with only 30 µg/ml showing statistical significance compared to resting platelets. (C) Different 
concentrations of collagen-related peptide (CRP) with 3 and 10 µg/ml showing statistical significance 
compared to resting platelets. (D) Different concentrations of arachidonic acid with 10 µM and 30 µM showing 
statistical significance compared to ethanol stimulated and resting platelets. (E) Different concentrations of 
oxidised low-density lipoprotein (oxLDL) with 30, 100 and 300 µg/ml showing statistical significance 
compared to nLDL stimulated and resting platelets. (F) Different concentrations of adenosine diphosphate 
(ADP) show no statistical significance compared to resting platelets. Statistical significance was analysed from 
4 independent experiments using one-way ANOVA with Bonferroni post-test; P-value < 0.0001 (****), P-
value < 0.001 (***), and P-value <0.01 (**). Error bars represent mean + SEM. 
 
 
The new optimised method with DHE was further validated with using ROS scavenger NAC 
and NOX inhibitors. NAC concentration-dependent experiments were carried out using 
thrombin (0.3 unit/ml) as a physiological stimulus to determine the optimal concentration of 
NAC to be used in future experiments for DHE.  The results are shown in Figure 4.9 (A).  
NAC concentrations of 3 mM, 100 µM, 30 µM, and 10 µM, significantly decreased 
superoxide anion generated by thrombin. NAC at 3 mM seems to ideally abolish ROS and 
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bring the fluorescence values of platelets down to basal level similar to the resting state. 
Therefore, another set of experiments were also carried out testing its efficiency with other 
physiological stimuli and the results are show in Figure 4.9 (B). 3 mM NAC significantly 
reduced superoxide generated by CRP (3 µg/ml), and oxLDL (30 µg/ml) but not platelets 











Figure 4.9: Investigation of the effects of the ROS scavenger NAC at different concentrations on 
platelet superoxide anions formation by different physiological stimuli.  
After platelets were isolated and resting for 30 min in water baths, 5 µM DHE was added for 15 min. (A) 
Different concentrations of NAC were pre-incubated with platelets for 10 min before adding 0.3 u/ml thrombin 
to investigate optimal NAC concentration to be used. At the end of the incubation time, platelet suspensions 
were diluted 1:10 in cold modified Tyrode’s-HEPES buffer and samples were analysed immediately by flow 
cytometry. All the different concentration of NAC (3 mM, 1 mM, 100 µM, 30 µM, and 10 µM) shown statistical 
significance. (B) Other stimuli (collagen related peptide (CRP, 3 µg/ml), arachidonic acid (AA, 10 µM), and 
oxidised low density lipoprotein (oxLDL, 30 µg/ml)) were tested with 3 mM NAC (which seemed to be ideal 
concentration based on results in (A)) and both CRP and oxLDL showed statistical significance with NAC but 
not AA. Statistical significance was analysed using one-way ANOVA with Bonferroni post-test; P-value < 




Different NOX inhibitors were assessed next on platelets stimulated with thrombin (0.3 
u/ml) including NOX inhibitor VAS2870 (10 µM), NOXA1ds (10 µM), and scrambled 
NOXA1ds (control). The results are presented in Figure 4.10 and showed that only the NOX 
inhibitor VAS2870 significantly eliminated the generation of superoxide anion, which 
suggests that thrombin-stimulated superoxide anion generation is mainly NOX-dependent. 
When NOX1 inhibitor (NOXA1ds) was used, no significant decrease in the fluorescence 
was observed when compared to vehicle or scrambled NOXA1ds (control), indicating that 
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Figure 4.10: The effects of NOXs inhibition in platelets stimulated by thrombin. After platelets were 
isolated and rested for 30 min in a water bath, 5 µM DHE was added for 15 min. The following inhibitors were 
used (10 µM NOX inhibitor VAS2870, 10 µM scrambled NOXA1ds control for NOXA1. These inhibitors 
were incubated with platelets for 10 min before being stimulated with thrombin (0.3 unit/ml) for another 15 
min. At the end of the incubation time, platelets were diluted 1:10 in cold modified Tyrode’s-HEPES buffer 
and samples were analysed immediately by flow cytometry. VAS2870 significantly abolished superoxide anion 
produced by thrombin when compared to thrombin alone (Vehicle). Statistical significance was analysed from 
4 independent experiments using one-way ANOVA with Bonferroni post-test; P-value < 0.0001 (****) and P-
value <0.01 (**). Error bars represent mean + SEM.  
 
From these results, both NAC at 3 mM and VAS2870 at 10 µM inhibited ROS and 
superoxide anion generation respectively in our experimental conditions, and thus were 
utilized at those concentrations in future experiments. Since superoxide detection assay with 
DHE was optimised, the effects of Aβ peptides on platelet redox homeostasis was finally 
tested and the results are shown in Figure 4.11. Only Aβ1–42 (20 μM) had a significant 
effects on superoxide generation compared to resting platelets and scrambled Aβ1–42 as 
control (Figure 4.11).  
 
Figure 4.11: Superoxide anion formation induced by Aβ peptides. Superoxide anion formation was 
measured as described in previous figures using DHE in response to 20 μM Aβ1–40, Aβ1–42, scrambled Aβ1–
42 or Aβ25-35. Only Aβ1–42 showed a significant statistical increase in superoxide anion formation compared 
to scramble control and the other peptides. Statistical significance was analysed using one-way ANOVA with 








































































Since Aβ1-42 peptide had shown significant superoxide generation, a concentration-
response study was carried out to find the optimum and minimum concentration of Aβ1-42 
peptide that could be used in our experimental conditions, and the results are shown in Figure 
4.12 (A). The results showed, a pronounced increase in superoxide anion generation with 
concentrations of Aβ1-42 greater than 10 μM. Since NAC (3 mM) and NOX inhibitor 
VAS2870 (10 μM) had been shown to be effective at abolishing ROS as seen previously 
with thrombin, CRP, and oxLDL, these concentrations were also tested with Aβ1-42 
stimulated platelets. Both the ROS scavenger NAC and the NOX inhibitor VAS2870 
significantly reduced Aβ1-42 peptide-dependent increase in superoxide anion formation as 
shown in Figure 4.12 (B). These results show that Aβ1-42-stimulated ROS generation in 
platelets is NOX-dependent.  
 
                     
Figure 4.12: Aβ1-42 concentration-dependent response of superoxide anion formation and the effects of 
ROS inhibition. Superoxide anion formation was measured as described in previous figures using DHE. (A) 
Different concentrations of Aβ1–42 (1–100 μM). (C) Superoxide anion formed after stimulation by Aβ1–42 
(100 μM) and inhibited by 10 min pre-incubation with ROS scavenger NAC (3 mM) or NOX inhibitor 
VAS2870 (10 μM). Statistical significance was analysed from 4 independent experiments using one-way 
ANOVA with Bonferroni post-test; P-value <0.05 (*), P-value <0.01 (**) and P-value < 0.0001 (****). Error 
bars representing mean + SEM.  
 
The new optimised methodology with DHE is easily accessible and promising, and the 
exciting results obtained with regards to the effects of Aβ peptides on platelet redox 










4.3.3. Superoxide detection in platelet using electron paramagnetic resonance (EPR)  
 
To confirm and further determine Aβ peptides-induced superoxide generation in platelets, 
electron paramagnetic resonance (EPR) experiments were carried out in collaboration with 
the EPR expert in our group, Dr. Dina Vara. Electron spin or paramagnetic resonance (ESR 
or EPR) spectroscopy is considered the “gold standard” technique among quantitative ROS 
detection assays in terms of accuracy and reliability [402, 403]. Generation of superoxide anion 
can be detected using the cell-permeable cyclic hydroxylamine spin probe, known as 1-
hydroxy-3 methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine (CMH). CMH is specific for 
the detection of intracellular superoxide anions and is resistant to auto-oxidation.  
When CMH crosses the plasma membrane and enters the cells, it can interact with oxygen 
radicals and form more stable radicals (nitroxide radical CM•) that last several hours and are 
detectable by EPR [395, 404, 405]. EPR operates by exciting transitions of unpaired electrons in 
a sample placed in an applied magnetic field through the absorption of microwave energy. 
The number of unpaired electrons present in the sample is proportional to the strength or 
amplitude of the EPR signal detected. The rate of (O2
-•) generated is measured as the rate of 
CMH oxidation and is represented as amplitude strength signal detected by EPR [251, 402, 406]. 
Using this technique, superoxide anion formed in platelets stimulated by scrambled Aβ1-42, 

















        
Figure 4.13: Detection of superoxide anion generated in response to Aβ peptide stimulation of platelets 
using EPR. (A-C) Different magnitude of EPR spectral peaks generated by the level of superoxide anion 
formed in platelets stimulated by scrambled Aβ1-42, Aβ25-35, Aβ1-42 and Aβ1-40 at 20 μM for 10 min. (D) 
Quantification and analysis of CMH oxidation rate from 3 or more independent experiments. Aβ1-42 and 
Aβ25-35 induced platelet activation show significant CMH oxidation rate compared to scrambled Aβ1-42 
(control) Statistical significance was analysed using one-way ANOVA with Bonferroni post-test; P-value 
<0.05 (*). Error bars representing mean + SEM.  
 
In support of the previous results with DHE methodology, Aβ1-42 induced significant 
superoxide anion generation compared to scrambled Aβ1-42. However, not only did Aβ1-
42 induce significant superoxide anion generation, but so did Aβ25-35 as shown in the 
results in Figure 4.13 (D). Therefore, the effects of Aβ1-42 and Aβ25-35-induced superoxide 
generation were further probed using NOX inhibitors to potentially identify the types of 
NOX involved. A series of EPR experiments were conducted testing several NOX inhibitors 
at 10 μM. These NOX inhibitors included:  VAS2870, which is a commercially available 
triazolo pyrimidine derivative that is a selective NADPH oxidase inhibitor but not isoform 
specific [381, 407]; 2-APT (2-acetylphenothiazine), a NOX1-selective inhibitor [383]; scrambled 
NOXA1ds (control); and NOXA1ds (also known as NOXA1 docking system), which is a 
cell-permeable peptide that exhibit selectivity for NOX1 and prevents the binding of the 
NOX activator 1 subunit [408, 409]; scrambled NOX2ds-TAT (control), and NOX2ds-TAT 
A B 
C D 




(also known as NOX2 docking sequence TAT or gp91ds-TAT) that is a peptide designed to 
inhibit the interaction between NOX2 and p47phox.  
The TAT portion of the last two inhibitors mentioned corresponds to 9 amino acids that 
facilitate cell membrane entry and internalization of the peptide [408, 410]. EPR results using 
all of the NOX inhibitors with Aβ1-42 and Aβ25-35 are shown in Figures 4.14 and 4.15 
respectively. Stimulated platelets revealed noticeable and statistically significant superoxide 
inhibition for both NOXs. These results confirm that superoxide generation from Aβ1-42 
and Aβ25-35-induced platelet activation is NOX-dependent and highlights the underlying 





Figure 4.14: Aβ1-42 induced superoxide anion generation in platelets is NOX dependent. (A-C) Different 
magnitude of EPR spectral peaks generated by the level of superoxide anion formed in platelets upon Aβ1-42 
(20 µM) stimulation in the presence or absence of VAS2870 (10 μM), 2-APT (0.5 μM), scrambled NOX2ds-
TAT (control), NOX2ds-TAT (10 μM), scrambled NOXA1ds (control) and NOXA1 (10 μM). (D) 
Quantification and analysis of CMH oxidation rate from 3 or more independent experiments. Inhibition of 
either NOXs significantly abolished superoxide generation in platelets stimulated with Aβ1-42 compared to 
controls. Statistical significance was analysed using one-way ANOVA with Bonferroni post-test; P-value 











                  
Figure 4.15: Identifying sources of Aβ25-35-induced superoxide anion generation in platelets using 
different NOX inhibitors with EPR. (A-B) Different magnitude of EPR spectral peaks generated by the level 
of superoxide anion formed in platelets upon Aβ25-35 (20 µM) stimulation in the presence or absence of 
VAS2870 (10 μM), 2-APT (0.5 μM), scrambled NOX2ds-TAT (control), NOX2ds-TAT (10 μM), scrambled 
NOXA1ds (control) and NOXA1 (10 μM). (D) Quantification and analysis of CMH oxidation rate from 3 or 
more independent experiments. Inhibition of either NOXs significantly abolished superoxide generation in 
platelets stimulated with Aβ25-35 compared to controls Statistical significance was analysed using one-way 
ANOVA with Bonferroni post-test; P-value <0.05 (*). Error bars representing mean + SEM.  
 
The fibrillar form of Aβ peptides has previously been reported to have significant effects on 
platelet activation and aggregation [302, 307, 336, 345, 353]. For example, it has been shown that 
the fibrillar form of Aβ1-40 induced platelet aggregation in a time-dependent manner and 
Aβ1-40 fibrils could activate platelets through scavenger receptor CD36/P38 MAPK/ TXA2 
release, and also through GPIbα-mediated aggregation [302]. In addition, strong evidence for 
platelet contribution to CAA was shown by modulation of soluble Aβ1-40 into the fibrillar 
form, which facilitated platelet adhesion at vascular Aβ deposition sites [295, 307]. 
Furthermore, fibrillar Aβ1-40 and Aβ1-42 have been previously demonstrated to bind to 
APP on neurons at a concentration range of 5-20 µM [353]. APP and its homologues have 
been shown to be able to homo- or heterodimerize and form cell surface receptor-like 
complexes that are able to modulate signalling events and facilitate integrin-mediated cell 








This notion has been recently supported by our group with APP KO mice, where it has been 
demonstrated that adhesion on immobilized Aβ peptides Aβ1–40, Aβ1–42 and Aβ25–35 was 
completely abolished in platelets lacking APP, but did not affect their aggregation. It also 
showed that Aβ-promoted potentiation of thrombus formation under flow and APP may 
facilitate an early step in thrombus formation [354]. These studies demonstrated the 
importance of understanding the effects of the fibrillar forms of Aβ peptides on platelets.  
However, there is a lack of studies on the effects of fibrillar Aβ peptide-induced platelet 
activation on ROS generation. Therefore, since soluble Aβ peptides, particularly Aβ1-42, 
had been shown to induce ROS production, an assessment to test ROS generation in platelets 
induced with fibrillar form of Aβ peptides was desirable. A pilot study was therefore first 
carried out for the fibrillization of Aβ peptides using the Thioflavin T (ThT) assay following 
the BMG LABTECH handbook protocol (see below). Aβ fibrils are naturally large, 
insoluble, non-crystalline, and resistant to degradation, and their formation usually occurs 
from normal soluble proteins. Structural studies using X-ray diffraction, electron microscopy 
(EM), and solid-state nuclear magnetic resonance (NMR) [413-415] have revealed that Aβ 
fibrils are composed of a β‑sheet structure, where the β-strands are arranged perpendicular 
to the fibrillar axis. The β-sheet strand edges are unstable, and can grow by interacting with 
any other β-strands they encounter [416]. Due to the repetitive nature of peptide self-assembly, 
recurrent side-chain interactions arise that run across β-strands within a β-sheet layer, 
parallel to the long axis of the fibril. This specific arrangement of side chains is called the 
“cross strand ladder” [413-415, 417].  
The most convincing theoretical model of fibril formation is known as the “nucleation-
dependent polymerization model”, where the fibrillation process consists of three distinct 
stages known as nucleation, elongation, and equilibrium, leading to a sigmoid-shaped profile 
[418, 419] as shown in Figure 4.16 (A). The hydrophobic and fibrillogenic nature of amyloid 
peptides, especially Aβ1-42, allows them to undergo fibrillation in a self-propagating 
manner. It starts with a relatively long lag-phase (nucleation phase), where oligomeric 
nucleus ‘seeds’ are formed, which then allows further addition of monomers in a fast 
propagation phase (elongation phase), ultimately resulting in the formation of amyloidogenic 
β-sheet fibrils that are stabilized (equilibrium phase) [418]. Thioflavin T (ThT) is a 
benzothiazole dye that binds along the surface side-chain grooves of β-sheet fibrils and 
becomes fluorescent, thus allowing the monitoring of amyloid fibrillization [417].  
Using the ThT assay, 100 µM Aβ peptides (scrambled Aβ1-42, Aβ1-42, Aβ1-40, and Aβ25-
35) were added to a well-plate containing aggregation buffer and ThT, and their fluorescence 




was measured under agitation for 40 hours by microplate reader. The results in Figure 4.16 
(B) show fluorescence intensity endpoints and high fibrillization profiles for Aβ1-42, Aβ25-
35, and Aβ1-40, compared to scrambled Aβ1-42. However, the fibrillization of these 
peptides were not statistically significant when compared to control, possibly due to the high 
error bars. Samples of these fibrils were tested on platelets for superoxide detection with 
DHE at 5 µM (data not shown) but no response was detected and these results suggested that 
the protocol required further optimisation and characterisation of peptide fibrils with 
transmission electron microscopy (TEM) before testing on platelets.  
Since these fibrils were to be mainly used as tools in this project, we collaborated with 
experts in misfolded protein chemistry, Dr. Janet Kumita and Prof. Christopher Dobson, 
from the University of Cambridge. They were able to provide us with a small sample of only 
fibrillar Aβ1-42, but not the other peptides. Flash-frozen fibril samples were prepared in 
Cambridge from 100 µM monomeric Aβ1-42 with 4% DMSO in PBS, and were stored at -
20 °C. The effect of Aβ1-42 fibrils upon platelet superoxide anion generation was then tested 
in our laboratory in Bath. Platelets were stimulated with scrambled Aβ1-42, soluble Aβ1-42, 
and fibrillar Aβ1-42 in the presence of DHE, and the results showed that both soluble and 
fibrillar Aβ1-42 induced significant superoxide generation in platelets as displayed in Figure 
4.16 (C).  
Since fibrillar Aβ1-42 had been shown to induce superoxide anion generation, a follow up 
aggregation experiments were carried out to test the ability of this form of the peptide to 
promote platelet aggregation. Fibrillar Aβ1-42 was tested as an agonist alone or as a co-
agonist with either 0.05 unit/ml thrombin or 3 µg/ml collagen. The aggregation results are 
presented in Figure 4.16 (D, E and F). Surprisingly, fibrillar Aβ1-42 did not induce even 
moderate platelet aggregation at a concentration of 1 µM, but platelet aggregation was 
slightly potentiated in the presence of collagen or thrombin. These results suggest that higher 





























Figure 4.16: Effects of Aβ1-42 fibrils on superoxide anion formation and platelet aggregation.  
(A) Nucleation dependent polymerization model for predicted amyloid fibril formation (modified from [418]. 
(B) Fluorescence intensity endpoints were quantified and analysed from 3 independent experiments for Aβ1-
42, Aβ25-35, and Aβ1-40 and scrambled Aβ1-42 as control. (C) Superoxide anion formation upon fibrillar 
Aβ1-42 stimulation that was measured as described in previous figures using DHE.  (D-E) Representative 
aggregation curves induced solely by 1 µM Aβ1-42 fibrils or co-stimulated with 0.05 u/ml thrombin (D) or 
collagen 3 µg/ml (E). (F) Quantification of average percentage aggregation of fibrillar Aβ1-42 stimulated 
platelet from 4 independent experiments. Statistical significance was analysed using one-way ANOVA with 
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4.4. SUMMARY OF RESULTS 
 The use of DCFDA for the detection of ROS appears promising as it showed ROS 
generation in platelets upon stimulation with thrombin (0.3 and 1 unit/ml), collagen 
(30 µg/ml), CRP (10 µg/ml), and Aβ25-35 (20 µM) but not Aβ1-40 or Aβ1-42. 
However, overall DCF fluorescence values and responses detected were quite low in 
spite of using high concentrations of different physiological agonists compared to 
normal concentrations used in vitro.  
 A novel and reliable method was developed using DHE as a molecular probe for the 
detection of superoxide anion. Superoxide anion was significantly detected upon 
stimulation with thrombin (0.1, 0.3, and 1 unit/ml), collagen (30 µg/ml); CRP (3 and 
10 µg/ml), arachidonic acid (10 and 30 µM), oxidised LDL (30, 100, 300 µg/ml) when 
compared to resting platelets; and also Aβ1-42 (20 µM), but not Aβ1-40 or Aβ25-35 
when compared to scrambled control. 
 3 mM NAC and 10 µM VAS2870 were sufficient to abolish ROS or superoxide 
generation in Aβ1-42 stimulated platelets   
 Thrombin-induced superoxide generation was abolished in the presence of VAS2870 
but not in the presence of NOX1 inhibitors indicating that thrombin-induced 
superoxide generation might potentially be NOX1-independent  
 Aβ1-42 shown to induce superoxide anion in platelets with DHE, while Aβ25-35 
shown to induce ROS using DCFDA.  
 Quantitative analysis with EPR confirmed the results obtained with the optimised DHE 
assay and showed that both Aβ1-42 and Aβ25-35 (to a lesser extent) induced 
superoxide anion generation in platelets. Superoxide generation in platelets stimulated 
with Aβ1-42 or Aβ25-35 is NOX-dependent.  
 Fibrillar Aβ1-42 induced superoxide anion formation in platelets, but did not result in 
platelet aggregation at 1 µM as an agonist alone. However, fibrillar Aβ1-42 potentiated 
platelet aggregation in the presence of collagen or thrombin. This suggests that low 
concentration of fibrillar Aβ1-42 can result in partial activation of platelets through 
ROS generation but requires the presence of a secondary agonist to potentiate full 
platelet activation.  
 
 





Several publications have now shown the important role of reactive oxygen species (ROS) 
as second messengers and as critical intracellular signalling modulators of platelet activities 
in health and disease for the subsequent amplification of platelet responses and agonist 
release [355-359]. Under pathological conditions, such as ischemia, hypercholesterolemia, 
cardiovascular diseases, and AD, studies have shown platelets to be altered or hyperactive 
with prominent involvement of ROS that may lead to excess clot formation and pro-
thromboembolic complications associated with these diseases [312, 364, 370, 420]. Few studies 
have reported the formation of ROS upon Aβ peptides stimulation of platelets [295, 297, 340], 
and therefore, the present study assessed redox changes in platelets upon Aβ peptides 
stimulation using different ROS detection methodologies.  
At the initial stages of this study, the molecular probe DCFDA was used for the detection of 
ROS generation in platelets, mainly for H2O2 
[421]. The pilot study for the detection of DCF 
fluorescence using a microplate reader displayed high basal saturation levels causing 
inaccurate ROS readings. The high basal saturation levels were thought to be due to the long 
incubation with DCFDA or potential artificial amplification of the fluorescence signal 
intensity due to certain limitations associated with DCFDA [395, 421, 422]. The idea of using 
microplate reader was discarded after several follow up failed experiments. The use of flow 
cytometry for ROS measurement was the next step followed, since positive results were 
reported previously [357, 387, 423]. Our results obtained with flow cytometry appeared to be 
more promising in terms of ROS detection. Several platelet agonists were investigated to 
assess the validity of this ROS detection method, including collagen, thrombin, CRP, 
arachidonic acid, ADP, and oxidised LDL. The results from the present study are in 
agreement with previous publications in terms of ROS generation upon stimulation with 
collagen, thrombin, and CRP [310, 314, 357]. The ROS scavenger NAC was used to validate the 
results of this study with regards to the detected ROS at different concentrations and 
incubation time, and 30 mM NAC was able to bring down ROS to basal level of resting 
platelets upon collagen stimulation.  
When the effects of Aβ peptides on platelet ROS generation were then tested, Aβ25-35 
showed statistical significance compared to resting platelets, but not to scrambled Aβ1-42 
(control). The effects of Aβ25-35 on ROS generation in platelets in this study are in 
agreement with previously published work [296, 340], however, previous studies showed that 
Aβ1-40 also induced ROS generation in platelets, which we could not replicate in this study 
using DCFDA [295, 307]. Overall, DCF fluorescence seemed insufficient when looking at the 




results of different physiological agonists used as the concentrations to obtain a detectable 
response were too high compared to normal concentrations used in vitro. In addition, the 
NAC concentration needed to scavenge ROS was high compared to the ones used in other 
studies [153, 399, 424, 425]. Since superoxide anion (O2
-•) is considered central to ROS chemistry 
and platelet have been shown to mainly produce this species [312, 426], a second molecular 
probe dihydroethidium (DHE), was utilized.  
DHE was chosen as another detection fluoroprobe to further investigate the oxidative state 
in live platelets, and its use was optimised with flow cytometry. Several agonists were tested, 
the same ones previously mentioned with DCFDA experiments, and our results were in 
agreement with previous studies when using thrombin  [387, 388], collagen (and CRP) [383, 389], 
arachidonic acid [380], oxidised LDL [390], and shown to induce superoxide anion generation 
in platelets. The results also indicate that ADP alone as an agonist did not trigger superoxide 
generation in platelets, which suggests that ADP-mediated platelet activation is independent 
of NOX activity and ROS generation. To validate the results obtained, NAC concentration-
dependent experiments were carried out using thrombin as a physiological stimulus to 
determine the optimal concentration of NAC to be used in future experiments. NAC at 3 mM 
seemed to ideally abolish ROS and bring the fluorescence values of platelets down to basal 
levels similar to the ones in the resting state. Therefore, another set of experiments were also 
carried out testing its efficiency with other physiological stimuli including arachidonic acid 
(AA), oxLDL and CRP. Both CRP and oxLDL showed significant reduction in the 
superoxide detected, but this was not observed for platelets stimulated with AA.  
To further investigate and validate sources of superoxide anion generated in platelets, NOX 
inhibitors (VAS2870 and NOX1 inhibitor) were used in platelets stimulated with thrombin. 
Superoxide generation was significantly inhibited with VAS2870 but not with NOX1 
inhibitor, which might suggests that superoxide generated from thrombin is NOX1-
independent. This result with thrombin is not consistent with Delaney’s study [391] that 
highlighted the essential involvement of NOX1 in thrombin stimulation and it is most likely 
due to the experimental conditions used, but other previous studies are in agreement with 
our data [357, 383]. In addition, our most recent published work using EPR and transgenic mice, 
demonstrated that thrombin stimulation of platelets is NOX2-dependent [427], which further 
validates this result.  
Finally, Aβ peptide-induced superoxide anion generation in platelets was assessed. 
Interestingly, only soluble Aβ1–42 (20 μM) had a significant effect on superoxide 
generation, but not Aβ1–40 or Aβ25-35 when compared to the scrambled Aβ1-42 control. 




The ability of this peptide to produce these kind of responses in platelets compared to Aβ1-
40, is potentially associated with its more highly hydrophobic nature. This study revealed 
for the first time that Aβ1-42 peptide induced significant superoxide anion generation in live 
platelets. The concentration-response study with Aβ1-42 showed that concentrations greater 
than 10 μM induced significant increases in superoxide anion generation using the newly 
optimised protocol, and that this was significantly inhibited with previously determined 
concentrations of VAS2870 and NAC. These results demonstrated that Aβ1-42 induces 
platelet activation and superoxide generation in a NOX-dependent manner and these findings 
were published in 2017 [401]. 
When EPR became accessible in our laboratories, further experiments were conducted on 
Aβ peptides to confirm and further investigate the sources of superoxide anions generated. 
Since EPR has high quantitative accuracy for ROS detection, it not only confirmed Aβ1-42 
effects on platelet superoxide generation but also showed that Aβ25-35 is able to moderately 
induce superoxide generation in platelets, which can explain some of the ROS results 
previously reported in the literature with this peptide [297, 340], and in our earlier work using 
DCFDA.  
To further examine the sources of superoxide generated with these peptides, 
pharmacological NOX inhibitors for NOX1 and NOX2 were used. Aβ1-42 and Aβ25-35 
stimulated platelets revealed significant abolishment of superoxide when either NOXs were 
inhibited, which suggests that both NOXs are essential for superoxide generation in platelets 
stimulated by these peptides. Our group’s recent published work investigated the effects of 
Aβ1-42 on platelets using EPR, aggregation assays, and transgenic mice, and confirmed that 
both NOXs are important in Aβ1-42 induced platelet activation [427]. These results highlights 
the central importance of ROS in platelet activation by Aβ peptides, with the exception of 
Aβ1-40.  
Since soluble Aβ1-42 induced significant superoxide generation, the fibrillar form of Aβ1-
42 was also tested and the results showed significant superoxide generation at 1 µM by 
fibrillar Aβ1-42 and was at a higher level than superoxide generation by 20 µM soluble Aβ1-
42. This might be due to the highly hydrophobic nature of this form of the peptide and 
cytotoxicity associated with it. The N-terminus of Aβ1-42 peptide is thought to be important 
for initiating the conformational switching from α-helical (monomer) to β-sheet structure 
(oligomer), and the peptide shows enhanced susceptibility for self-aggregation to oligomers 
and fibrillar β-sheet structures, due to intermolecular interactions between its hydrophobic 
regions [428-430].  




The formation of these oligomers and fibrils has been markedly connected with cell toxicity 
[431], and are shown to be protease-resistant with oligomers being were reported to form Ca2+-
permeable Aβ channels and elevating intracellular Ca2+ [432]. Since soluble Aβ1-42 had been 
shown previously to induce moderate platelet aggregation and potentiation as an agonist or 
co-agonist in the presence of another physiological agonist, the effects of fibrillar Aβ1-42 
on platelet aggregation were also assessed.  
Surprisingly, fibrillar Aβ1-42 did not induce platelet aggregation as an agonist nor 
potentiated aggregation as a co-agonist in the presence of thrombin (0.05 u/ml) or collagen 
(3 µg/ml), despite its profound effects in generating superoxide anion in platelets. An 
explanation for these results might be due to the low concentration of Aβ1-42 (1 µM) used 
as other studies using the fibrillar form of Aβ have been reported to use higher initial 
concentrations [302, 345, 353]. The very recent Elaskalani’s study [345], demonstrated that Aβ1-
42 fibrils does induce platelet activation in a concentration-dependent manner (5, 10, and 20 
µM). However, they also used Tyrode buffer containing 1.8 mM CaCl2 while ours was Ca
2+ 
free.  
The difference between our methodology and that used by the Elaskalani’s group is the 
buffer composition and fibril concentrations used, which could explain the lack of strong 
platelet aggregation observed in our experiments upon Aβ fibril stimulation. Nonetheless, 
fibrillar Aβ1-42 potentiated platelet aggregation in the presence of collagen or thrombin 
which suggests that low concentrations of fibrillar Aβ1-42 can result in partial activation, 
and in the presence of a secondary agonist can potentiate full platelet activation. This may 
reflect on the effects of fibrillar forms of Aβ peptides that accumulation in the 
cerebrovasculature of AD patients, and future experiments for platelet aggregation with 
higher fibril concentrations are therefore worth investigating to further understand their 
underlying mechanism of action.  
One limitation in the study here was that time and cost constraints did not permit the potential 
exploration of various other ROS or RNS. The detection of such species both intra- and 
extracellularly in platelets using EPR and the effect of using other effective pharmacological 
inhibitors of ROS is an area which may be investigated further. The lack of availability of 
fibrillar Aβ1-40 also did not allow its effect on platelet adhesion and aggregation to be 
investigated in this study, and similarly the effects of both fibrillar Aβ1-40 and Aβ1-42 on 
platelets under flow conditions. Structural characterization of fibrillar Aβ (e.g. using TEM 
imaging) that was indicated by the ThT assay could also have been carried out to elaborate 
further on the aggregation results obtained with fibrillar Aβ1-42 and platelets.  




In summary, the present study proposes a novel flow cytometry-based assay for the detection 
of superoxide formation using DHE in live platelets that is reliable and easily accessible in 
academic institutions and clinical laboratories. Even though EPR is considered the ideal 
standard method for the detection of intracellular ROS, it requires highly specialised 
equipment and dedicated specialist personnel to handle procedural complexities and lengthy 
data analysis, which makes its usage limited to only certain research and clinical institutions 
that can meet these demands. Therefore, the development of a widely available, cost 
effective, and reliable ROS detection methodology was desired and here we have proposed 
a novel alternative methodology that can be utilized in haemostasis and thrombosis studies. 
In addition, the results of this study highlight the importance of NADPH oxidase enzymes 
and oxygen radical formation in platelet function and activation in response to Aβ peptides, 
especially Aβ1-42. Moreover, this study confirms the association of ROS generation with 
platelets stimulated with physiological stimuli such as collagen, thrombin and arachidonic 
acid, and is consistent with previously published studies. Furthermore, the current study also 
reveals that ADP-mediated platelet activation is independent of NOX activity and ROS 
generation and shows that thrombin induces superoxide anion generation in a NOX1-
independent manner. Aβ1-42 was demonstrated to induce superoxide generation in platelets 
in a NOX-dependent manner. These findings suggest that NADPH oxidases can potentially 
be used as therapeutic targets to address the effects of Aβ peptides on platelet activation and 
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It has becoming increasingly evident that the role of oxidant in platelet function and biology 
is critical and that the balance between oxidants and antioxidants regulation systems can be 
affected in health and disease [433]. Dysregulation in platelet activation and function can lead 
to thrombogenesis and death by cardiovascular diseases [177]. The effects of oxidants on 
platelet activation and aggregation from both exogenous and endogenous sources have been 
documented by several studies. For example, some studies have documented that exposure 
of platelets to H2O2 showed inhibitory effects on platelet function 
[434-436], while other studies 
showed enhanced aggregation and involvement of superoxide radicals [437, 438]. Much of the 
discrepancies between the studies on whether oxidants enhanced or inhibited platelet 
aggregation are usually attributed to the differences in experimental protocols followed.  
In recent years several studies have highlighted the importance role of endogenous oxidants 
in regulating platelet activity and signalling upon stimulation with physiological agonists, 
such as collagen, TXA2, thrombin, and arachidonic acid [357, 358, 383, 387-391, 427, 439], 
Endogenous ROS generation and release from platelets whether stimulated or unstimulated 
were reported and indicate their role in facilitating platelet activation in an autocrine or 
paracrine fashion with similar effects to exogenous ROS [358, 440]. Platelets have been shown 
to be in a hyperactive state in many pathological conditions, such as, in AD, and diabetes 
mellitus [151, 441, 442], which creates a highly prothrombotic environment. Inhibition of 
platelets and anti-thrombotic effects of antioxidants in previous studies have demonstrated 
the dependency of platelet activation on ROS generation.  
Several studies have reported the involvement of Aβ in platelet activation, adhesion and 
aggregation and their supportive role in thrombus formation at vascular lesions or CAA [295-
298, 300, 302, 303, 306, 307], and while fewer studies have reported the formation of ROS upon 
stimulation of platelets by Aβ peptides [295, 296]. However, several aspects of the effects of Aβ 
peptides on platelets remain unclear and the exact cellular mechanism by which Aβ peptides 
activate platelets and regulate haemostasis and thrombosis remains to be defined. 
Therefore, the main aims of the previous Chapters 3 and 4 in this project, were to determine 
the effects of Aβ peptides i.e. Aβ25-35, Aβ1-40, Aβ1-42, and scrambled Aβ1-42 as control, 
on platelet adhesion, activation, and aggregation under static and flow conditions, and assess 
their effects on redox changes in platelets. The findings in these studies revealed that, Aβ 
peptides support platelet adhesion, particularly with Aβ1-42, where it induced significant 




platelet adhesion and spreading under static condition. It also induced and potentiated 
platelet aggregation, increased thrombus formation in whole blood under physiological 
venous flow conditions, and induced significant superoxide anion generation in live platelets 
in a NOX-dependent manner. Since Aβ1-42 appeared to be the most active peptide in our 
experimental conditions, the present Chapter aimed to investigate redox-dependent changes 
in platelet functional responses upon stimulation with Aβ1-42 peptide, and the potential 





















5.2. AIMS & OBJECTIVES 
 Determine the effects of ROS and NOX inhibition on platelet adhesion and spreading 
to Aβ1-42 peptide using adhesion assay under static conditions. 
 Determine the effects of NOX inhibition on platelet adhesion to Aβ1-42 under 
physiological shear stress. 
 Determine whether integrin αIIbβ3 activation by Aβ1-42 is NOX-dependent. 
 Determine the effects of NOX inhibition on Aβ1-42 stimulated platelet aggregation 
and potentially which NOX isoform is involved.  
 Determine the effects of Aβ1-42 on platelet intracellular signalling activation using 
phosphospecific immunoblotting.    
 Determine the effects of PAR1, CD36, and GPVI receptors inhibition on platelet 

















5.2.1. Effects of ROS inhibition on Aβ1-42-induced platelet adhesion and spreading 
under static conditions 
The initial aim of this study was to examine the effects of redox changes on platelet 
functional responses in terms of adhesion, activation, and aggregation. A series of 
experiments were carried out using an adhesion assay (see Chapter 2 for methodology) to 
determine the effects of ROS inhibition on platelet adhesion and spreading on Aβ1-42, Aβ1-
42 with collagen, or Aβ1-42 with fibrinogen. This was due to the profound effects of Aβ1-
42 on platelet adhesion and spreading compared to the other peptides, as demonstrated in 
Chapter 3. Previously determined concentrations of ROS scavenger NAC (3 mM), and NOX 
inhibitor VAS2870 (10 µM) (from Chapter 4) were used.  
The results for ROS inhibition with NAC are presented in Figures 5.1, 5.2, and 5.3, while 
results for NOX inhibitor VAS2870 are presented in Figure 5.4, 5.5, and 5.6. Panels A-B for 
all these figures are representative images of platelet adhesion and spreading for each of the 
conditions, while panels C-D show quantitative analysis of adhesion and spreading area. 
Unexpectedly, the presence of NAC produced an increased platelet adhesion and spreading 
area onto Aβ1-42 but this was not statistically significant when compared to Aβ1-42 without 
NAC (see Figure 5.1 (C and D)).   
Platelet adhesion and spreading onto Aβ1-42 with collagen (Figure 5.2 (C and D)) was not 
inhibited with NAC compared to BSA, but a noticeable decrease was observed (Figure 5.3 
(C and D)) on Aβ1-42 with fibrinogen. Interestingly, BSA showed increased platelet 
adhesion and spreading area in the presence of NAC when compared to experiments without. 
Overall, ROS inhibition with NAC at 3 mM was not sufficient to prevent Aβ1-42-induced 
platelet adhesion and spreading with or without the presence of collagen or fibrinogen under 
static conditions. Further NAC concentration-dependent future experiments on platelet 
adhesion should be explored. In addition, error bars in these previously mentioned figures 
with NAC show large variability in the repeats, which indicates that additional repeat 
experiments are required.  
On the other hand, the NOX inhibitor VAS2870, strongly impaired both platelet adhesion 
and spreading onto Aβ1-42, alone or in the presence of collagen or fibrinogen but the number 
of adhering platelets was not completely abolished as shown in Figures 5.4, 5.5, and 5.6. 
These results indicate the importance of NOXs in mediating platelet adhesion and activation.  





        
 
          
 
Figure 5.1: Effects of ROS inhibition with NAC on platelet adhesion and spreading over Aβ1-42-coated 
surfaces.  
(A-B) Representative images of platelets with or without NAC presence that were allowed to adhere onto glass 
coverslips coated with 10 µM Aβ1-42 or BSA 5mg/ml. Platelets were then fixed, stained, then visualized under 
the fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and mean spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.01 (**) refers to significance in the mean number of adhered platelets to Aβ1-42 compared to 




































































































































































































              
Figure 5.2: Effects of ROS inhibition with NAC on platelet adhesion and spreading over dual coated 
surfaces with collagen and Aβ1-42.  
(A-B) Representative images of platelets with or without NAC presence that were allowed to adhere onto glass 
coverslips coated with bovine serum albumin (BSA, 5 mg/ml), collagen (25 µg/ml), or collagen with Aβ1-42 
peptide (10 µM). Platelets were then fixed, stained, then visualized under the fluorescence microscope and 
images were taken at 10x and 100x magnification. (C-D) Quantification and evaluation of the mean number of 
adhered platelets and spreading area per optical field from at least 4 independent experiments. Statistical 
significance was analysed using one-way ANOVA with Bonferroni post-test; P-value < 0.001 (***) and P-
value < 0.0001 (****) refers to significance in the mean number of adhered platelets to either collagen or 











       
 






Figure 5.3: Effects of ROS inhibition with NAC on platelet adhesion and spreading area over dual coated 
surfaces with fibrinogen and Aβ1-42.  
(A-B) Representative images of platelets with or without NAC that were allowed to adhere onto glass 
coverslips coated with bovine serum albumin (BSA, 5 mg/ml), fibrinogen (100 µg/ml), or fibrinogen with Aβ1-
42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the fluorescence microscope and 
images were taken at 10x and 100x magnification. (B) Quantification and evaluation of the mean number of 
adhered platelets and spreading area per optical field from at least 4 independent experiments. Statistical 
significance was analysed using one-way ANOVA with Bonferroni post-test; P-value < 0.05 (*), P-value < 
0.01 (**), P-value < 0.001 (***) and P-value < 0.0001 (****) refers to significance in the mean number of 
adhered platelets and spreading area to either fibrinogen or fibrinogen with Aβ1-42 compared to BSA (control). 








































































































           
 
           
 
 
Figure 5.4: Aβ1-42 induces NOX-dependent platelet adhesion and spreading under static conditions.  
(A-B) Representative images of platelets with or without NOX inhibitor VAS2870 (10 µM) that were allowed 
to adhere onto glass coverslips coated with 10 µM Aβ1-42 or BSA 5mg/ml. Platelets were then fixed, stained, 
then visualized under the fluorescence microscope and images were taken at 10x and 100x magnification. (C-
D) Quantification and evaluation of the mean number of adhered platelets and spreading area per optical field 
from at least 4 independent experiments. Statistical significance was analysed using one-way ANOVA with 
Bonferroni post-test; P-value < 0.05 (*), P-value < 0.01 (**), and P-value < 0.001 (***) refers to significance 
in the mean number of adhered platelets and spreading area to Aβ1-42 compared to BSA (control) and also the 
decrease in the mean number of adhered platelets and spreading area upon treatment with NOX inhibitor 
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Figure 5.5: NOX-dependent inhibition of platelet adhesion and spreading over dual coated surfaces with 
collagen and Aβ1-42.  
(A-B) Representative images of platelets with or without NOX inhibitor VAS2870 (10 µM) that were allowed 
to adhere onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), collagen (25 µg/ml), or 
collagen with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the 
fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.0001 (****) refers to significance in the mean number of adhered platelets and spreading area 
to collagen or Aβ1-42 with collagen compared to BSA (control) and also the decrease in the mean number of 
adhered platelets and spreading area upon treatment with NOX inhibitor VAS2870 (+) compared to the ones 















































































































Figure 5.6: NOX-dependent inhibition of platelet adhesion and spreading over dual coated surfaces with 
fibrinogen and Aβ1-42.  
(A-B) Representative images of platelets with or without NOX inhibitor VAS2870 (10 µM) that were allowed 
to adhere onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), fibrinogen (100 µg/ml), or 
fibrinogen with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the 
fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.05 (*), P-value < 0.01 (**), and P-value < 0.0001 (****) refers to significance in the mean 
number of adhered platelets and spreading area to fibrinogen or Aβ1-42 with fibrinogen compared to BSA 
(control) and also the decrease in the mean number of adhered platelets and spreading area upon treatment with 








5.2.2. NOX inhibition attenuated thrombus formation potentiated by Aβ1-42 under 
physiological venous flow conditions 
In order to examine the effects of NOX inhibition on Aβ1-42-stimulated platelet adhesion 
and thrombus formation under physiological shear stress in vitro, an experiment was carried 
out using an ExiGo microfluidic pump (see Chapter 2 for methodology). Platelet adhesion 
on 10 μM Aβ1-42, scrambled Aβ1-42, or 0.1 mg/ml fibrillary collagen were tested in human 
whole blood at arterial shear rates of 1,000 sec-1 and a venous shear rate of 200 sec-1 and the 
results are shown in Figure 5.7.  Representative images of platelet surface area coverage are 
shown in Figure 5.7 (A-E), while quantification and analysis of surface area coverage is 
shown in Figure 5.7 (F). NOX inhibitor VAS2870 significantly inhibited platelet adhesion 















Figure 5.7: Effects of NOX inhibition on platelet adhesion to Aβ1-42 under physiological shear stress. 
Vena 8 Fluoro microchips were coated with 10 μM Aβ peptides or 0.1 mg/ml fibrillary collagen. Platelet 
adhesion with or without NOX inhibitor VAS2870 was tested in human whole blood at shear rates 1,000 sec-1 
and 200 sec-1 using an ExigGo pump and images were obtained and shown in (A-E). (F) Quantification and 
analysis of surface area coverage from 3 independent experiments using Image J. Statistical significance was 
analysed using one-way ANOVA with Bonferroni post-test; P-value < 0.0001 (****) refers to significant 
decrease in the surface area coverage with adhered platelets to Aβ1-42 upon treatment with VAS2870. Error 















































5.2.3. Aβ1-42 stimulated platelets induce αIIbβ3 activation in a NOX-dependent 
manner 
In Chapter 3, Aβ1-42 had been shown to support platelet adhesion under static conditions 
and under venous flow, promote and potentiate platelet aggregation, and integrin αIIbβ3 
activation. Aβ1-42-induced integrin αIIbβ3 activation and P-selectin expression was next 
assessed in the presence of 10 μM NOX inhibitor VAS2870. NOX inhibition abolished Aβ1-
42-induced αIIbβ3 activation as shown in Figure 5.8 (E). Aβ1-42 effects on platelet 
degranulation and translocation of P-selectin to the surface membrane of the platelets was 
also investigated in the presence of VAS2870. Aβ1-42 was not able to effectively induce 
platelet degranulation on its own but there is a noticeable decrease in the intensity of PAC1 
staining in the presence of VAS2870, although the results are not significant compared to 
control. Figure 5.8 (A) shows side scattering (SSC) and forward scattering (FSC) dot plot of 
platelets detected and suggests high purity for the platelet preparation. (B-D) are 






                                           
Figure 5.8: Activation of integrin αIIbβ3 by Aβ1-42 is NOX-dependent.   
Isolated human platelets in suspension were stimulated with Aβ1-42 and scrambled Aβ1-42 or 0.5 unit/ml 
thrombin in the presence or absence of VAS2870 for 10 minutes and then labelled with FITC-PAC1 or PE-
Cy5-P-selectin for further 10 minutes. (A) Side scattering (SSC) / forward scattering (FSC) dot plot suggests 
high purity for the platelet preparation. (B-D) Representative histograms for the intensity of PAC1 staining in 
the different conditions. (E-F) Quantification and statistical analyses of 3 independent experiments for the 
detection of P-selectin expression or integrin αIIbβ3 activation using one-way ANOVA with Bonferroni post-
test; P-value < 0.0001 (****) refers to significance in fluorescence with PAC1 staining for Aβ1-42 compared 
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Thrombin was used as positive control in the experiments. (E-F) shows quantification and 
statistical analysis for P-selectin expression or integrin αIIbβ3 activation. The results indicate 
the important role of NOX in integrin αIIbβ3 activation in platelets when stimulated with Aβ1-
42 and thus suggesting that Aβ1-42-induced integrin αIIbβ3 activation is NOX-dependent. 
In order to examine the effects of Aβ1-42 on redox changes in platelet functional responses 
in terms of aggregation, three agonists were initially used: thrombin, CRP, and arachidonic 
acid (AA). These agonists previously induced ROS generation in platelets as reported in 
Chapter 4. Therefore the present study investigated the effects of ROS inhibition on platelet 
aggregation stimulated by these agonists. This also allowed the confirmation of the activity 
of these peptides under our experimental conditions before examining the effects of ROS 
inhibition in Aβ1-42-stimulated platelet aggregation. The source of superoxide anion 
generated in response to 0.1 units/ml thrombin and 3 μg/ml CRP was investigated using 
NOX inhibitor VAS2870, since both agonists showed ROS inhibition with 3 mM NAC 
previously in Chapter 4.  
The results are presented in Figure 5.9 (A), which shows representative aggregation curves 
induced by collagen (3 µg/ml) or thrombin (0.1 u/ml) in the presence or absence of NOX 
inhibitor VAS2870. Figure 5.9 (B) presents quantification analysis of average percentage 
absorbance. VAS2870 significantly inhibited platelet aggregation indicating that platelet 
stimulation with thrombin or CRP is NOX-dependent. The effect of ROS inhibition on 
platelet aggregation stimulated with 30 μM AA was also examined and the results are shown 
in Figure 5.9 (C and D). Interestingly, superoxide generated by AA seem to be NOX-
independent with VAS2870, and was partially inhibited with 3 mM NAC, while the 
cyclooxygenase inhibitor indomethacin (Indo.), completely abolished AA induced platelet 
aggregation. This highlights the importance of cyclooxygenases in converting AA to 












                            
 
                          
 
Figure 5.9: Effects of NOX inhibition on platelet aggregation stimulated by physiological agonists.  
Platelet aggregation experiments were performed using a 490D aggregometer. (A) Representative aggregation 
curves induced by collagen (3 µg/ml) or thrombin (0.1 u/ml) in the presence or absence of NOX inhibitor 
VAS2870. (B) Quantification of average percentage absorbance from 4 independent experiments. (C) 
Representative aggregation curves induced by arachidonic acid (AA) (30 µM) in the presence or absence of 
ROS scavenger NAC, NOX inhibitor VAS2870, or cyclooxygenase inhibitor, indomethacin (Indo.). (D) 
Quantification of average percentage absorbance quantified from 4 independent experiments. Statistical 
significance analysed by one-way ANOVA with Bonferroni post-test; P-value < 0.001 (***), and P-value < 
0.0001 (****) refers to significant decrease in the percentage platelet aggregation in the presence of inhibitors. 
Error bars represent mean + SEM.  
                   
 
5.2.4. Aβ1-42-induced platelet aggregation is NOX-dependent 
The effect of NOX inhibition on Aβ1-42-stimulated platelet aggregation was finally 
examined, since Aβ1-42 was shown to induce superoxide generation in platelets and it was 
NOX-dependent as previously demonstrated with the DHE assay and EPR in Chapter 4. 
Aβ1-42 was also shown previously to significantly potentiate platelet aggregation in the 
presence of a physiological agonist. Since AA had been shown to induce platelet aggregation 
in a NOX-independent manner, it was used as a second physiological agonist with Aβ1-42. 
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80% in the presence of 20 μM Aβ1-42 peptide. The effect of Aβ1-42 with AA on platelet 
aggregation was significantly attenuated in the presence VAS2870 from 80% to 40% 
percentage absorbance as shown in Figure 5.10. These results suggest that NOX activity is 




                 
Figure 5.10: Aβ1-42 induced platelet aggregation is NOX-dependent. 
Platelet aggregation experiments were performed using a 490D aggregometer. (A) Representative aggregation 
curves induced by 20 µM Aβ1-42 or Aβ1-42 as control. (B) Representative aggregation curves induced by 10 
µM arachidonic acid (AA) with 20 µM Aβ1-42 or Aβ1-42 as control in the presence or absence of NOX 
inhibitor VAS2870. (C) Quantification of average percentage absorbance from 4 independent experiments. 
Statistical significance analysed by one-way ANOVA with Bonferroni post-test; P-value < 0.01 (**), and P-




Since there are two NOX isoforms that have been discovered in human platelets, the next 
step was to identify which of the NOXs is involved upon Aβ1-42-induced platelet 
aggregation. NOX1 (NOXA1ds) and NOX2 (NOX2ds-TAT) inhibitors (both 10 µM) were 
used in the following aggregation assay. Representative aggregation curves induced by 20 
µM Aβ1-42 or Aβ1-42 as control in the presence of NOXA1ds or NOX2ds-TAT are shown 
in Figure 5.11 (A-B). Quantitative analysis showed statistically significant inhibition of both 
NOXs as shown in (C). This suggests that either of the NOXs are needed for Aβ1-42 induced 
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Figure 5.11: NOX1 and NOX2 inhibition attenuated by Aβ1-42-induced platelet aggregation. 
Platelet aggregation experiments were performed using a 490D aggregometer. (A-B) Representative 
aggregation curves induced by 20 µM Aβ1-42 or Aβ1-42 in the presence of 10 µM NOX inhibitors scrambled 
NOX2ds-TAT (control), NOX2ds-TAT, scrambled NOXA1ds (control) and NOXA1. (C) Quantification of 
average percentage absorbance from 3 independent experiments. Statistical significance analysed by one-way 
ANOVA with Bonferroni post-test; P-value < 0.001 (***). Error bars represent mean + SEM.  
 
Aβ1-42 peptide had been shown to affect platelet functional responses in a redox-dependent 
manner, and in order to investigate its effect on platelet intracellular signalling, a 
phosphospecific immunoblotting was carried out in collaboration with Canobbio’s group 
(refer to publication for methodology [351]). Both unstimulated and Aβ1-42-stimulated 
human platelets were treated with either DMSO (control) or VAS2870. They were then 
lysed, and their protein extracts were separated by SDS-PAGE. Antibodies against 
phosphorylated PKC substrates, tyrosine protein substrates, and pleckstrin (which is used as 
a loading control), were used to detect the activation of tyrosine phosphorylation cascades 
and PKC substrate phosphorylation upon Aβ1-42 treatment. The results of this 
immunoblotting analysis, shown in Figure 5.12, only provides a qualitative evidence of 
signalling activation and not target identification in the phosphorylation events.  
 
This can however be provided as a proof that Aβ1-42 induces platelet signalling activation 
since tyrosine phosphorylation is one of the pivotal events that occurs upon platelet 
activation. Figure 5.12 (A) shows the tyrosine phosphorylation profile for unstimulated and 
Aβ1-42-stimulated human platelets treated with either DMSO as control or VAS2870. 
Several bands are observed in Figure 5.12 (A) upon stimulation with Aβ1-42 compared to 
DMSO-treated controls and the pre-treatment with NOX inhibitor VAS2870 obliterated 
tyrosine phosphorylation in response to Aβ1-42. The generation of tyrosine-phosphorylated 
protein substrates suggests that Aβ1-42 activates tyrosine kinase-dependent pathways, and 
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PKC is one of the main essential intracellular protein kinase enzymes associated with platelet 
activation and thrombus formation that is activated by DAG and increased intracellular Ca2+ 
resulting in the phosphorylation of regulatory serine/threonine residues in PKC substrate 
proteins [443, 444]. Upon immunoblot profile analysis for the phosphorylation of PKC 
substrates shown in Figure 5.12 (B), several intense bands corresponding to different 
substrate proteins for PKC can be seen upon Aβ1-42 stimulation compared to DMSO 
(control). In addition, the pre-treatment of VAS2870 abolished phospho-PKC 
immunostaining indicating that Aβ1-42-dependent platelet signalling requires NOX 







Figure 5.12: Aβ1-42 induced signalling in platelets. 
Unstimulated and Aβ1-42-stimulated human platelets were treated with either DMSO (control) or VAS2870, 
lysed, and their protein extracts were separated by SDS-PAGE. Protein phosphorylation was analysed by 
immunoblotting with the indicated antibodies: (a) anti-p-Tyr and anti-pleckstrin antibody, and (b) anti-PKC 








5.2.5. Identification of potential platelet receptors involved in binding to Aβ1-42 using 
inhibitors  
Several studies have investigated the engagement of many receptors for Aβ peptides on 
platelets and demonstrated the involvement of PAR1, CD36, GPIbα, integrin αIIbβ3, APP 
(partially), and most recently GPVI [296, 302, 307, 341, 345, 353, 354]. However, the receptor 
responsible for the initial engagement of Aβ1-42 to platelets still remains unclear. In order 
to assess PAR1, CD36, and GPVI involvement in platelet adhesion and activation induced 
by Aβ1-42, the following receptor inhibitors were used: ML161, sulfosuccinimidyl oleate 
(SSO), and losartan were used.  
 







































        
 














































Figure 5.13: Effects of PAR1 inhibition on platelet adhesion and spreading over Aβ1-42 under static 
conditions.  
(A-B) Representative images of platelets with or without PAR1 antagonist ML161 that were allowed to adhere 
onto glass coverslips coated with 10 µM Aβ1-42 or BSA 5mg/ml. Platelets were then fixed, stained, then 
visualized under the fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) 
Quantification and evaluation of the mean number of adhered platelets and spreading area per optical field 
from at least 4 independent experiments. Statistical significance was analysed using one-way ANOVA with 
Bonferroni post-test; P-value < 0.01 (**) refers to significance in the mean number of adhered platelets to Aβ1-









The allosteric inhibitor, ML161, for the thrombin receptor, PAR1, was used to test the effect 
of PAR1 inhibition on Aβ1-42-induced platelet adhesion and spreading and the results are 
shown in Figures 5.13, 5.14, and 5.15. PAR1 inhibition with ML161 noticeably reduced the 
number of adhered platelets onto Aβ1-42 (Figure 5.13 (C)); Aβ1-42 with collagen (Figure 
5.14 (C)), and with statistical significance onto Aβ1-42 with fibrinogen (Figure 5.15 (C)). 
However, no significant spreading area was observed when compared to control with all the 


























































        




























































































Figure 5.14: Effects of PAR1 inhibition on platelet adhesion and spreading over dual coated surfaces 
with Aβ1-42 and collagen.  
(A-B) Representative images of platelets with or without PAR1 antagonist ML161 that were allowed to adhere 
onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), collagen (25 µg/ml), or collagen with 
Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the fluorescence microscope 
and images were taken at 10x and 100x magnification. (C-D) Quantification and evaluation of the mean number 
of adhered platelets and spreading area per optical field from at least 4 independent experiments. Statistical 
significance was analysed using one-way ANOVA with Bonferroni post-test; P-value < 0.05 (*), P-value < 
0.001 (***) and P-value < 0.0001 (****) refers to significance in the mean number of adhered platelets and 
spreading area to either collagen or collagen with Aβ1-42 compared to BSA (control). Error bars represent 













































































































Figure 5.15: Effects of PAR1 inhibition on platelet adhesion and spreading over dual coated surfaces 
with Aβ1-42 and fibrinogen.  
(A-B) Representative images of platelets with or without PAR1 antagonist ML161 that were allowed to adhere 
onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), fibrinogen (100 µg/ml), or fibrinogen 
with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the fluorescence 
microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and evaluation of the 
mean number of adhered platelets and spreading area per optical field from at least 4 independent experiments. 
Statistical significance was analysed using one-way ANOVA with Bonferroni post-test; P-value < 0.05 (*), P-
value < 0.01 (**), and P-value < 0.0001 (****) refers to significance in the mean number of adhered platelets 
and spreading area to either fibrinogen or fibrinogen with Aβ1-42 compared to BSA (control) in the presence 









Next, inhibition of scavenger receptor CD36 was investigated using an irreversible CD36 
inhibitor SSO, and the results are shown in Figures 5.16, 5.17, and 5.18. Inhibition of CD36 
with SSO significantly impeded Aβ1-42 induced platelet adhesion and spreading, as shown 
in Figure 5.16 (C and D). There was a significant decrease in spreading area of platelets 
adhering to Aβ1-42 in the presence of collagen (Figure 5.17 (D)) or fibrinogen (Figure 5.18 
(D)). There was a noticeable decrease in the number of platelets adhering to collagen or Aβ1-
42 with collagen (Figure 5.17 (C)) but a significant decrease was observed on Aβ1-42 with 
fibrinogen, as shown in Figure 5.18 (C). These results are interesting, as the irreversible 
inhibition of CD36 apparently affected fibrinogen interaction with the integrin αIIbβ3 receptor 
or GPVI on platelets and prevented full platelet activation. An alternative explanation could 
be that SSO may have cytotoxic effects on platelets at the concentration studied and further 
























































































































Figure 5.16: Effects of CD36 inhibition on platelet adhesion and spreading over Aβ1-42 under static 
conditions.  
(A-B) Representative images of platelets with or without CD36 inhibitor SSO (100 µM) that were allowed to 
adhere onto glass coverslips coated with 10 µM Aβ1-42 or BSA 5mg/ml. Platelets were then fixed, stained, 
then visualized under the fluorescence microscope and images were taken at 10x and 100x magnification. (C-
D) Quantification and evaluation of the mean number of adhered platelets and spreading area per optical field 
from at least 4 independent experiments. Statistical significance was analysed using one-way ANOVA with 
Bonferroni post-test; P-value < 0.05 (*), P-value < 0.01 (**); and P-value < 0.001 (***) refers to significance 
in the mean number of adhered platelets and spreading area to Aβ1-42 compared to BSA (control) and also the 
decrease in the mean number of adhered platelets and spreading area upon treatment with CD36 inhibitor SSO 















































































































Figure 5.17: Effects of CD36 inhibition on platelet adhesion and spreading over dual coated surfaces 
with Aβ1-42 and collagen.  
(A-B) Representative images of platelets with or without CD36 inhibitor SSO (100 µM) that were allowed to 
adhere onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), collagen (25 µg/ml), or 
collagen with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the 
fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.01 (**); and P-value < 0.001 (***); and P-value < 0.0001 (****) refers to significance in the 
mean number of adhered platelets and spreading area to collagen or collagen with Aβ1-42 compared to BSA 
(control) and also the decrease in the mean platelet spreading area upon treatment with CD36 inhibitor SSO 










































































































Figure 5.18: Effects of CD36 inhibition on platelet adhesion and spreading over dual coated surfaces 
with Aβ1-42 and fibrinogen.  
(A-B) Representative images of platelets with or without CD36 inhibitor SSO (100 µM) that were allowed to 
adhere onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), fibrinogen (100 µg/ml), or 
fibrinogen with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the 
fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.01 (**), and P-value < 0.0001 (****) refers to significance in the mean number of adhered 
platelets and spreading area to fibrinogen or fibrinogen with Aβ1-42 compared to BSA (control) and also the 
decrease in the mean adhered platelet and spreading area upon treatment with CD36 inhibitor SSO (+) 








The effects of GPVI receptor inhibition with losartan on platelet adhesion and spreading 
induced by Aβ1-42 was also examined, either with Aβ1-42 alone, or in the presence of 
collagen or fibrinogen. The results are shown in Figures 5.19, 5.20, and 5.21. Losartan is an 
angiotensin II (Ang II) type I receptor (AT1R) antagonist shown to inhibit thromboxane A2 
(TXA2) receptor (TP) and GPVI in a selective, competitive, and dose-dependent manner 
[445]. The results show a significant decrease in the spreading area of adhered platelets 
induced by Aβ1-42 (Figure 5.19 (D)), collagen or Aβ1-42 with collagen (Figure 5.20 (D)), 
but not with fibrinogen or Aβ1-42 with fibrinogen (Figure 5.21 (D)). Losartan also 
significantly reduced the number of adhered platelets with Aβ1-42 (Figure 5.19 (C)), 
collagen, and Aβ1-42 with collagen (Figure 5.20 (C)). There is an overall decreasing trend 
regarding the effect of losartan on platelet adhesion and spreading in this study. Panels A-B 
for all these figures are representative images of platelet adhesion and spreading for each of 
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Figure 5.19: Effects of GPVI inhibition by losartan on Aβ1-42 induces platelet adhesion and spreading 
under static conditions.  
(A-B) Representative images of platelets with or without GPVI inhibitor losartan (30 µM) that were allowed 
to adhere onto glass coverslips coated with 10 µM Aβ1-42 or BSA 5mg/ml. Platelets were then fixed, stained, 
then visualized under the fluorescence microscope and images were taken at 10x and 100x magnification. (C-
D) Quantification and evaluation of the mean number of adhered platelets and spreading area per optical field 
from at least 4 independent experiments. Statistical significance was analysed using one-way ANOVA with 
Bonferroni post-test; P-value < 0.05 (*), P-value < 0.01 (**) and P-value < 0.001 (***) refers to significance 
in the mean number of adhered platelets and spreading area to Aβ1-42 compared to BSA (control) and also the 
decrease in the mean platelet spreading area upon treatment with GPVI inhibitor losartan (+) compared to the 

















































































































Figure 5.20: Effects of GPVI inhibition by losartan on platelet adhesion and spreading over dual 
coated surfaces with Aβ1-42 and collagen.  
(A-B) Representative images of platelets with or without GPVI inhibitor losartan (30 µM) that were allowed 
to adhere onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), collagen (25 µg/ml), or 
collagen with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the 
fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.01 (**), P-value < 0.001 (***), and P-value < 0.0001 (****) refers to significance in the mean 
number of adhered platelets and spreading area to collagen or collagen with Aβ1-42 compared to BSA (control) 
and also the decrease in the mean platelet spreading area upon treatment with GPVI inhibitor losartan (+) 









































































































Figure 5.21: Effects of GPVI inhibition by losartan on platelet adhesion and spreading over dual 
coated surfaces with Aβ1-42 and fibrinogen.  
(A-B) Representative images of platelets with or without GPVI inhibitor losartan (30 µM) that were allowed 
to adhere onto glass coverslips coated with bovine serum albumin (BSA, 5 mg/ml), fibrinogen (100 µg/ml), or 
fibrinogen with Aβ1-42 peptide (10 µM). Platelets were then fixed, stained, then visualized under the 
fluorescence microscope and images were taken at 10x and 100x magnification. (C-D) Quantification and 
evaluation of the mean number of adhered platelets and spreading area per optical field from at least 4 
independent experiments. Statistical significance was analysed using one-way ANOVA with Bonferroni post-
test; P-value < 0.01 (**), and P-value < 0.0001 (****) refers to significance in the mean number of adhered 
platelets and spreading area to fibrinogen or fibrinogen with Aβ1-42 compared to BSA (control). Error bars 









5.3. SUMMARY OF RESULTS 
 Aβ1-42-induced platelet adhesion and spreading is mediated via NOX activation under 
static conditions.  
 NOX inhibition also attenuated fibrinogen or collagen platelet adhesion and spreading 
with or without the presence of Aβ1-42 under static conditions.  
 Aβ1-42-stimulated platelets induced αIIbβ3 activation in a NOX-dependent manner 
but did not affect platelet degranulation and P-selectin surface membrane translocation  
 Arachidonic acid induces superoxide anion generation in a NOX-independent manner  
 Aggregation of Aβ1-42-stimulated platelets is NOX-dependent. 
 Inhibition of either NOX1 or NOX2 attenuated Aβ1-42-induced platelet aggregation 
suggesting a differential role of these NOXs in Aβ1-42 induced platelet aggregation 
 Aβ1-42 induced platelet signalling activation and required NOX activation, it also lead 
to PKC activation. 
 PAR1 inhibition with ML161 significantly inhibited platelet adhesion over Aβ1-42 
with fibrinogen only. However, there is an observable decrease in the number of 
platelets adhering to Aβ1-42 with or without the presence of fibrinogen or collagen.  
 CD36 inhibition with SSO profoundly abolished the number of platelets adhering and 
spreading area over Aβ1-42 coated surfaces and also impaired platelet spreading area 
over collagen and fibrinogen alone or in the presence of Aβ1-42 peptide.  
 GPVI inhibition with losartan significantly impaired platelet adhesion and spreading 















In the previous Chapters of 3 and 4, Aβ1-42 showed a high activation profile in our 
experimental conditions compared to Aβ25-35 and Aβ1-40. The disparity in Aβ peptides 
influence on platelet responses in terms of adhesion and aggregation is quite intriguing. Our 
results on the effects Aβ25-35 and Aβ1-40 on platelet adhesion and spreading under static 
conditions disagree partially with previously published work and is most likely due to 
modifications in the experimental conditions, such as platelet density, Ca2+ presence in 
HEPES Tyrode, incubation time, or the form of peptides used [300, 306, 307, 333, 336, 341]. On the 
other hand, our Aβ1-42 peptides demonstrated a profound ability to induce platelet adhesion 
and spreading under static condition, potentiate platelet aggregation, and increase thrombus 
formation in whole blood under physiological venous flow conditions.  
In the present study Aβ1-42-induced platelet adhesion and spreading revealed to be mediated 
via NOX activation under static conditions and that inhibition of NOX, attenuated platelet 
adhesion and spreading over fibrinogen or collagen with or without the presence of Aβ1-42. 
This indicates the important role of NOX and ROS-dependent platelet activation, adhesion and 
spreading on different extracellular proteins. In Chapter 3, Aβ1-42 showed profound ability to 
induce platelet adhesion and thrombus formation by itself under venous flow. In this study, 
NOX inhibition attenuated thrombus formation potentiated by Aβ1-42 under physiological 
venous flow conditions and also showed that Aβ1-42-stimulated platelets induced “inside-out” 
αIIbβ3 activation in a NOX-dependent manner. The most recent publication by our group has 
confirmed that both NOXs are important in Aβ1-42-induced platelet activation using EPR, 
aggregation, and transgenic mice, and that only platelet adhesion to Aβ1-42 under low shear 
seemed exclusively NOX1-dependent [427]. 
Aβ1-42 induction of ROS generation and integrin activation without platelet degranulation 
or full activation, indicates a distinct signalling pathway. However, the underlying activation 
mechanisms remain difficult to explain due to the variability in the peptides used in various 
previous studies that involved different receptors and signalling pathways and led to 
discrepancies in the results obtained. However, looking back at the overall results in this 
study, Aβ1-42-induced platelet activation has consistently shown the importance of either 
NOX1 or NOX2 in platelet functional responses in terms of adhesion and activation under 
both static and venous flow conditions. The effects of Aβ1-42 on redox changes in platelet 
functional responses in terms of aggregation showed that aggregation of Aβ1-42-stimulated 
platelets is also NOX-dependent. In addition, inhibition of either NOX1 or NOX2 attenuated 
Aβ1-42-induced platelet aggregation suggesting a differential role for these NOXs.  




Aβ1-42-induced platelet signalling activation was confirmed using phosphospecific 
immunoblotting analysis. The results showed that Aβ1-42-dependent platelet signalling 
requires NOX activation, and it leads to PKC activation, which is central and common 
signalling molecule upon stimulation with most platelet agonists [220, 446]. PKC can also directly 
become activated in the presence of oxidants [447]. This highlights the important role of NOX in 
mediating Aβ1-42-induced platelet activation. Different forms of Aβ peptides have previously 
reported to activate the platelet receptors PAR1 [296], GPIbα and CD36 [302], integrin αIIbβ3 
[307], 
and most recently GPVI [345]. Therefore, the present study investigated the potential 
involvement of PAR1, GPVI, and scavenger receptor CD36 in Aβ1-42-induced platelet 
adhesion and spreading.  
Inhibition of GPVI receptor by losartan significantly impaired platelet adhesion and 
spreading over Aβ1-42, collagen, and Aβ1-42 with collagen but not in the presence of 
fibrinogen. These results suggest that Aβ1-42 induces platelet adhesion and spreading 
potentially via the GPVI receptor, which supports the recently published work of Elaskalani’ 
group [345]. Due to the hydrophobic nature of Aβ1-42 and its high tendency to self-aggregate 
and form fibrils, it might act in a similar manner to fibrillar collagen and activate GPVI and 
other adjacent receptors causing receptor dimerization and initiation of signalling activation.  
Previous studies have shown that co-localisation of Aβ and fibrinogen can lead to fibrinogen 
binding to Aβ enhancing fibrinogen aggregation and Aβ fibrillization [273, 306, 346], which 
explains the enhancement of adhesion and spreading of platelets to dual coated surfaces of 
Aβ with fibrinogen in our studies. This suggests that if GPVI preferentially binds to 
substrates in a fibrillary form, then there should be a significant decrease in platelet adhesion 
and spreading when GPVI was inhibited with losartan. On the contrary, our results showed 
no significant decrease in the number of adhered platelets and spreading area with GPVI 
inhibition in the presence of Aβ1-42 with fibrinogen. This suggests that different forms of 
Aβ1-42 (particularly fibrillar form) may act through receptors other than GPVI or bind to 
multiple ones.  
A previous study showed that fibrillar Aβ peptides can bind to a complex formed by CD36, 
CD47 and α6β1 integrin receptors on the surface of microglial cells resulting in the activation 
of intracellular signal transduction cascades [448]. This signalling transduction cascade 
involves the activation of specific Src family kinases (Lyn, Fyn or Syk) that phosphorylates 
Vav which in turn acts as a guanine nucleotide exchange factor for Rac-1, which is an 
essential component NADPH oxidase, leading to NADPH oxidase-mediated generation of 
reactive oxygen species [449, 450]. CD36 shown to activate different intracellular signalling 




pathways depending on the ligand, co-receptor, and cell type [451]. However, the downstream 
signalling mechanisms that link CD36 to classical platelet activation pathways are unclear. 
The importance of scavenger CD36 activation lies upon its multiple functions and assembly 
with other pattern recognition receptors, and it has been implicated in a variety of pathologies 
including atherosclerosis and thrombotic complications previously highlighted [390, 451, 452]. 
Fibrillar Aβ1-40 shown to induce platelet aggregation through the activation of 
CD36/p38MAPK/TXA2 release [302], thus its potential involvement with Aβ1-42 was 
investigated in the present study using the CD36 irreversible inhibitor, SSO.  
CD36 inhibition with SSO profoundly abolished the number of platelets adhering and 
spreading area over Aβ1-42 coated surfaces, and also impaired platelet spreading area over 
collagen and fibrinogen alone or in the presence of Aβ1-42 peptide. These results are 
interesting, as SSO affected the fibrinogen interaction with its receptors on platelets and 
prevented full platelet activation. These results may suggest some cytotoxic effects on 
platelets at that concentration and further experiments with lower SSO concentrations or 
other CD36 inhibitors might be needed to further test Aβ1-42 effects on CD36. Both GPVI 
and CD36 seems to be key receptors for Aβ1-42 and further confirmatory future experiments 
with regards to these two receptors are required.  
The involvement of thrombin receptor PAR1 (using ML161 inhibitor) in Aβ1-42 induced 
platelet adhesion and spreading was also examined. ML161 is an allosteric inhibitor that 
selectively blocks part of the receptor-mediated response [453]. Our results show an 
observable decrease in the number of platelets adhering to Aβ1-42 with or without the 
presence of collagen, and the only significant decrease in the number of adhered platelets 
was over Aβ1-42 with fibrinogen. These results suggest that fibrillar form of Aβ1-42 can 
potentially activate PAR1, but when looking at the overall results of PAR1 inhibition with 
ML161, the large error bars make these data inconclusive and further inhibition studies of 
this receptor are required.  
Putting these findings together, it is possible to hypothesize that Aβ1-42 activates 
platelets through GPVI and NOX1 under low flow conditions, and other receptors 
such as CD36 may also be potentially involved, but further work is required to gain 
more insight. The present study sheds a new light on the importance of NADPH 
oxidase activation and platelet prothrombotic responses induced by Aβ1-42 that 
accumulates in the brain of Alzheimer’s and cerebral amyloid angiopathy (CAA) 
patients. Interestingly on another note, human platelets also express the angiotensin 
II (Ang-II) receptor (AT1R), which is a main target for angiotensin II receptor blockers 




(ARBs), such as losartan, used in the treatment of hypertension [454]. It is tempting 
to investigate the potential binding of Aβ peptides to AT1R especially when this 
receptor has been shown to activate platelets via NOX activation upon stimulation 
with Ang-II [455]. Early phase clinical trials are currently investigating the effects of 
anti-hypertensive drugs on reducing and intervening in the development of AD [456]. 
However, the effects of these drugs on platelets in AD patients may have been 
overlooked. Therefore, the effects of losartan on platelets adhesion to Aβ peptides 
in this study appears promising and it provides an additional avenue to explore 
potential treatment options for AD patients, since antiplatelet drugs, such as aspirin 
or clopidogrel, which are used to prevent stroke are also associated with an 
increased risk of cerebral haemorrhage [457]. Using an alternative treatment option, 
such as anti-hypertensive drugs, to also target platelets can potentially modify and 
reduce the pre-activated state in platelets and their contribution towards the 
thromboembolic events associated with AD. 
In order to extend the current work, it would be necessary to address some limitations 
accompanying the use of the adhesion assay. For instance, the concentration of agonists 
remaining on the coated coverslips after wash remains unknown. Therefore, it is difficult to 
accurately determine their relevant effects in the body at a particular concentration. 
Additional experiments are also needed to confirm the identified Aβ receptors in platelets 
with knockout mice and accurately identify the signaling mechanisms involved so that the 
receptors can be used as potential therapeutic targets. In this work, time and cost constraints 
did not permit the potential exploration of various other pharmacological inhibitors, which 
would be interesting as some of the inhibitors used for the identification of potential 
receptors involved with Aβ, might not be as effective. Drugs available in the market to treat 
hypertension and hypercholesterolemia may also have additional involvement with platelet 

































6. GENERAL CONCLUSIONS 
The overall aim of this research project was to test the hypothesis as to whether 
amyloidogenic Aβ peptides within the blood stream cause cerebrovascular complications 
associated with Alzheimer’s disease via redox-dependent activation of platelets. Despite 
several studies highlighting the important role of Aβ peptides on platelet activation, these 
studies lacked consistency in their methodology and the forms of peptides used, which made 
the precise effects of Aβ peptides on platelets unclear. There is no previous study that has 
compared the effects of the different peptides side-by-side in a systematic manner. 
Therefore, a series of experiments were carried out utilizing several Aβ peptides, i.e. Aβ1-
40, Aβ1-42, and Aβ25-35 and scrambled Aβ1-42 (as control) to investigate their effects on 
human platelets.  
In the first phase of this project, the effects of Aβ peptides on platelet functional responses, 
i.e. adhesion, aggregation, and thrombus formation under static and physiological flow 
conditions were investigated. The study revealed that all Aβ peptides (i.e. Aβ1-40, Aβ1-42, 
and Aβ25-35) support platelet adhesion under static conditions, but with substantial 
preferential adhesion to Aβ1-42 compared to the other Aβ peptides. Aβ1-42 was shown to 
significantly promote platelet adhesion and spreading with extensive lamellipodia formation 
indicating that this peptide induces platelet intracellular signaling. Adhesion experiments in 
the presence of another physiological stimulus such as collagen with Aβ1-42, revealed 
similar potency in terms of the number of adhered platelets with Aβ1-42 without collagen 
suggesting that Aβ1-42 may induce platelet adhesion via an independent mechanism to 
collagen that is potentially mediated through a different receptor.  
Aβ1-42 may also potentially be competing with collagen for the same receptor, i.e. GPVI. 
On the other hand, the presence of fibrinogen with Aβ1-42 enhanced platelet adhesion and 
full activation. This may reflect the potential augmentation of platelet recruitment, activation 
and thrombus formation at the site of CAA. The effect of Aβ peptides on platelet aggregation 
as an agonist revealed that Aβ1-42 induced moderate aggregation compared to the other 
peptides and potentiated aggregation in the presence of other physiological agonists, 
collagen or thrombin. In addition, Aβ1-42 induced partial platelet activation, but not granule 
release, as assessed by the expression of surface P-selectin and integrin αIIbβ3 activation. 
Furthermore, Aβ1-42 was shown to have a negligible effect on platelets under high shear 
stress or arterial blood flow, while it appears to potentially have a greater influence upon 
induced thrombus formation under venous flow. These results highlight the profound 
biological effects of Aβ1-42 on platelets. 




In the second line of investigation, oxidative changes in platelets upon treatment with Aβ 
peptides was assessed by exploring different ROS detection methodologies. Aβ25-35 
showed significant ROS generation using DCFDA, but the other peptides did not produce 
the same effects. The lack of strong detectable DCF signal in this assay under our 
experimental conditions despite the high concentrations of physiological agonists used, 
prompted an initial ROS detection assay optimization. A novel easy and accessible flow 
cytometry assay using DHE was developed that detected significant superoxide generation 
in platelets upon Aβ1-42 stimulation (including fibrillar Aβ1-42), but not with the other 
peptides. Further investigations of oxidative state in live platelets using the DHE assay 
revealed for the first time that superoxide anion generation in platelets by Aβ1-42 is NOX-
dependent, and this finding was published in 2017 [401]. In addition, generation of superoxide 
anion in platelets by thrombin stimulation was shown to be NOX1 independent, and ADP-
mediated platelet activation was independent of NOX activity and ROS generation.  
Follow-up studies using EPR, confirmed that not only superoxide anion was generated by 
Aβ1-42, but was also moderately generated by Aβ25-35, which can explain some of the ROS 
results previously reported. Additionally, further examination using NOX1 and NOX2 
inhibitors revealed that both NOXs are essential for the generation of superoxide anion in 
platelets stimulated by either Aβ1-42 or Aβ25-35 peptides. These results greatly highlights 
the central underlying relationship between ROS and human platelet activation upon Aβ 
peptide stimulation, and provides a novel alternative methodology that can easily and 
reliably be utilized in haemostasis and thrombosis studies. 
Since Aβ1-42 appeared to be the most active peptide in our experimental conditions, the 
final phase of this project focused on investigating the redox-dependent changes in platelets 
and functional responses upon stimulation with Aβ1-42 peptide, and the potential receptors 
that might be involved. The results from adhesion studies revealed that Aβ1-42 induced 
platelet adhesion is mediated via NOX activation under static conditions and under 
physiological venous flow. In addition, Aβ1-42 induces platelet adhesion and spreading most 
likely via the GPVI receptor and potentially involves the CD36 receptor, but further 
experimental validations are required for this receptor. Aβ1-42-stimulated platelets induced 
“inside-out” αIIbβ3 activation and platelet aggregation in a NOX-dependent manner.  
Moreover, inhibition of either NOX1 or NOX2 attenuated platelet aggregation and thus 
highlights the important role of NOX in mediating Aβ1-42 induced platelet activation, 
adhesion and aggregation. Since several control physiological agonists were tested alongside 
Aβ1-42 for the effects of NOX inhibition on platelet aggregation, this study reports for the 




first time that superoxide anion generated by arachidonic acid was NOX-independent and 
these results were also published in 2017. Finally, phosphospecific immunoblotting analysis 
revealed that Aβ1-42-dependent platelet signaling requires NOX activation and this 
signaling also leads to PKC activation, which is known to be involved in mediating a range 
of intracellular events leading to platelet activation.  
The work done in this project sheds a new and important light on the significance of NADPH 
oxidase activation and platelet prothrombotic responses induced by Aβ1-42 that accumulates 
in the brain of Alzheimer’s and cerebral amyloid angiopathy (CAA) patients. Aβ1-42 was 
shown to activate platelets, enhance their adhesion, and potentiate the responses of low levels 
physiological agonists, which can trigger unwanted hemostatic response and create a vicious 
cycle with feed-forward loop of platelet hyperactivity within the bloodstream. This supports, 
thrombus formation at vascular lesions or CAA at an accelerated rate, and possibly 
contribute to the microthrombosis in neurovasculature and cardiovascular complications 
observed in AD. Taken together these results and data from previous studies on how platelets 
contributes to the overall picture of the pathogenesis of AD, a model is proposed in support 
of the vascular hypothesis as the main contributor to the etiopathogenesis of AD. As 
summarized in Figure 6.1, this starts from childhood and this figure also shows the potential 
causative role of pre-activated state of platelets found in AD patients.  
 
Figure 6.1: Proposed model for the etiopathogenesis of AD and the role of platelets.  
 




The process of atherosclerosis often starts in childhood as fatty streaks and it is usually a 
long asymptomatic phase of development with minor vascular changes that can be 
minimized following a healthy lifestyle [458]. However, with increased risk factors or disease 
during development, it initiates early onset of cardiovascular diseases (CVDs) [458]. Over 
time, the development of atherosclerotic plaques, causes chronic inflammation, oxidative 
stress, and vascular changes with increased risk of hypertension, perivascular diseases, and 
thrombotic events, such as transient ischemic attack or stroke. Acute thrombotic events can 
cause or be a result of cerebrovascular damage and contributes to the onset of vascular 
dementia [129]. Cerebrovascular damage can lead to blood vessel constriction, hypoperfusion, 
compromised BBB barrier, pericytes loss, and the accumulation of toxins including Aβ in 
brain parenchyma and within the cerebral vessel wall [23, 129]. 
Compromised blood vessels influences the balance between Aβ production and clearance 
mechanisms causing its accumulation within the blood vessels and the onset of CAA. Aβ 
peptides have been shown to support platelet adhesion and activation at vascular injury and 
CAA sites. This allows the secretion of potent molecules and Aβ from platelets into the 
circulation that promotes the activation of other platelets within their vicinity creating a 
highly thrombotic environment. Aβ shown to increase the activity of ACE-1 that results in 
the increase of Ang-II (potent vasoconstrictor) affecting blood vessels and also activating 
platelets through AT1R contributing to further activation of platelets in the blood [454]. The 
presence of inflammatory mediators, coagulation and growth factors, activated immune 
cells, platelet secretory molecules, Ang-II, adhesion molecules, Aβ, exposed ECM, and 
oxidative stress, are strong candidate for the formation of the pre-activated state in platelets 
and coated platelets [459]. As these events feeds into progressive cerebrovascular damage 
cycle, it eventually leads BBB breakdown and to the accumulation of toxins and Aβ in the 
brain parenchyma and neuronal cells and resulting the formation of amyloid plaques, tau 
pathology, neurodegeneration, cognitive decline and ultimately Alzheimer’s dementia [23, 
460].  
The results of this project suggests a potential therapeutic avenue aiming at limiting the 
vascular component contributing to Alzheimer’s disease by targeting potential hypertensive 
drugs that affect platelet activation, develop antiplatelet drugs selectively targeting specific 
NADPH oxidase isoenzyme activities and developing relative pharmacotherapy, and finally 
developing efficient screening systems for identifying children at risk for atherosclerosis to 
provide an early intervention or delay the progression of atherosclerosis and CVDs as a 
preventative method.    






When looking at the larger picture from all the work accomplished during this project, there 
are still several gaps that provides new avenues to be explored in future work regarding this 
topic and some are listed in the following:  
 
 Aβ1-42 induced platelet adhesion in the presence of new CD36 inhibitors and CD36 
knockout mice, PAR1 inhibitors, selective GPVI inhibitors, GPIbα inhibitor, αIIbβ3 
inhibitors, and α2β1 inhibitors 
 Conduct adhesion assay experiments to investigate the effect of other anti-
hypertensive drugs, such as Telmisartan, Candesartan, and Irbesartan (potent and 
selective to AT1R), on platelet adhesion to amyloid peptides under both static and flow 
conditions 
 Conduct protein-receptor co-immunoprecipitation or radioligand binding studies in 
order to provide a better explanation and understanding of the receptors involved 
with Aβ peptides. 
 Assess the effect of fibrillar Aβ1-40 on platelet adhesion and aggregation and ROS 
generation.  
 Assess the effects of fibrillar Aβ1-42 and Aβ1-40 under physiological flow 
conditions and whether they are NOX dependent or not.  
 Explore other types of ROS and RNS that might be involved in Aβ stimulated 
platelets using EPR.  
 Conduct a concentration dependent experiments for with regards to fibrillar Aβ1-42 
with regards to platelet aggregation.  
 Investigate the effect of extracellular calcium on Aβ stimulated platelet adhesion, 
aggregation, and ROS generation with EPR.  
 Conduct signaling studies such as targeted phosphoimmunoblotting of potential key 
signaling molecules involved in Aβ stimulated platelets to understand their 
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